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Protein kinase A (PKA) is activated by elevated intracellular cAMP downstream of β-adrenergic
signalling. PKA’s subcellular localisation is determined by its affinity for A-kinase anchoring
proteins (AKAPs), scaffolds that sequester PKA proximal to its substrates. The regulatory RIα
subunits present in type I PKA can form two intermolecular disulphide bonds, each flanking its
AKAP-binding domain, in response to oxidants. Rationally this change in the redox state of
PKARIα may alter its affinity for AKAP, with potential for consequential regulation of substrate
phosphorylation.
I made the novel observation that co-treatment of cells with H2O2 and cAMP caused increased
global PKA substrate phosphorylation compared to cAMP or H2O2 alone in HEK 293 cells. This
suggested RIα serves as a co-incidence detector that integrates the two signals to
synergistically enhance PKA substrate phosphorylation. Chronic cAMP treatment increased
PKARIα expression in HEK 293 cells and PKARIα was also upregulated in a mouse model of
hypertrophy, whilst PKARIIα was downregulated. This may represent a switch to an oxidant
sensitive PKA signalling phenotype during chronic β-adrenergic stimulation.
AKAP7 was identified as a potential redox-dependent PKARIα AKAP. Examination of the AKAP7
crystal structure revealed putative redox sensitive cysteines adjacent to its A-kinase binding
domain, leading to the hypothesis that the redox state of this AKAP may alter its affinity for
PKARIα. I developed and validated the ‘PEG-maleimide switch assay’, a method used to
identify proteins that are susceptible to reversible oxidative modification. Using the PEG-
maleimide switch assay I found AKAP7 to be insensitive to oxidation. Furthermore, I
demonstrated that PKARIIα, but not PKARIα, is a binding partner for AKAP7δ and this
interaction was redox modulated.
I described, for the first time, that cAMP can modulate PKARIα disulphide dimer levels. DTT-
dependent PKARIα reduction was potentiated by cAMP, and cAMP-agarose induced PKARIα
reduction. Furthermore, a mutant PKARIα that could not bind cAMP formed disulphide-linked
complexes under oxidative conditions. These complexes may be cAMP-regulated
intermediates that form during a novel oxidant-dependent mechanism of PKARIα targeting to
AKAPs. LC-MS/MS identified the novel AKAP tubulin as part of a disulphide linked complex with
PKARIα. Consistent with the hypothesis that oxidants target PKARIα to tubulin,
phosphorylation of the microtubule associated protein GEF-H1 was enhanced after co-
treatment with cAMP and H2O2 compared to cAMP alone. Thus PKARIα is a co-incidence
detector at the interface of cAMP and oxidant signalling that is able to integrate both
modalities to fine-tune phosphorylation events.
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1.1 Reactive oxygen species
Historically oxidants were implicated primarily as perpetrators of cellular dysfunction and
pathologies including cancer, neurodegenerative and cardiovascular diseases1-5. The traditional
view asserted that oxidants, produced largely by unregulated processes, indiscriminately and
detrimentally ‘attacked’ biological molecules6. Antioxidant treatment ameliorated disease
progression in a great many pre-clinical animal models, and therefore it was anticipated that
these positive outcomes would translate to human patients7-10. However antioxidant therapy
has not been efficacious with respect to reducing disease risk or progression in large scale
human clinical trials, with some studies showing the intervention was in fact detrimental9,11,12.
Whilst the unselective and damaging aspect of oxidants persists, it is now generally accepted
that they also play a crucial homeostatic role as signalling molecules in the maintenance of
normal cellular function13. Within the cardiovascular system, oxidants have been implicated in
numerous physiological processes including, excitation-contraction coupling, the regulation of
vascular tone, stress responses to hypoxia, ischemia, angiogenesis, and inflammation4,14.
Reactive oxygen species (ROS) is a term used to collectively describe free radicals (a species
with an unpaired electron in its outer shell) and non-radical derivatives of molecular oxygen
(O2) also termed oxidants. ROS are generally unstable molecules that react with and alter the
structure of organic substances including proteins, lipids and DNA15. ROS can be generated
from enzymatic activity or by electrons that leak from the electron transport chain and are
transferred to O2 to form the superoxide radical (O2·-) (O2 + e- O2·-)16 . Addition of a second
electron to O2·- can occur spontaneously or can be catalysed by superoxide dismutase (SOD) to
yield the more stable, and less reactive, signalling molecule hydrogen peroxide (H2O2) (2 H+ + 2
O2·-  H2O2 + O2) . Further electron addition to H2O2 via the Fenton reaction, where Fe2+
donates an electron to become Fe3+, produces the hydroxyl radical (OH·), a strongly oxidising
molecule which is highly reactive and is consequently not considered to be a viable signalling
molecule17. There are many different ROS, including the peroxyl radical (ROO·), hydroperoxyl
radical (HOO·-), hydroxyl ion (OH-) and the hypochlorite ion (OCl-). Oxidative signalling
molecules also involve reactive nitrogen species (RNS) including the nitroxyl ion (NO-),
peroxynitrite (ONOO-), dinitrogen trioxide (N2O3), nitroxyl radical (NO·), nitrosonium ion (NO+),
nitronium ion (NO2+), nitrite ion (NO2-), nitrate ion (NO3-). All of these molecules vary in their
abundance, stability, reactivity and selectivity with protein thiols18.
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Redox signalling can be defined as a specific, usually reversible, modification of cellular
signalling pathway components by a reactive species19. As discussed in more detail below,
oxidant signal transduction can be mediated by ROS-induced modifications of protein structure
resulting in alterations to protein function. This thesis focuses on cAMP-dependent protein
kinase A RIα (PKARIα), which forms disulfide bonds in the presence of oxidants and this is
associated with its activation.
Protein cysteine thiols serve as a major class of ROS sensors. The reactivity of a cysteine thiol
depends on the surrounding tertiary structure of the protein and its solvent environment,
which will govern access by oxidants. Most intracellular cysteine thiols have a high acid
dissociation constant (pKa) of ~8.5 and are therefore relatively unreactive and unlikely to
undergo oxidation at physiological pH of ~7.1. Reactive cysteine thiols tend to have a low pKa,
meaning that they exist within the cell primarily as the deprotonated thiolate anion (-RS-) at
physiological pH and as such have enhanced reactivity to oxidants. Basic amino acid residues
such as arginine, histidine or lysine in close proximity to cysteines can lower the pKa of the thiol
as the amino group can accept protons and stabilise the thiolate ion. Only a small proportion
of the total cellular proteins contain thiolates, and this provides a basis for selectivity in thiol-
mediated redox signalling. Further selectivity is mediated through co-localisation of the sensor
thiol to the oxidant source20,21.
Reactive cysteines can undergo numerous post-translational modifications (Figure 1.1). H2O2
reversibly reacts with a thiol to produce sulfenic acid (R-SOH). When large amounts of oxidants
are present the sulfenic acid can be further oxidised to sulfinic acid (R-SO2H) and sulfonic acid
(R-SO3H), which are usually considered to be biologically irreversible events termed
hyperoxidation. Under mild oxidising conditions the sulfenic acid intermediate can rapidly
react with thiol reducing equivalents to form disulfide bonds (R-S-S-R), before being recycled
back to the reduced state by intracellular antioxidants, discussed in more detail below. The
location of the reducing thiol determines whether the protein forms an intramolecular
disulfide or an intermolecular disulfide with an adjacent protein. Certain cysteines can also
form mixed disulfides with low molecular weight thiols such as free cysteine or glutathione,
termed S-cysteinylation (-R-S-Cys) or S-glutathionylation (R-S-SG) respectively. As well as
oxidant signal transduction, disulfide bond formation has been considered as an important
form of protection against irreversible thiol hyperoxidation mentioned above13,16.
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1.2 Sources of reactive oxygen species
The mitochondria are a primary source of cellular ROS. Under normal circumstances O2 is the
terminal electron acceptor at complex IV of the electron transport chain where it is reduced to
form H2O. However electrons can ‘leak’ at complexes I and III where they can be transferred to
O2 to generate O2·-22. Although these mitochondrial-derived ROS can be detrimental, they can
also contribute to homeostatic redox signalling27. Located on the outer membrane of the
mitochondria is the ubiquitous enzyme monoamine oxidase (MAO) which catalyses the
oxidative deamination of adrenaline (A), noradrenaline (NA), serotonin (5-HT) and other
related monoamines. Here, H2O2 is produced as a by-product of monoamine catabolism to an
aldehyde intermediate23. MAO-dependent ROS production has been confirmed in the
cardiovascular system, for example there is elevated O2- in homogenates of cardiac valves or
blood vessels after incubation with serotonin, which can be blocked by the MAO inhibitor
clorgyline24. Furthermore pharmacological inhibition of MAO has demonstrated a role for
MAO-dependent ROS production in both 5-HT and NA-induced cardiac hypertrophy25.
ROS is not simply generated as a by-product of metabolism. For example, NADPH oxidases
(NOX) are a family of enzymes which generate O2·- as a primary outcome by transferring
electrons from NADPH to flavin and then on to molecular O2 to form O2·- (2O2 + NADPH 2O2·-
+ H+ + NADP+)14. The NOX enzyme is a complex of several protein components including the
membrane spanning flavocytochrome b558 (composed of flavin, the haem-binding (gp91phox)
and p22phox), the cytosolic regulators (p47phox, p67phox, p40phox) as well as the small
GTPase, Rac 1 or 2. Upon stimulation, the four cytosolic proteins translocate to the membrane
and assemble with flavocytochrome b558 to enhance O2·- production26. ROS derived from NOX
enzymes have been extensively studied as part of the innate immune system. For over 80
years professional phagocytes such as macrophages and neutrophils have been known to
utilise ROS upon activation, known as the ‘respiratory burst’, to destroy invading
microorganisms27. The importance of physiological ROS generation as part of the innate host
defence is highlighted in patients afflicted with chronic granulomatous disease whom lack a
functional NOX and suffer from microbial infections more frequently as a consequence28. The
death of the pathogens also highlights the destructive capacity of indiscriminate ROS, and why
oxidants were consistently associated with detrimental effects on biological molecules by the
scientific community29. However there is now a greater appreciation for the role of NOX
enzymes in a broad range of cell types and various physiological processes including apoptosis,
cell proliferation, angiogenesis, and fibrosis29,30 (Table 1.1).
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Within the cardiovascular system the NOX isoforms are expressed differentially. Both the
endothelium and cardiomyocytes contain NOX2 and NOX4 whereas vascular smooth muscle
cells also additionally express NOX131. NOX2 is found on the plasma membrane and its
activation appears to be directly linked to acute receptor agonism by hormones, growth
factors and cytokines including angiotensin II, insulin, platelet-derived growth factor (PDGF)
and tumour necrosis factor α (TNFα). The constitutively active NOX4 is located intracellularly
and its activity appears to be directly related to its abundance32. Physiologically, the targeting
of NOX to specific subcellular compartments may serve to ensure specificity and selectivity of
the oxidant signal within the microenvironment that it is generated in16. Despite this
physiological role, NOX4 is upregulated and is associated with pathogenesis in the
cardiovascular system, including ischemic injury, hypoxia, reperfusion, atherosclerosis,
hypertrophy and hypertension33.
The effectiveness of O2·- as a signalling molecule may be limited by its inability to penetrate
cellular membranes and its rapid conversion into H2O2. There are three mammalian isoforms
of SOD; copper-zinc SOD (SOD1) located in the cytosol, manganese SOD (SOD2) located in the
mitochondria, and copper-zinc SOD (SOD3) located in the extracellular space34. SOD catalysed
dismutation of O2·-occurs at a near diffusion limited rate, and the high concentration of SOD in
the cytosol and the mitochondria is such that the probability of O2·- undergoing a reaction
other than dismutation is unlikely. The exceptions occur when a reaction with O2·- has a rate
constant that is comparable to its dismutation by SOD, such as the reaction between O2·- and
NO to form OONO-. Further exceptions occur in subcellular compartments where SOD is low or
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Table 1.1 Overview of NOX isoforms. Table adapted from Bedard and Krause 200736, Santillo
et al. 201537 and Panday et al. 201538.
1.3 Overview of biological antioxidants
H2O2 has the advantage of being a small and neutral molecule, making it highly diffusible and
able to cross cellular membranes. It is also less reactive than O2·- and therefore considered by
some to be a more important redox signalling second messenger16. H2O2 has multiple
physiological roles within the cell but given its cytotoxic effect at high concentrations its
abundance must be tightly regulated. Oxidative stress can be defined as an imbalance
between endogenous oxidants and antioxidants in favour of the former thus ROS and RNS are
counterbalanced by antioxidant systems to maintain the redox homeostasis in the
cell39. Furthermore for H2O2 to be considered as a signalling molecule, cysteine modifications




H2O2 concentration is controlled non-enzymatically by intracellular antioxidants such as
glutathione (GSH) or the antioxidant vitamins C and E40-42. GSH, with a cellular concentration in
the millimolar range, is the most abundant non-protein thiol in cell and thus has key role in the
adaptive response to oxidative stress. However its concentration is depleted in response to
oxidative insults43. Biosynthesis of GSH is dependent upon the availability of intracellular
cysteine and the rate-limiting enzyme, glutamate cysteine ligase (GCL), a heterodimer
comprising a catalytic (GCLC) and a modifier (GCLM) subunit44. Elevated cellular oxidants lead
to increased Nrf2 transcriptional activity (discussed below in more detail) and consequently
increased downstream expression of GCLC and GCLM. The result is a ‘rebound’ effect post-
oxidative insult whereby the intracellular concentration of GSH exceeds initial levels after
oxidant-induced depletion. This ‘rebound’ effect is lost in cells lacking Nrf2, highlighting the
importance of the transcription factor for adaptive GSH-dependent cytoprotection45.
Throughout this thesis, H2O2 is routinely used to acutely induce oxidative stress (10 mins) in
various cell types; therefore the rebound increase in glutathione concentrations will only play
a potential role in conditions of chronic oxidative stress.
Enzymatic regulation of H2O2 concentration is primarily mediated by peroxidases, which
include catalase, glutathione peroxidase (Gpx1), and peroxiredoxin (Prx) that can neutralise
the oxidant signal. The tetrameric enzyme catalase exists predominantly within cytosolic
peroxisomes. High concentrations of H2O2 undergo catalase-dependent decomposition into
H2O and O2. Gpx1, a key antioxidant enzyme localised in the cytosol, is a H2O2 scavenger that
utilises GSH as a reductant and generates oxidised glutathione (GSSG) as a metabolic product,
whilst glutathione reductase (Gsr) uses NADPH as source of reducing power to regenerate GSH
from GSSG. Prxs make up around 1% of total cellular protein content. All 6 members of the Prx
family contain a peroxidatic cysteinyl thiol which has a very low pKa (~5.5) in comparison to
those in other proteins, thus making them highly reactive oxidant scavengers. 2-Cys Prxs react
with H2O2 to form intermediate sulfenic acids before transitioning to intermolecular disulfides
by reacting with thiols on a neighbouring Prx molecule46. Oxidised Prx then is reduced by
thioredoxin (Trx) via thiol disulfide exchange (R-S-S-R + R'-S-  R'-S-S-R + R-S-) to restore the
catalytic activity of Prx. The nucleophilic N-terminal Trx catalytic thiolate attacks a disulfide
thiol in Prx which breaks the bond and creates a new mixed disulfide between Trx and Prx. The
second Trx catalytic thiol attacks the thiol in the newly formed mixed disulfide, resulting in an
internal disulfide bond in Trx as well as restoring reduced Prx which is now available again to
react with another H2O2 molecule47. Trx is a universal disulfide reductase that can also directly
reduce oxidised substrates to reverse the oxidative modifications induced by H2O2, again
resulting in the formation of an intramolecular disulfide bond via thiol disulfide exchange. The
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catalytic activity of oxidised Trx is restored by thioredoxin reductase (TR) which utilises NADPH
and FAD as reducing power48. Glutaredoxin (Grx) is another enzyme capable of reducing
disulfide containing substrates via thiol disulfide exchange, and is reduced and restored non-
enzymatically by GSH.
As Prx is such an effective antioxidant it is difficult to reconcile how H2O2 could effectively
oxidise target substrates before being scavenged. One explanation, the floodgate hypothesis,
is that oxidation occurs only after the local 2-Cys Prxs have been inactivated49. A burst of local
H2O2 would lead to sulfination and consequent inhibition of the local peroxiredoxin
‘gatekeepers’ permitting substrates in close proximity to the be oxidised. The activity of
sulfiredoxin, an antioxidant enzyme that utilises ATP to reduce sulfinated Prx, would restore
the catalytic activity of Prx thus closing the ‘floodgates’, but in the interim less reactive local
substrates can become oxidised. A complimentary hypothesis is that Prx enzymes are initially
oxidised to sulfenates or disulfides which can then react with less reactive substrates as a
potential mechanism of oxidant signal transduction14,50. For example, oxidised Prx 4 in the
endoplasmic reticulum can pass on its redox state to protein disulfide isomerase via thiol-
disulfide exchange51.
1.4 Biological roles of oxidants
Oxidants play a role in a diverse range of physiological and pathophysiological effects that
depends on the abundance, duration, location and of the composition of the oxidant signal.
Susceptible proteins to oxidation include receptors, ion transporters, transcription factors and
kinases which are structurally modified to produce specific functional outputs20. How H2O2 can
transduce signals through modification of proteins to alter function is a major focus of this
thesis.
1.4.1 Pathophysiological roles of oxidants
Apoptosis: Dysregulated and/or excessive concentrations of H2O2 can accelerate cell death
through activation of apoptosis signal-regulating kinase 1 (ASK1). This mechanism contributes
to ischemia/reperfusion injury and heart failure. In adult cardiomyocytes, β-adrenoceptor–
induced apoptosis leads to oxidant-dependent activation of c-Jun N-terminal kinase (JNK) and
the programmed mitochondrial death downstream of ASK152. Under basal conditions reduced
Trx is negative regulator of ASK1 activity and the two proteins exist together in complex. H2O2
leads to the formation of an intra-molecular disulfide bond in Trx. This oxidation event disrupts
the complex and permits autophosphorylation of ASK1 Thr838 leading to its activation and
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downstream phosphorylation of JNK to induce apoptosis53. The importance of this pathway is
demonstrated in ASK-1−/− mice which exhibit attenuated ventricular remodelling in a model of
cardiac hypertrophy as a consequence of decreased apoptosis54.
Arrhythmias and cardiac hypertrophy: Oxidative signalling has been shown to be pro-
arrhythmic and pro-hypertrophic via the redox activation of Ca2+/calmodulin-dependent kinase
II (CaMKII). CaMKII is a ubiquitously expressed multimeric serine/threonine kinase responsible
for the phosphorylation of key excitation-contraction coupling proteins as well as regulating
genes associated with pathological cardiac hypertrophy. CaMKII phosphorylates key Ca2+
handling proteins the net effect of which is diastolic accumulation of arrhythmogenic Ca2+ and
Na+55. Each monomer of the dodecameric CaMKII multimer associates via its C-terminal
domain to form a double-ringed hexameric complex55. The catalytic N-terminal of the kinase is
responsible for substrate phosphorylation but under basal conditions is inhibited by the C-
terminal regulatory domain56. The activation of CaMKII is mediated by binding of Ca2+-
calmodulin to the regulatory domain. This induces a conformational change in the kinase
structure which disrupts the association between the regulatory and catalytic domains and
permits substrate phosphorylation. CaMKII can also be activated via oxidative modification of
methionine (Met281 and Met282) residues on the regulatory subunit which maintains the
kinase in the active conformation. Angiotensin II-dependent activation of NOX2, in vitro and in
vivo, increased M281/282 oxidation and induced apoptosis, which was lost in M281/282V
CaMKII knock-in (KI) mice55,57. Furthermore treatment of cardiomyocytes with H2O2 increases
the incidence of pro-arrhythmic Ca2+ sparks and pro-hypertrophic Ca2+ overload downstream
of CaMKII activation58.
Atherosclerosis: Atherosclerosis is a disease of the arterial blood vessels that is characterised
by the formation of a complex fatty plaque surrounded by a fibrous cap. Loss of fibrous cap
integrity leads to thrombus formation, and consequently impinged blood flow and oxygen
delivery to the affected tissue59. Rupture of the fibrous cap is intrinsically linked to
macrophage activity as they express matrix degrading enzymes such as matrix
metalloproteinases and cathepsins that degrade the fibrous cap and reduce the stability of the
plaque60. ROS derived from a variety of systems including NOX enzymes, lipooxygenases and
cycloxogenases contributes to the oxidation of low density lipoproteins (ox-LDL) within the
atheroma. Ox-LDL induces the expression of adhesion molecules VCAM-1 and ICAM-1 on
endothelial cells; serves as a chemoattractant for circulating monocytes; promotes
differentiation and activation macrophages; and induces the production of pro-inflammatory
cytokines (TNFα, interleukin-1β)61-63. The detrimental role of H2O2 in disease progression is
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further highlighted as atherogenic ApoE-/- mice crossed with mice over-expressing both SOD1
and catalase had markedly reduced atherosclerosis64.
Vascular permeability: Numerous in vitro and in vivo studies have demonstrated that oxidants
can induce endothelial permeability65,66. Elevated vascular permeability is associated with
various pathologies such as atherosclerosis, diabetes, ischemia/reperfusion injury and sepsis65.
The perfusion of H2O2 into isolated lungs of guinea pigs or rabbits increased their capillary
filtration coefficient, leading to pulmonary oedema65. Treatment of endothelial cells with
H2O2 increased albumin flux through their monolayer and decreased transendothelial electrical
resistance in a dose-dependent manner67. Disruption of VE-cadherin at cell-cell junctions and
increased junctional protein phosphorylation, often associated with increased permeability,
has been observed downstream of vascular endothelial growth factor (VEGF)-dependent ROS
generation66. This may further be perpetuated by the ability of H2O2 to upregulate VEGF
expression68. Oxidants can also regulate endothelial cell activation and junctional permeability
through the re-organisation of the actin cytoskeleton upregulate on69. O2·- is generated
downstream of oedemagenic TNFα and IL-1, cytokines that are d during sepsis. This
contributes to actin stress fibre formation which is thought to drive endothelial contraction
and thus increases permeability70. In Chapter 6 I explore the role of oxidant-dependent
activation of PKARIα on actin stress fibre formation in the pathogenesis of sepsis.
1.4.2 Physiological roles of oxidants
Gene transcription: Cells have evolved mechanisms that sense high concentrations of ROS and
upregulate the expression of antioxidant enzymes accordingly. This stress response is
exemplified by the transcription factor OxyR in bacteria. H2O2 induces oxidation of OxyR
Cys199 to a sulfenic acid intermediate which then reacts with Cys208 to form an
intramolecular disulfide bond. This activates OxyR to increase transcription of antioxidant
enzymes including catalase and SOD71,72. In eukaryotic cells the transcription factor nuclear
factor-erythroid-2-related factor 2 (Nrf2) is sequestered to the cytoplasm in an inactive
complex with Kelch-like ECH-associated protein 1 (Keap1). Here Nrf2 is ubiquitinated,
signalling it for its proteasomal degradation. Keap1 contains reactive cysteines that sense
cellular oxidants73. Oxidation of these critical cysteine residues leads to a change in Keap1
conformation, thus stabilising Nrf2 and facilitating translocation of de novo synthesised Nrf2 to
the nucleus74. Here, it binds to the antioxidant response element (ARE) located in the
promoter region of genes to upregulate transcription of various cytoprotective proteins
including but not limited to sulfiredoxin, Prx1 and TR (Figure 1.2)75,76. APE1 is a dual function
protein involved with the base excision repair pathway of DNA damage by oxidative stress77. If
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these lesions are not adequately repaired they may promote a variety of diseases such as
cancer. Independent of the DNA repair action of APE1 is its co-transcriptional activity,
modulating gene expression directly regulated by various transcription factors, including AP-1,
CREB, NF-κB, p53 and HIF77. APE1 maintains such transcription factors in their active, reduced
state, to enhance their DNA binding, providing another link between oxidative signals and
gene expression78. Cys65 of APE1 is critical for its redox control and is thought to be
responsible for the nucleophilic attack of oxidised transcription factor thiols79. Interestingly,
Cys65 is not a solvent accessible residue and therefore APE1 must undergo a conformational
change for it to serve as a nucleophilic cysteine80. In Chapter 5, I propose a model whereby the
novel AKAP tubulin similarly undergoes a conformational change that reveals a cysteine
residue capable of reducing disulfide PKARIα.
Figure 1.2 Effect of oxidative stress on Nrf2 activation. Keap1 is bound to Nrf2 under basal,
unstressed conditions thus facilitating the degradation of Nrf2 via the ubiquitin-proteasome
pathway. Oxidative stress leads to modification of Keap1 cysteine residues thus stabilizing Nrf2
whilst allowing de novo synthesised Nrf2 to translocate to the nucleus. Expression of
cytoprotective genes is mediated via heterodimerisation with small Maf (sMAF) proteins and
binding to the antioxidant response element (ARE).
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Blood pressure: NO is a well characterised mediator of vascular tone and is produced by
plasma membrane endothelial nitric oxide synthase (eNOS), through the oxidation of L-
arginine. NO diffuses into smooth muscle cells binding to and activating soluble guanylate
cyclase (sGC), which produces cyclic guanosine monophosphate (cGMP) that activates protein
kinase G Iα (PKGIα) to decrease contractility (Figure 1.3)81. Cellular oxidants can influence this
signalling cascade to further regulate vascular tone and consequently blood pressure. Cellular
NO can be lost by reacting with O2·-, forming the highly reactive OONO-. Such reductions in NO
bioavailability, as well as OONO--mediated protein nitration, may contribute to disease
pathogenesis18,33. eNOS can itself produce O2·- when it becomes uncoupled. For example, if the
concentration of the co-factor tetrahydrobiopterin (BH4) is depleted it is unable to accept an
electron leading to the generation of O2·- instead of NO82. ROS generation and the depletion of
NO caused by eNOS uncoupling is strongly associated with the endothelial dysfunction
associated with atherosclerosis and hypertension83. S-glutathionylation of two highly
conserved cysteine residues in eNOS reversibly decreases NO and increases O2·- generation
which is also associated with impaired endothelium-dependent vasodilation84. Furthermore
NO species can modify reactive cysteines to generate nitrosothiols (-R-SNO) in a reaction
termed S-nitrosation. There is controversy about whether this is a stable oxidative signalling
modification in its own right, or whether it is a transitory intermediate prior to more stable
disulfide bond formation85,86. Nevertheless, this laboratory identified PKGIα as being sensitive
to oxidation by either H2O2 or the NO derivative nitrosocysteine (CysNO) that directly leads to
its activation81,85. Exogenously applied H2O2 caused the formation of an interprotein disulfide
bond between the two Cys42 residues in the PKGIα homodimers whilst simultaneously
decreasing coronary perfusion pressure in a correlative manner. This led to the hypothesis that
PKGIα disulfide formation may activate the kinase independently of the classical NO-cGMP
pathway. Indeed, pharmacological inhibition of sGC with 1H-[1,2,4]oxadiazolo[4,3-
a]quinoxalin-1-one (ODQ) did not attenuate H2O2-induced vasorelaxation of isolated thoracic
aorta rings and in vitro experiments. Furthermore, recombinant PKG showed it was directly
activated by oxidation, which was abrogated when Cys42 was mutated to a serine81. Cys42,
which is unique to the Iα isoform, oxidation to disulfide induced by H2O2 is likely to initially be
‘primed’ by means of sulfenation of one monomer thiol. The Cys42 sulfenate is subsequently
reduced by the Cys42 residue on the adjacent subunit to yield an interprotein disulfide. The
susceptibility of Cys42 to oxidation can be explained by the surrounding basic residues and the
proximity of the thiol residues (∼8 Å)81. Finally KI mice expressing only a C42S 'redox-dead'
version of PKGIα are not susceptible to the vasodilatory action of H2O2 on resistance vessels
and are consequently basally hypertensive in vivo87.
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Figure 1.3 Classical-NO and oxidative-dependent activation of PKGIα. NO derived from eNOS
activity diffuses from endothelial cells into  smooth muscle cells where it binds to the haem-
centre of sGC, leading to the catalysis of  GTP to cGMP. The binding of four cGMP molecules to
PKG is for classical activation of the kinase, and subsequently leads to downstream substrate
phosphorylation. The oxidative activation of PKG is caused by reactive nitrogen/oxygen species
inducing disulfide bond formation between the two subunits of the PKG homodimer which
enhances kinase activity in the absence of cGMP, and is thought to lead to differential
substrate phosphorylation in vivo.
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Growth factor signalling: Growth factor receptor stimulation is commonly coupled to NOX
activation which elicits an increase in cellular ROS. Enzymes that contain a catalytic thiol in
their active site such as protein tyrosine phosphatases (PTP) can be inactivated by oxidation
and are a potential target for NOX-derived oxidants downstream growth factor signalling.
Inactivation of PTPs allows propagation of the extracellular growth factor signal
downstream88,89. H2O2 signalling is important for vascular endothelial cell growth and
consequently angiogenesis which is an important process in tissue development and
maintenance, as well as wound healing and re-vascularisation of ischemic tissue. Growth
factors can stimulate angiogenesis via oxidase-dependent ROS generation. VEGF increases
cellular H2O2 downstream of vascular endothelial growth factor receptor 2 and NOX4
activation. H2O2 directly activates extracellular signal-regulated kinase (ERK1/2), a well-
established mediator of growth factor signalling that results in the upregulation of genes
involved with endothelial cell proliferation90. Recently PKARIα oxidation has also been shown
to mediate vessel growth downstream of growth factor receptor activation. A novel Cys17Ser
PKARIα ‘redox-dead’ KI mouse line that cannot undergo oxidant-dependent activation suffered
from impaired angiogenesis in models of hind-limb ischaemia and tumour vascularisation. This
highlights the importance of oxidant signalling in control of angiogenesis91. How the oxidant-
induced structural change of PKARIα affects its function is a major focus of these investigations
and is discussed in more detail below.
1.5 Overview of PKA
The ubiquitous holoenzyme PKA regulates many cellular processes including cardiac
contraction and relaxation92,93, vascular tone94,95, vascular permeability96,97, gene
transcription98,99, cellular proliferation100-102 and apoptosis102. PKA exists as a tetramer
comprising of a homodimer of regulatory subunits (R) and two catalytic subunits (C) (R2C2)103.
There are four isoforms of the R subunit that are derived from distinct genes, namely RI (type I
PKA) and RII (type II PKA) which can both be further classified into α and β subunits (RIα, RIβ,
RIIα, RIIβ)104. Each R subunit monomer consists of a disordered linker region that connects the
N-terminal dimerisation and docking domain (D/D) to the two 3’-5’- cyclic adenosine
monophosphate (cAMP) binding domains (Figure 1.4)105.
The C subunits, of which there are three isoforms (Cα, Cβ, Cγ), each consists of a small and
large lobe with an active site that forms a cleft between the two lobes. The small lobe provides
the binding site for adenosine 5-triphosphate (ATP), and the large lobe provides a docking
surface for peptide/protein substrates with serine/threonine residues, typically with an -R-R-X-
General Introduction
36
S/T-X- motif106. The activation loop in the large lobe contains a phosphorylation site, Thr197,
essential for catalysis106. Investigators have demonstrated that the Cys199 in the activation
loop can form a disulfide bond with Cys97 of RIIα which inactivates the kinase, although this
laboratory has never observed this putative oxidant-dependent interaction107. Under basal
conditions when cAMP levels are low, the regulatory subunits are bound to and inhibit the
catalytic subunits; however when cAMP levels are elevated, two molecules bind to each R
subunit to induce dissociation of the catalytic subunits and facilitate substrate phosphorylation
(Figure 1.5).
All four R isoforms share a similar domain organization but they are not functionally
redundant. For example, RIα is constitutively expressed by all cells whilst RIβ is primarily
expressed in neurons and adipose tissue108. RIα KO mice are embryonically lethal with notable
heart and vasculature deformations, implying that its function is critical for normal
development108. However whilst the RIIα is also constitutively expressed, RIIα KO mice have no
clear phenotype highlighting that the R isoforms have explicit roles within the cell109.
Dysregulated expression of RIα is suspected to play a role in malignant transformation, and
constitutive over-expression of RIα leads to tumour growth in several cancers which is
associated with poor patient prognosis110. Furthermore mutations in the RIα gene cause
familial cardiac myxomas and Carney complex, an autosomal dominant disease where patients
suffer from multiple neoplasms including lentiginosis, adrenal hyperplasia, and pituitary
tumours that result in endocrine over activity111. The R isoforms differ in their subcellular
location and substrate phosphorylation profile primarily due to structural differences, as
highlighted below. The susceptibility of RIα to oxidants via disulfide bond formation is the key





Figure 1.4 PKARIα holoenzyme. (A) Schematic representing PKARIα regulatory subunit domain
structure. Each subunit contains an N-terminal dimerisation and docking domain (D/D) which is
the point of contact for the adjacent R subunit and A-kinase anchoring proteins (AKAPs); an
inhibitor site (IS) that sequesters the PKA catalytic subunits and two C-terminal cyclic
nucleotide binding domains (CNBA and CNBB). (B) The crystal structure regulatory subunits
(ribbons) complexed with the two catalytic subunits (surfaces) and representative cartoons.
Figure adapted from Taylor et al. 2012112
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Figure 1.5 Classical activation of PKA. Cartoon depicting PKA in its inactive conformation
before four molecules of cAMP (black circles) induce a conformational change in the regulatory
(R) subunits (green) to facilitate the release of the catalytic (C) subunits (yellow) and permit
phosphorylate substrates.
1.5.1 PKA structure
The co-discoverer of cAMP, Ted Rall, expressed his dissatisfaction at the idea of the “…catalytic
subunit of protein kinase swimming about, happily phosphorylating a variety of cellular
constituents whether they need to or not”113. Our current understanding of the structure of
the R subunits confirms his assertions. The D/D at the N-terminal of the R subunits provides
the interface for R subunit homodimerisation, and is also the point of contact between PKA
and A-kinase anchoring proteins (AKAPs), scaffold proteins that tether PKA to specific
subcellular locations to regulate substrate phosphorylation (discussed in more detail below)114.
The two R subunits of PKA assemble in an “X-type, anti-parallel four helix bundle” which forms
a binding pocket for the helical amphipathic A-kinase binding domain (AKB) of the AKAP to
bind (Figure 1.6)103. Nuclear magnetic resonance and X-ray crystallography experiments
demonstrate that the dimer interface of the D/D domain is formed predominantly from
hydrophobic side chains. This critical cluster of hydrophobic residues provides a surface for the
complimentary hydrophobic residues on the exterior of the AKAP helix to interact with115,116.
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Figure 1.6 The D/D domain of PKA binds to an AKAP amphipathic helix. Cartoon depicting the
PKA holoenzyme with an AKAP. Ribbon diagram of the RIIα subunit dimer (1–43, green) which
forms an X-type, anti-parallel four helix bundle to create a binding pocket for the AKAP helix
peptide (blue). Figure adapted from Newlon et al. 2001114
Fundamentally the R subunits bind the catalytic subunits to render them inactive and unable
to phosphorylate target substrates. The inhibitory site (IS) that binds to the catalytic subunits
in type II PKA is a bona fide phosphorylation site (Arg-Arg-Val-Ser(P)-Val), whilst in type I PKA it
is a pseudosubstrate that contains a non-phosphorylatable alanine in place of the serine117.
Both R subunits of the holoenzyme contain two carboxyl-terminal cyclic nucleotide binding
domains. The binding of two cAMP molecules per R subunit is necessary to induce dissociation
of the catalytic subunits and facilitate substrate phosphorylation. cAMP binds cooperatively to
the A and B sites as occupation of one site alone (i.e. low intracellular cAMP concentrations) is
insufficient to activate PKA. A conformational change upon cAMP binding to the B site is
required to increase accessibility of the A site. Consequently co-operative binding to both sites
causes a profound change in conformation that permits the release of the catalytic subunits
and leads to substrate phosphorylation118.
1.5.2 Classical PKA activation in the cardiovascular system
Activation of β-adrenergic receptors by catecholamines is the primary mechanism by which
cAMP is generated and contraction of the heart is modulated119. Binding of agonists such as
noradrenaline or adrenaline causes a conformational change in the receptor and leads to
dissociation of the Gαs subunit from the heterotrimeric G protein. Gαs then activates adenylate
cyclase (AC) which catalyses the conversion of ATP to cAMP, a ubiquitous second messenger
that has three downstream effectors120,121. cAMP interacts with cyclic-nucleotide gated ion
channels to regulate their open probability122. cAMP also targets exchange protein directly
activated by cAMP 1/2 (Epac1/2), which function as guanine nucleotide exchange factors for
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the G proteins Ras-related protein 1 and 2123. The principal target of cAMP is PKA which is well
known for phosphorylating key regulators of excitation-contraction coupling that govern the
inotropic (force of contraction), lusitropic (rate of relaxation) and chronotropic (rate of
contraction) effects associated with β-adrenergic receptor activation124,125 (Figure 1.7).
Figure 1.7 Classical activation of PKA. GPCR activation leads to translocation of Gαs to bind
and activate adenylate cyclase (AC). AC converts ATP to cAMP which binds and activates PKA
and leads to substrate phosphorylation.
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An elevation of cytosolic Ca2+ is essential for coupling cardiomyocyte excitation to contraction.
Ca2+ induces a conformational change in the troponin complex to expose the myosin binding
site of actin and facilitate their interaction to generate force and initiate contraction118. PKA
phosphorylates the L-type calcium channel at Ser1928 on α1c and Ser478 and 479 on β2a to
increase channel open probability, allowing more Ca2+ into the cytosol upon arrival of an action
potential to increase cardiac contractility118,126. Phosphorylation of the ryanodine receptor 2
(RyR2) at Ser-2030 or Ser-2808 sensitises it and causes increased calcium release from the
sarcoplasmic reticulum (SR) during excitation-contraction coupling which consequently
increases inotropy. Whilst phosphorylation of Ser-16 on PLB enhances the active transport of
Ca2+ back into SR via sarco/endoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) to reduce
intracellular Ca2+ levels and consequently increases the rate of myocyte relaxation (Figure
1.8)127. Regulation of PKA substrate phosphorylation is mediated by phosphodiesterases (PDEs)
that hydrolyse cAMP to an inactive it, therefore PDEs can determine the duration and
amplitude of the cyclic nucleotide signal. Furthermore, phosphatases directly oppose the
action of kinases to dephosphorylate proteins and return them to their basal state128.
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Figure 1.8 Classical cAMP-dependent activation of PKA leads to phosphorylation of ion
translocators involved with excitation-contraction coupling. cAMP (black circles) binding to
the regulatory subunits (R) causes the dissociation of the catalytic subunits (C) to permit
phosphorylation.
PKA has other roles beyond excitation-contraction coupling in the cardiovascular system. For
example, PKA phosphorylates the transcription factor cAMP response element binding protein
(CREB) at Ser133 to modify gene expression profile of its downstream targets129. Cardiac
myocyte-specific expression of dominant negative CREB revealed atrophic and hypertrophied
muscle fibres, as well as significant interstitial fibrosis emphasising the importance of CREB
activity regulation for normal cardiac function130 In the vasculature PKA regulates smooth
muscle tone, impairment of which can contribute to the pathophysiology of vascular diseases
including hypertension94,95. Ca2+-activated K+ channels (BK) are activated by changes in
membrane potential and increases in intracellular Ca2+ to passively allow K+ efflux from the
cytoplasm down its electrochemical gradient and induce hyperpolarisation and reduce cell
excitability131. PKA phosphorylates BK channels to increase open channel probability further
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decreasing the excitability of the cell to favour vasorelaxation132. In vascular smooth muscle
cells myosin light chain (MLC20) phosphorylation at Ser19 by myosin light chain kinase (MLCK) is
necessary for actin activation of myosin ATPase and subsequent crossbridge cycling133. cAMP
production downstream of β2 adrenergic receptors activates PKA which phosphorylates MLCK,
decreasing its activity and consequently inducing vasorelaxation. Furthermore PKA
phosphorylates a 20 kDa heat shock-related protein HSP20 at Ser16 which can modulate the
contractile apparatus to also induce vasorelaxation134. PKA also has a prominent role in
endothelial cells where it is able to influence actin filament dynamics which dictate cell shape
and consequently impact on vascular permeability96,97. The role of PKA on vascular
permeability is discussed in more depth in Chapter 6. The numerous roles of PKA highlight its
importance within the cardiovascular system.
1.6 Overview of AKAPs
Given the diversity of roles PKA has within the cell its localisation and activity has to be tightly
regulated to ensure specific and appropriate intracellular responses. This is mediated through
the interaction between PKA and AKAPs; scaffold proteins that typically have no intrinsic
enzymatic activity but assemble spatially discrete signalling complexes comprised of effectors
of the cAMP signalling cascade and tether them to a specific subcellular compartment. These
effectors certainly include PKA, PKA substrates and PDEs, and may also include phosphatases,
ACs and G-protein coupled receptors (GPCRs)135,136.
1.6.1 Structural features of AKAPs
AKAPs are a large family of scaffold proteins that are structurally diverse but functionally
similar. The first AKAPs were detected as contaminants that were co-captured with R subunits
on cAMP-agarose affinity columns137. Since then over 50 human genes that encode AKAPs
have been identified, this number increases when considering the tendency for AKAP genes to
undergo alternative splicing138. For example the AKAP9 gene has at least four known splice
variants including yotiao, AKAP350, AKAP450, and centrosome- and golgi- localised PKN-
associated protein139. Some AKAPs are ubiquitously expressed whereas others have niche roles
in a specialised cell type, for example AKAP7γ/δ is thought to specifically co-ordinate excitation
and contraction coupling in cardiomyocytes140. AKAPs bind the D/D on the R subunits of PKA
via the hydrophobic face of an amphipathic helix approximately 14-20 residues in length,
which can be categorised depending on the PKA isoform they bind, denoted RI-specific, RII-
specific or dual-specific accordingly103. Most known AKAPs are RII specific or bind RI subunits
with significantly less affinity (25-500 fold) in vitro141. This may explain why PKARII is basally
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localised to discrete parts of the cell (i.e. pre-targeted), whereas RI subunits tend to be
distributed diffusely in the cell (principally in the cytosol) before being dynamically recruited to
discrete sites such as the cap site of activated lymphocytes142,143. Many type II specific AKAPs
have been identified using blot overlays (or Far Westerns), however this approach to identify
RI-binding proteins has been unsuccessful for technical reasons that are unknown but may be
specifically characteristic of PKARI/AKAP interaction144,145. For example, Herberg et al.
demonstrate that the dissociation rate constant of PKARIα with Dual-AKAP 1 (DAKAP1) is 100-
fold accelerated compared to the RIIα subunit146.
The differences in AKAP affinity between RI and RII can be accounted for by structural
differences between the D/D domain and the amino acids presented on the surface that make
contact with the AKAP helix147. The AKAP helix lies diagonally in the D/D domain and its
importance has been demonstrated with proline mutations that disrupt the conformation and
consequently ablate PKA anchoring148. The RIIα D/D domain is non-polar, flat and rigid and
devoid of any bulky aromatic residues to form a shallow groove that compliments the
hydrophobic AKAP helix147. In contrast RIα forms a rugged, deep binding groove that is lined
with more basic and acidic residues that contact the AKAP helix. For example RIα contains
Gln26 in place of Ile17, suggesting that it forms larger more hydrophilic pockets capable of
accommodating the larger and polar amino acids but reduces its capacity to bind natural
AKAPs (Figure 1.9). Such larger pockets have been exploited to design AKAP-PKARI inhibitor
peptides that specifically disrupt RI from AKAPs147. Furthermore Ile3 and Ile5 in RIIα exist
within a short β-strand prior to the Helix A of the four helix bundle that makes up the D/D and
are available to make critical contacts with the AKAP helix to stabilise the interaction. In
contrast, RIα contains a small N-terminal helix before the D/D domain which incorporate these




Figure 1.9 Comparison of RIα and RIIα D/D domains. The RIα D/D domain (12–61) forms a
deep groove with N-terminal helices which restricts binding AKAP helix binding whilst the RIIα
D/D domain (1-44) forms a shallow hydrophobic pocket. Figure adapted from Pidoux et al.
2010128
AKAPs contain motifs that target them to specific subcellular locations via protein–lipid or
protein–protein interaction to facilitate recruitment of PKA to a particular site or to a given
organelle135. AKAPs have been identified in numerous cellular compartments, including but not
limited to the centrosomes, the Golgi apparatus, mitochondria, microtubules, cell and nuclear
membranes, and the cytoskeleton142. Interestingly different AKAPs can target PKA to the same
organelle, indicating that the assembly of signalling complexes with specific substrates even
within a subcellular compartment is necessary for appropriate integration of cAMP signals. At
least four anchoring proteins (D-AKAP1, D-AKAP2, PAP7, and Rab32) anchor PKA to the
mitochondria128. Furthermore, splice variants and isoforms of an AKAP may be diversely
targeted. The different isoforms of AKAP7 have distinct subcellular localisation in polarized
epithelial cells. AKAP7α is located at the lateral membrane whereas AKAP7β isoform is located
at the apical membrane, whilst AKAP7γ is predominantly cytoplasmic149. Some proteins
function as AKAPs although this is not classically considered to be their primary function. For
example membrane-bound proteins α4-integrin and ezrin are important for T-cell motility and
cell shape respectively, but have recently been found to also function as AKAPs150-152. Similarly
in Chapter 5 I propose that tubulin, a major component of the microtubules, is a redox-
dependent PKARIα AKAP. WAVE1 has previously been identified as PKARIIα-specific AKAP at
the actin cytoskeleton and is thought to regulate dorsal ruffle formation but little is known




AKAPs bind to PKA substrates and effectors of the cAMP signalling pathway such as
phosphatases and PDEs. Assembling such enzymes in close proximity allows integration and
termination of cAMP signals that govern phosphorylation and dephosphorylation events, thus
the amplitude and duration of signal transduction is tightly controlled (Figure 1.10)128.
Figure 1.10 AKAPs assemble multienzyme signalling complexes. AKAPs tether PKA, PKA
substrates and effectors of the cAMP signalling pathway, such as phosphatases and PDEs, to
specific subcellular locations and thus regulate cAMP dependent phosphorylation events.
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Disruption of the complexes has deleterious effects on PKA-dependent physiological functions.
The Ht31 peptide is a 24 amino acid α-helix derived from the AKAP-Lbc AKB domain that
directly competes with PKA to displace it from binding sites48. One of the first experiments
with Ht31 uncoupled PKA from AMPA type glutamate receptor ion channels in hippocampal
neurons leading to dysregulated synaptic transmission, whilst perfusion into pancreatic beta-
cells resulted in insulin secretion uncoupling139. At least 13 AKAPs have been found in the
cardiovascular system139. Delivery of Ht31 to cardiomyocytes decreased PKA-dependent
phosphorylation of RyR2, PLB, troponin I and myosin binding protein C. As such the peptide
attenuated the enhanced contractility normally induced by β adrenergic stimulation
reinforcing the functional significance of PKA localisation for cAMP signal transduction154.
AKAP-Lbc itself is thought to be a mediator of the pathological response associated with
angiotensin II type 1 receptor activation, and mitogenic signals through RAF/MEF/ERK1/2
kinase pathway155. Knockdown of AKAP-Lbc expression in rat neonatal ventricular
cardiomyocytes significantly reduced the ability of angiotensin II to induce RhoA activation and
transcription of pro-hypertrophic genes156. Furthermore, AKAP-Lbc mRNA is upregulated in
patients with cardiac hypertrophy, whilst AKAP-Lbc knockout mice die in utero due to
defective heart tube development, highlighting the importance of AKAP scaffolding complexes
in the functioning heart135.
Characterization of these complexes is critical to better understanding the cAMP signalling
pathway157. PKA-dependent phosphorylation of the KCNQ1 subunit of the slowly activating
delayed rectifier potassium channel (IKs) is necessary for sympathetic regulation of the cardiac
action potential158. The AKAP yotiao complexes PKARIIα, protein phosphatase 1 (PP1), PDE4D3
and AC to KCNQ1, a component of IKs. PKA dependent phosphorylation enhances channel open
probability whilst PP1 dependent dephosphorylation supresses IKs currents139. The importance
of the yotiao in assembling this complex is highlighted by familial mutations in the AKAP, which
can lead to the potentially lethal type 1 long QT arrhythmia syndrome. These mutations lead to
dysregulation of KCNQ1 phosphorylation, loss of control of the cAMP signal and membrane
repolarisation139. Certain AKAPs potentially permit the integration of inputs from other second
messenger systems such as Ca2+ by acting as scaffold for protein kinase C (PKC) and protein
kinase D. AKAP79, a product of the AKAP5 gene, tethers PKARIIα, PKC and protein phosphatase
2B (PP2B) to integrate cAMP and Ca2+ signals and as such has been implicated in persistent
Ca2+ signals (sparklets) that increase vascular tone159. In ventricular cardiomyocytes AKAP79
has been demonstrated to form a supramolecular complex containing a β-adrenergic receptor,
AC5/6, RIIα and PP2B tethered to a caveolin 3-associated complex containing L-type calcium
channel160. Thus AKAPs act as signalling nodes that are able to integrate signals from multiple
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inputs. A primary aim of the present study is to determine whether AKAPs and PKARIα can
integrate concomitant cAMP and oxidant signals.
Using a cAMP affinity-based chemical proteomics strategy a novel AKAP in the human heart
has recently been uncovered termed small membrane smAKAP. It is specifically localised at the
plasma membrane via potential myristoylation/palmitoylation anchors. in vitro binding assays
revealed that smAKAP has an approximate 8 fold nM specificity for PKARIα over PKA-RII
making it a dual-specific AKAP, but as yet the PKARIα substrate associated with this complex is
unknown116. In contrast, sphingosine kinase interacting protein (SKIP) has been described as
the first truly RI-specific mammalian AKAP. Interestingly it contains two AKB sites and is
therefore able to sequester two molecules PKARI of to the inner mitochondrial membrane
where it associates with the PKA substrate ChChd3, a coiled-coil helix protein161.
DAKAP1 is a regulator of mitochondrial dynamics identified in a wide range of tissues including
heart, liver, kidney, skeletal muscle and brain, and is so-named “dual” because it binds to both
type I and type II PKA. The N-terminal mitochondrial targeting sequence localises the protein
to the outer mitochondrial membrane where it has been reported to bind to several proteins
including various isoforms of PP1, RSK1, PDE4 and calcineurin162. The best characterised
effector associated with DAKAP1 is the PKA target dynamin-related protein 1 (Drp1). Drp1 is a
large GTPase that oligomerises to physically constrict mitochondria and induce fission. PKA
phosphorylates Ser637 resulting in Drp1 inhibition163. DAKAP1 promotes PKA-dependent
phosphorylation of Ser637 whilst the calcium-dependent phosphatase calcineurin
dephosphorylates Ser637, to relieve Drp1 inhibition163. In hippocampal neurons, DAKAP1
knockdown induces mitochondrial fragmentation and apoptosis presumably due to inefficient
targeting of PKA to Drp1. Conversely, over-expression of DAKAP1 and consequent Ser637
phosphorylation of Drp1 are neuroprotective, promoting mitochondrial elongation. Expression
of mutant DAKAP1 that cannot bind to PKA is ineffective at promoting neuronal survival,
indicating that appropriate PKA targeting to the mitochondrial membrane is essential for
mitochondrial integrity and neuronal survival163,164.
Genetic polymorphisms and AKAP knockout mice that exhibit symptoms similar to human
diseases reinforce that dysfunction of these scaffold proteins and inappropriate PKA targeting
can result in cardiovascular pathologies (Table 1.2). Thus appropriate targeting of PKA to




AKAP Modification/Intervention Disease outcome
DAKAP2 Genetic polymorphism Ile646Val Increased basal heart rate, reduced
heart rate variability165
AKAP-Lbc Down-regulation by shRNA α1-adrenergic receptor-induced cardiac
hypertrophy156
Knockout mice Defective cardiac development, death
by cardiac arrest166
mAKAP Down-regulation by shRNA Cytokine-and GPCR-induced cardiac
hypertrophy167
Yotiao Genetic polymorphism Ser1570Lys Long Q-T syndrome, cardiac
arrhythmias168
Table 1.2 Dysfunction or deletion of AKAPs in humans or animal models leads to cardiac
pathologies
1.7 PKARIα as an integrator of cAMP and oxidant signals
As previously mentioned the primary focus of this thesis is the redox sensitive RIα isoform of
PKA. PKARIα was first identified as susceptible to disulfide dimer formation in response to
oxidants via diagonal gel electrophoresis followed by proteomic analysis169,170. Conventional
lysate preparation means proteins can be artificially oxidised by oxygen in the air, explaining
why RIα homodimers were previously considered to exist constitutively as a disulfide dimer.
However these disulfide bonds between the two RIα subunits were in fact inducible in
response to exogenously applied H2O2170. Preparation of the lysates in the presence of an
alkylating agent such as maleimide prevented artificial air oxidation, enabling the authors to
conclude that the disulfide bonds were inducible. Treatment with the NO donor CysNO has
also been shown to induce PKARIα disulfide dimer via a transient S-nitrosation intermediate85.
Remarkably stimulating cardiomyocytes with H2O2 caused simultaneous phosphorylation of
known PKA substrates without elevating cAMP implying that PKA disulfide dimer formation
was a novel mechanism of kinase activation170. It remained unclear if the disulfide bonds
directly activated the kinase as is the case with PKGIα. Furthermore the PKA inhibitor H89 did
not completely attenuate the oxidant-dependent phosphorylation of PKA substrates.




Endogenous mediators of oxidant production have been demonstrated to induce PKARIα
disulfide formation and consequent PKA substrate phosphorylation. Members of this
laboratory have demonstrated that very high (0.1-1 mM) concentrations of monoamines such
as NA and 5-HT are capable of inducing PKARIα oxidation through the oxidative deamination
activity of MAO171. PDGF-BB induced PKARIα disulfide dimer and concomitant phosphorylation
of vasodilator-stimulated phosphoprotein (VASP) that was abrogated when rat glomerular
mesangial cells were pre-treated with the antioxidant diphenylene iodonium172. The authors
proposed the increased intracellular oxidants were NOX1 dependent172. Furthermore Beck et
al. induced PKARIα disulfide formation and consequent increase in VASP phosphorylation with
a cytokine mix of TNFα and IL-1β in rat mesangial cells173. The authors speculate that this may
be due to increased expression of iNOS and consequent OONO- formation rather than growth
factor-mediated oxidation173. Interestingly, the concentration of cAMP was not elevated in
either study highlighting a role for oxidant-dependant PKARIα activation.
A principal aim of this thesis is to determine how formation of disulfide bonds in PKARIα can
result in increased substrate phosphorylation. I hypothesise that the interaction between
PKARIα and AKAPs is critical for redox-dependent substrate phosphorylation. The crystal
structure of the bovine PKARIα D/D domain shows the alignment of Cys16 with Cys37 on
adjacent RIα subunits (17 and 38 respectively in human and mouse), creating the possibility of
two disulfide bonds existing simultaneously under conditions of oxidative stress (Figure
1.11)103. The PKARIα disulfide bonds directly flank the D/D domain and due to their proximity
to the AKAP α-helix, it is reasonable to suggest that the presence or absence of these bonds
may regulate the affinity for which PKARIα binds to AKAPs. This is based on structural data
produced by Sarma et al., who systematically mutated PKARIα Cys-16 and Cys-37 to alanine
residues to prevent disulfide bond formation103. The authors observed a 3-fold and 16-fold
decrease in nanomolar affinity to DAKAP2 respectively compared to wild-type PKARIα. They
reported that disulfide bond formation decreases the flexibility of the overall structure of the
molecule, enabling the assembly of binding pockets for the AKB, whilst simultaneously bringing
critical residues into close contact with the AKAP to improve binding (Figure 1.12). Thus the
observation that oxidants increase phosphorylation of specific PKA substrates can potentially
be explained by increased affinity to its associated AKAP. Investigating the potential oxidant-
dependent PKARIα-AKAP interaction is justified given their importance in governing
physiological responses. Furthermore oxidant-dependent interactions between PKARIα and
AKAPs would create a new paradigm, whereby PKARIα integrates cAMP and oxidant signals to





Figure 1.11 PKARIα forms inducible disulfide dimer. (A) Schematic of the PKARIα D/D domain.
Cys17 and Cys38 face each other on opposing RIα subunits. Interprotein disulfide bond
formation is inducible in the presence of an oxidant such as H2O2. (B) Crystal structure of RIα
D/D (gold and grey). Ball and stick model of disulfide bonds formed between Cys16 and Cys37
(bovine residues) on opposing RIα subunits are indicated with black arrows. Figure adapted
from Sarma et al. 2010103
Figure 1.12 PKARIα disulfide bonds directly flank the AKAP helix. Cartoon and crystal
structure of the RIα D/D domain (grey and gold) bound to DAKAP2 helix (red). Mutation of the
Cys16-Cys37 disulfide bonds of RIα that directly flank the AKAP helix have been shown to
decrease RIα and DAKAP2 affinity. Figure adapted from Sarma et al. 2010103
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Figure 1.13 Increased PKARIα disulfide dimer affinity for AKAP may lead to elevated
substrate phosphorylation.
1.8 Aims of the thesis
The primary effector of cAMP, PKA, is an enzyme involved in a wide variety of cellular
processes within the cardiovascular system. The PKARIα isoenzyme forms a disulfide dimer in
response to oxidants but the physiological consequences of this ‘redox switch’ are unknown. I
hypothesise that the disulfide dimer increases affinity for AKAPs which consequently leads to
enhanced phosphorylation of any associated substrates. This thesis is an attempt to ascertain
the biochemical and functional effects of concomitant cAMP and oxidant signals on PKARIα
disulfide and activity.
The following will be investigated:
 To determine whether cAMP can promote or inhibit PKARIα disulfide bond
formation
 To determine whether PKARIα can synergise cAMP and oxidant signals to
enhance substrate phosphorylation
 To determine whether PKARIα disulfide dimer has increased affinity for AKAPs
 To identify potential substrates in AKAP complexes that are differentially
phosphorylated by PKARIα disulfide dimer, and subsequently investigate the
functional effects of this interaction
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Chapter 3 documents that co-treatment of HEK 293 cells with cAMP and H2O2 leads to
enhanced PKA substrate phosphorylation compared to cAMP or H2O2 alone, hypothetically due
to enhanced PKARIα interaction with AKAPs. Chapter 4 describes the development and
optimisation of the PEG-maleimide switch assay, a novel method that can be used to
determine if a candidate protein is susceptible to reversible oxidative modifications. Chapter 4
also attempts to interrogate whether PKARIα disulfide dimer has enhanced affinity for AKAPs
using cAMP tethered to agarose beads as bait. Whilst this method yielded inconclusive results,
it led to the unexpected observation that cAMP can induce the reduction of PKARIα. Chapter 5
explores this observation of cAMP-mediated reduction of disulfide PKARIα further, which led
to the identification of tubulin as a redox sensitive AKAP. Tubulin forms a transient disulfide
with PKARIα in the presence of oxidants that enhances the interaction between the two
proteins. Chapter 6 investigates the consequences of this redox-dependent PKARIα-tubulin
interaction and identifies the microtubule associated protein, Rho guanine nucleotide
exchange factor (GEF-H1), as a PKARIα substrate. Interestingly, H2O2 potentiates GEF-H1
phosphorylation in a PKARIα disulfide dimer dependent manner, which may have physiological
implications is pathologies such as sepsis. Thus PKARIα is a co-incidence detector that is






All materials used throughout this thesis were purchased from Sigma-Aldrich (St. Louis, MO)
unless otherwise stated.
2.2 Molecular Biology
2.2.1 Polymerase chain reaction
DNA fragments were amplified with Phusion® High-Fidelity DNA polymerase (New England
Biolabs) according to standard protocols174. Agarose gel (1% agarose in tris acetate
ethylenediaminetetraacetic acid (TAE) buffer) electrophoresis was conducted accordingly. 0.01
% of GelRed Nucleic Acid Gel Stain (Biotium) was added to allow visualisation of DNA. 15 μl of
PCR products were loaded and run until the samples had run to the bottom of the gel, DNA
fragments were subsequently visualised using UV light, excised and extracted with the gel
extraction kit (Qiagen) according to the manufacturer’s protocol.
2.2.2 Bacterial transformations
For cloning and plasmid amplification transformation of E.coli DH5-α (Invitrogen) was
conducted according to standard protocols174. Briefly, DH5-α cells were allowed to thaw on ice
and incubated for 30 min with 1-10 μg of the appropriate DNA plasmid. Cells were
subsequently subjected to heat shock for 45 seconds at 42°C and incubated on ice for a further
2 min. Cells were then diluted in 10x S.O.C medium (2% tryptone, 0.5% yeast extract, 10 mM
NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM glucose) (Invitrogen) and
incubated on a shaker for 1 hour at 37°C. Cells were then spread on agar plates (prepared with
50-100 μg of the appropriate antibiotic from a x1000 stock) and incubated overnight at 37°C.
The next day, one colony was scraped using a sterile pipette tip, added to 5 ml of E.coli LB
broth (with the appropriate antibiotic) and incubated overnight at 37°C ready for plasmid
purification by mini-preparation (Qiagen) according to the manufacturer’s protocols. For maxi-
preparation (Qiagen), 5 ml culture was added to 250 ml LB broth (with the appropriate
antibiotic) and incubated overnight before using the plasmid purification kit. The sequences of





The high sequence identity of PKARIα across species meant experiments concerning disulfide
formation or reversal could be investigated in numerous cell types without expectation that
the species type would influence the outcome (Table 2.1). Myocytes, aortic vascular smooth
muscle cells and endothelial cells are all relevant cell types to study in the context of
cardiovascular physiology. HEK 293 cells are a useful to study protein-protein interactions due
to the ease of which they can be transfected. In experiments where cells were treated,
treatments were for conducted for 10 min unless otherwise stated.
Human       mesgstaaseearslrecelyvqkhniqallkdsivqlctarperpmaflreyferleke
Bovine      mesgstaaseearslrecelyvqkhniqallkdsivqlctarperpmaflreyferleke
Rat         masgsmaaseeerslrecelyvqkhniqallkdsivqlctarperpmaflreyferleke
Mouse       masgsmatseeerslrecelyvqkhniqallkdsivqlcttrperpmaflreyferleke
* *** *:*** ****************************:*******************
Human       eakqiqnlqkagtrtdsredeisppppnpvvkgrrrrgaisaevyteedaasyvrkvipk
Bovine      eakqiqnlqkagtrtdsredeisppppnpvvkgrrrrgaisaevyteedaasyvrkvipk
Rat         earqiqslqksgirtdsredeisppppnpvvkgrrrrgaisaevyteedaasyvrkvipk
Mouse       earqiqclqktgirtdsredeisppppnpvvkgrrrrgaisaevyteedaasyvrkvipk
**:*** ***:* ***********************************************
Human       dyktmaalakaieknvlfshlddnersdifdamfsvsfiagetviqqgdegdnfyvidqg
Bovine      dyktmaalakaieknvlfshlddnersdifdamfsvsfiagetviqqgdegdnfyvidqg
Rat         dyktmaalakaieknvlfshlddnersdifdamfpvsfiagetviqqgdegdnfyvidqg
Mouse       dyktmaalakaieknvlfshlddnersdifdamfpvsfiagetviqqgdegdnfyvidqg
********************************** *************************
Human       etdvyvnnewatsvgeggsfgelaliygtpraatvkaktnvklwgidrdsyrrilmgstl
Bovine      etdvyvnnewatsvgeggsfgelaliygtpraatvkaktnvklwgidrdsyrrilmgstl
Rat         emdvyvnnewatsvgeggsfgelaliygtpraatvkaktnvklwgidrdsyrrilmgstl
Mouse       emdvyvnnewatsvgeggsfgelaliygtpraatvkaktnvklwgidrdsyrrilmgstl
* **********************************************************
Human       rkrkmyeeflskvsilesldkwerltvadalepvqfedgqkivvqgepgdeffiilegsa
Bovine      rkrkmyeeflskvsilesldkwerltvadalepvqfedgqkivvqgepgdeffiilegsa
Rat         rkrkmyeeflskvsilesldkwerltvadalepvqfedgqkivvqgepgdeffiilegta
Mouse       rkrkmyeeflskvsilesldkwerltvadalepvqfedgqkivvqgepgdeffiilegta
**********************************************************:*
Human       avlqrrseneefvevgrlgpsdyfgeiallmnrpraatvvargplkcvkldrprfervlg
Bovine      avlqrrseneefvevgrlgpsdyfgeiallmnrpraatvvargplkcvkldrprfervlg
Rat         avlqrrseneefvevgrlgpsdyfgeiallmnrpraatvvargplkcvkldrprfervlg
Mouse       avlqrrseneefvevgrlgpsdyfgeiallmnrpraatvvargplkcvkldrprfervlg
************************************************************
Human       pcsdilkrniqqynsfvslsv
Bovine      pcsdilkrniqqynsfvslsv
Rat         pcsdilkrniqqynsfvslsv
Mouse       pcsdilkrniqqynsfvslsv
*********************
Table 2.1 Sequence alignment of PKARIα in species used throughout this thesis (cysteines of
interest highlighted in red).
2.3.1 Cardiomyocytes
Adult rat ventricular myocytes (ARVM) were isolated from male Wistar rats (250–300 g,
Charles River) by collagenase-based enzymatic digestion and was performed by Dr. Shiney Reji
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as previously described175. After isolation, cardiomyocytes were washed at room temperature
with serum-free M199 culture medium (#31150, Invitrogen) modified with 2 mM creatine, 2
mM carnitine and 5 mM taurine and 1% (vol/vol) penicillin/streptomycin (P/S) before plating. 6
well plates were pre-coated with laminin (Sigma) for 2 hours prior to the plating. Once plated
cardiomyocytes were then allowed to adhere for 90 min in an incubator (37 °C, 95% air/5%
CO2). At this point, the culture medium was replaced with fresh serum-free modified M199
medium and incubated overnight. The following day cells were treated and harvested in non-
reducing SDS-PAGE sample buffer containing 100 mM maleimide.
2.3.2 Vascular smooth muscle cells
Vascular smooth muscle cells (VSMCs) were isolated from the aorta of 8-10 week old mice by
dissection from connective tissue and collagenase-based enzymatic digestion. Cells were
washed at room temperature with Gibco® DMEM (#31966-047, Invitrogen) and 10% vol/vol
foetal calf serum (Invitrogen) and stored in liquid nitrogen until ready for use. In preparation
for experimental interventions cells were thawed and maintained in Gibco® DMEM
supplemented with 10% vol/vol foetal calf serine and 1% vol/vol P/S. Cells were subsequently
seeded onto 12-well plates to ~80% confluency and incubated overnight. The following day
cells were treated and subsequently harvested directly into SDS-PAGE sample buffer
containing 100 mM maleimide. Cells were used between passage 3-7.
2.3.3 Human embryonic kidney 293 cell culture and transfections
Human embryonic kidney 293 cells (HEK 293) obtained from American Type Culture Collection,
(Manassas, VA, USA) were maintained in Gibco® DMEM (#31966-047, Invitrogen)
supplemented with 10% vol/vol foetal calf serum and 1% vol/vol P/S. In preparation for
experimental interventions HEK 293 were seeded onto 12-well plates or T75 flasks. The
following day DNA was transfected into cells that were ~80% confluent using Lipofectamine®
2000 (Invitrogen) according to the manufacturer’s protocol. Cells were treated and harvested
between 24-72 hours depending on the experiment. Cells were used between passage 3-20.
2.3.4 Bovine aortic endothelial cells
Bovine aortic endothelial cells (BAECs) (Cell Applications, B304K-05) were maintained in Gibco®
DMEM supplemented with 10% (vol/vol) foetal calf serum and 1% (vol/vol) P/S. For
experimental treatments, BAECs were grown until 80% confluent before being starved
overnight in DMEM containing 1% (vol/vol) P/S without FBS. The following day cells were
treated and subsequently harvested directly into SDS-PAGE sample buffer containing 100 mM




Unless indicated, all cells were cultured and treated in full media. In some indicated
experiments cells were serum starved. For this, cell culture was replaced with the equivalent
media that was free of serum, 24 hours prior to treatment.
2.4 Langendorff perfusion
Langendorff perfusions throughout this thesis were performed by various members of the
Eaton lab, and are described in full here176. Briefly, hearts were excised from anesthetised rats,
cannulated and perfused with Krebs buffer (118 mmol/L NaCl, 4.75 mmol/L KCl, 1.18 mmol/L
KH2PO4, 25 mmol/L NaHCO3, 1.19 mmol/L MgSO4 and 11 mmol/L glucose) under constant
pressure. Each heart was aerobically perfused for 20 min before treatment. Hearts were then
perfused for an additional 10 min with Krebs buffer alone (control) or H2O2. Hearts were snap
frozen in liquid nitrogen and homogenised in 100 mM Tris pH 7.4 and protease inhibitor
cocktail (Roche) to make a 10% weight to volume homogenate.
2.5 SDS-polyacrylamide electrophoresis and immunoblotting
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was performed using
BioRad Protean system. 5-15 μl of sample was loaded into the wells of each gel which were
made according to Table 2.2.
Resolving Stacking
8% 10% 12% 12.5% 15% -
1M Tris-HCl pH8.8 (ml) 3.8 3.8 3.8 3.8 3.8 -
Water (ml) 3.3 2.7 2.04 1.85 1 2.8
Acrylamide solution (ml) 2.7 3.3 3.96 4.15 5 0.6
10% SDS (μl) 100 100 100 100 100 40
TEMED (μl) 10 10 10 10 10 7
10% APS (μl) 90 90 90 90 90 75
1M Tris-HCl pH6.8 (ml) - - - - - 0.48
Table 2.2 Composition of different percentage gels used throughout this thesis
Proteins were separated by one-dimensional SDS-PAGE and then transferred onto
polyvinylidene fluoride (PVDF) membranes (GE Healthcare, UK) using a semi-dry transfer
blotter. All gels were run under non-reducing conditions unless otherwise stated. Blocking of
PVDF membranes were performed using PBS-Tween-20 containing 10% (wt/vol) non-fat milk
(Premier International Foods, UK) powder. The membranes were incubated with agitation for
3 hours at room temperature or overnight at 4 °C with a primary antibody diluted in PBS-
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Tween-20 containing 2% (wt/vol) non-fat milk. Membranes were subsequently washed for 1
hour, changing the PBS-Tween buffer regularly and then incubated with a HRP-conjugated
secondary antibody for 1 hour at room temperature (Table 2.3). After washing the membrane
with PBS-Tween, changing the buffer regularly, the membrane was subjected to
chemiluminescence detection according to the manufacturers protocol (ECL, Thermo Scientific
Pierce, Illinois, US) and blots were developed onto autoradiographic film (GE healthcare, UK)
using a film developer (Fuji, JPN). Digitised immunoblots were quantitatively analysed using
Gel-Pro Analyzer 3.1.
Antibody Company Dilution
Anti-mouse IgG HRP Cell Signaling 1:1000
Anti-goat IgG HRP Dako 1:1000
Anti-rabbit IgG HRP Cell Signaling 1:1000
Table 2.3 Secondary antibodies used in throughout this thesis
2.5.1 Immunoblot controls
It was established that acute treatment of cells (10 min) with an agent that elevates cAMP,
H2O2, or co-treatment with both, did not cause any cell/protein loss as determined by a marker
protein. Figure 2.1 is a representative immunoblot from HEK 293 cells that demonstrates this,
with anti-tubulin being used to detect the marker protein. Furthermore, immunoblots that
were probed with PKARIα do not necessarily require loading controls, as they are quantified as
percentage of dimer relative to the total amount of PKARIα in the sample, thus in this sense,
PKARIα acts as its own control. As such it was not always necessary to run a loading control.
Loading controls were run as standard for all experiments conducted with animals due to the
increased chance of variability from organ harvest and processing.
Figure 2.1 Representative tubulin immunoblot demonstrating equal sample loading in HEK
293 cells. 8-CPT-cAMP and H2O2 for 10 minutes were standard treatments used throughout
the thesis. Tubulin is a standard protein used as a loading control and remains unchanged




HEK 293 cells or VSMCs were fixed with 4 % paraformaldehyde in PBS for 10 min at room
temperature, washed in PBS and permeabilised with 0.2% Triton X-100 in PBS for 5 min . To
avoid non-specific antibody binding the cells were incubated with blocking buffer (5% non-
specific goat serum diluted in 1 % bovine serum albumin, Tris-base 20 mmol/L, NaCl 155
mmol/L, EGTA 2 mmol/L, MgCl2 2 mmol/L, pH 7.5) for 1 hour at room temperature. Cells were
incubated in primary antibodies diluted (1:100) in blocking buffer overnight at 4 °C and washed
with PBS the next day. Cy3-conjugated anti-rabbit (Jackson ImmunoResearch) and Cy5-
conjugated anti-mouse (Jackson ImmunoResearch) secondary antibodies were used in a 1:100
dilution for 1 hour at room temperature. Diamidine-2-phenylindole dihydrochloride (D8417,
Sigma) was added with the secondary antibodies to stain the nucleus. Slides were viewed using
a laser scanning confocal microscope (Zeiss LSM510).
2.7 Animals
Animals received humane care in compliance with the Principles of Laboratory Animal Care
formulated by the National Society for Medical Research and the Guide for the Care and Use of
Laboratory Animals prepared by the National Academy of Sciences and published by the
National Institutes of Health.
2.8 Statistical Analysis
Quantitative data are presented as mean ± standard error of the mean (SEM). In cell
experiments, n= replicate measurements in n different cultures. Statistical analysis was
conducted with Students’ t-tests, one-way or two-way analysis of variance (ANOVA), followed
by post hoc Tukey corrections where applicable. Statistical analysis was carried out using
GraphPad Prism (GraphPad Software, Inc). p-values of <0.05 were considered significant.
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3 Assessing the effect of concomitant cAMP and H2O2
signals on PKARIα disulfide and PKA phosphorylation
events
3.1 Introduction
3.1.1 Compartmentalised cAMP signalling
How can a cell produce a specific response when a single molecule is responsible for
transducing multiple input signals? This question, which is especially pertinent to cAMP
signalling, is important to address. Numerous factors contribute to the localisation and
duration of a cAMP signal, for example, the isoform of adenylate cyclase and the type of GPCR
can be constrained to distinct locations within the plasma membrane and determine precisely
where the cAMP is generated177. Historically it was confounding that prostaglandins could
activate Gαs-coupled EP2 and EP4 receptors to elevate intracellular cAMP levels but did not
produce the same functional effects as β-adrenoceptor activation. Heyes et al. first
demonstrated that both isoprenaline and prostaglandin E1 (PGE1) were capable of increasing
cAMP content in mammalian hearts to similar levels but only isoprenaline activated glycogen
phosphorylase and enhanced ventricular pressure development178. Furthermore PGE1
appeared to activate PKA in the soluble fraction of hearts but not in the particulate fraction,
whilst isoprenaline induced cAMP elevation primarily in the particulate. This evidence lead to
the postulation of “hormonally specific compartmentation of cyclic AMP and cAMP-dependent
protein kinase”179.
The physiochemical properties of cAMP mean that it is free to rapidly diffuse throughout the
aqueous cellular environment102. This would ostensibly contradict any perceived notion of
compartmentalised cAMP signalling. Föster resonance energy transfer (FRET), a phenomenon
whereby the excited state energy of a donor fluorophore is transferred to a nearby acceptor
fluorophore, which then emits its own characteristic fluorescence, has been utilised to visually
detect changes in subcellular cAMP concentrations in real time180. These FRET probes are
constructed from cyclic nucleotide binding domains and upon cAMP binding the transfer of
energy significantly increased, providing biosensors that allow cAMP compartmentalisation to
be monitored181,182. Such probes have confirmed that upon hormonal stimulation cAMP is
elevated in discrete microdomains within the cell rather than increasing globally182,183.
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Inhibition of PDEs abolishes these microdomains leading to ‘leakage’ of cAMP across
subcellular compartments. Thus PDEs ensure compartmentalisation of cAMP and prevents its
unabated cell-wide diffusion184,185. Isoform-specific PDE inhibitors demonstrated that PDE3 or
PDE4 are responsible for degrading β-adrenergic-derived cAMP signals whilst PDE4 subtypes B
and D are responsible for degrading those triggered by PGE1181,185. This suggests that the cell is
organised to convey precise messages and cAMP is generated and terminated in distinct
subcellular locations, by specific mediators, to ensure explicit control of the hormonal input.
The formation of these cAMP microdomains has been attributed to AKAPs that bind to PDEs
and assemble the signalling complexes. As such, AKAPs co-ordinate and regulate the location
and duration of the cAMP signal and consequently the extent of PKA substrate
phosphorylation186.
3.1.2 PGE1 elevates cAMP in type I PKA domains
Activation of different GPCRs leads to elevation of cAMP in specific subcellular
microdomains181. Furthermore, all four PKA isozymes expressed in cardiomyocytes
demonstrate distinct subcellular localisation. Type I PKA, which this thesis focuses on, is
associated with the cytosol whereas Type II PKA is purified in the particulate fraction of cell
lysates187. Differential cAMP production in these locations where the expression of the PKA
isozymes differs provides a further level of regulation to cAMP signalling. FRET sensors linked
to the AKAP binding regions of RI and RII have been used to monitor cAMP concentration in
their respective specific subcellular regions after myocytes were challenged with a GPCR
agonist. The RI sensor, but not the RII sensor, detected an elevation in cAMP after cells were
challenged with PGE1. In contrast, isoprenaline caused an elevation in cAMP that was
selectively detected by the RII-based sensor. The authors conclude that PGE1 predominately
activates type I PKA188. This suggests I may be able to use the propensity for PGE1 to elevate
cAMP in RI domains to identify potential PKARIα-specific substrates.
3.1.3 Substrate-induced dissociation of PKARIα
Central to this thesis is investigating how formation of PKARIα disulfide bonds results in
increased phosphorylation of the kinases substrates? As highlighted in Chapter 1.7, I
hypothesise that the interaction between PKARIα and AKAPs is necessary for its redox-
dependent substrate phosphorylation. Cys16Ala mutation of PKARIα decreased its affinity for
DAKAP2103 and due to the proximity of the disulfide bonds to the D/D domain, it is reasonable
to suggest that the presence these bonds may increase the affinity between PKARIα and
AKAPs, and lead to enhanced substrate phosphorylation (Figure 1.10 and 1.11).
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Our understanding that cAMP leads to the physical dissociation of the catalytic subunits is
supported by in vitro ion exchange chromatography, gel filtration and ultracentrifugation
experiments that demonstrated high concentrations of cAMP were necessary to induce
dissociation from the regulatory subunits189. However these methods exert artificial forces
upon the molecules that are not present in cells. As such there is also contradictory evidence
to suggest that PKA can remain associated even in the presence of high cAMP
concentrations189-191. Kopperud et al. acutely observed that addition of substrate could
destabilise the type I holoenzyme192. Small angle x-ray scattering revealed PKA type I, but not
type II, was sensitised to cAMP by the presence of PKA substrate. They found a higher
concentration of PKARIα was necessary to inhibit kinase activity at a given cAMP concentration
if substrate was present189,193. In other words, cAMP induces partial dissociation of the
holoenzyme whilst cAMP and substrate together leads to full dissociation of PKARIα but not
PKARII (Figure 3.1).
This substrate-induced dissociation may be a physiological means to enhance substrate
phosphorylation at a given concentration of cAMP. It is particularly interesting given that the
phenomenon is restricted to PKARIα, the only PKA isoform that forms disulfide bonds. Taken
together, the hypothesised increase in affinity between PKARIα disulfide dimer and AKAPs
could be a means to localise PKARIα to its substrates within an assembled complex and
consequently undergo substrate-induced dissociation to enhance phosphorylation.
3.1.4 cAMP-dependent modulation of PKARIα disulfide dimer
As previously mentioned our laboratory also identified PKG, another AGC kinase, as being
modified by oxidants to form a disulfide bond dimer. Interestingly binding of PKGIα to cGMP,
its associated nucleotide, precludes its ability to form a disulfide dimer194. Although there is no
complete crystal structure available for PKGIα, cGMP blockade of the interprotein disulfide is
likely due to the conformational change induced by nucleotide binding that increases the
distance between the two cysteines involved in disulfide formation194. Whether cAMP can also
prevent PKARIα disulfide bond formation is still uncertain, but if so, this would likely regulate
PKARIα mediated oxidant-dependent substrate phosphorylation. In fact, agents capable of
simultaneously elevating intracellular cAMP and also inducing disulfide dimer formation would
be interesting in the context of PKARIα oxidant activation. Monoamines, including
noradrenaline and serotonin, are capable of increasing cAMP concentration via β-
adrenoceptor and serotonin receptor agonism respectively. In addition, members of this
laboratory demonstrated that these monoamines, albeit at millimolar concentrations, are
capable of inducing PKARIα oxidation through the oxidative deamination activity of MAO
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which generates H2O2. Furthermore pharmacological inhibition of MAO ablated the increase in
PKARIα disulfide dimer formation171. PKARIα potentially represents a point of convergence
between oxidant and cAMP signals and may be able to conflate them to dictate specific
phosphorylation events.
The primary aim of this chapter was to characterise the effects of cAMP on oxidant-induced
PKARIα disulfide dimer formation. A key finding is that cAMP and oxidants act synergistically to
enhance PKA substrate phosphorylation. I also present evidence that cAMP can modulate
PKARIα expression, providing another mechanism, in addition to alterations to redox state, by
which the amount of disulfide kinase may be modulated by the cell.
Figure 3.1 Substrate-induced dissociation of PKARIα holoenzyme. Substrates sensitise the
PKARIα to cAMP; a feature that is specific to this isoform.




Antibody Purchase Code Company Species Dilution








PKARIIα 612242 BD Transduction
Laboratories
Mouse 1:1000
PKACα 610980 BD Transduction
Laboratories
Mouse 1:1000
Calsequestrin PA1 Thermo Scientific Rabbit 1:1000
Table 3.1 Antibodies used in Chapter 3
3.2.2 Cardiac hypertrophy by suprarenal aortic constriction
Myocardial hypertrophy induced by pressure overload following suprarenal aortic constriction
was performed by Dr. Andrii Boguslavskyi and is described in full here195. Briefly, 6-week-old
C57BL/6J mice (20-22 g) were anesthetized by inhalation of isoflurane/O2 mixture (2/98%) and
aortic constriction was performed by placing a suture around the abdominal aorta and a 28-
gauge blunted needle stent, which was subsequently removed. Sham surgery was an identical
procedure with the exception of band placement. After 3 or 14 days hearts were harvested,
dissected and left ventricles were frozen and stored at -80°C. Left ventricle homogenates (10%
w/v) were re-suspended in reducing SDS-PAGE buffer (5% 2-mercaptoethanol).
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3.3 Results
3.3.1 H2O2 induces PKARIα dimerisation
Increasing concentrations of H2O2 (50-500 μM) induced PKARIα disulfide dimer formation in
adult rat ventricular myocytes (ARVM) and HEK 293 cells in a dose-dependent manner (Figure
3.2A). The disulfide dimer was fully reducible upon the addition of 2-mercaptoethanol
confirming the observation that had been previously described by the group (Figure 3.2B).
Due to their inherent relevance in the cardiovascular system it could be argued that cultured
ARVMs should be the cell type of choice when characterising PKARIα dimerisation. However
ARVMs tended to have a high basal rate of kinase oxidation likely induced by to the stress of
the isolation. This was a problem when attempting to detect differences in PKARIα oxidation
after treatments in this cell type. Furthermore, the basal dimerisation between isolations was
more widely varied than HEK 293 cells (Figure 3.3). This meant that comparing results between
different experiments was extremely challenging. Therefore in many of the following
characterisation experiments other cells lines including HEK 293 cells, VSMCs or BAECs were
used. Whilst there was still some baseline variability in the percentage of PKARIα disulfide
dimer these preparations were acceptably consistent and are also pertinent models.
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Figure 3.2 H2O2 induces disulfide bond dimerisation in PKARIα. Treatment of cells with H2O2
(50-500 μM) caused dose-dependent disulfide bond formation which was fully reducible upon
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Figure 3.3 Preparations of adult rat ventricular myocytes had variable baseline PKARIα
disulfide dimer. 5 separate isolations of adult rat ventricular myocytes were cultured
overnight and PKARIα was detected by immunoblotting. The percentage PKARIα dimer of each
preparation is plotted in the graph below.
50 -
100 -
1 2 3 4 5Prep No.
IB:PKARIα
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3.3.2 Investigating the role of agents that elevate cAMP on PKARIα dimerisation
Since PKARIα is able to sense the oxidative state of the cell through disulfide dimer formation
and is a kinase that is activated by elevated levels of intracellular cAMP, an agonist that could
produce both effects concomitantly would be interesting for further investigation. Monoamine
deamination via MAO in freshly isolated and cultured cardiomyocytes induces PKARIα
disulfide171, however there was no indication of whether this mechanism of PKARIα oxidation
was present in HEK 293 cells. To determine if the catalysis of monoamines by MAO induced
PKARIα oxidation in HEK 293 cells, cells were treated with increasing concentrations of
noradrenaline or serotonin (1 nM – 1 mM) for 30 min, however there was no evidence of
PKARIα oxidation post treatment (Figure 3.4).
Another elevator of intracellular cAMP in the cardiovascular system is PGE1-dependent
activation of EP receptors. Receptor-mediated oxidation of proteins via NOX is a phenomenon
that has been attributed to the angiotensin II receptor and a subset of receptor tyrosine
kinases including the insulin receptor. I could find no evidence in the literature to suggest that
EP receptors are coupled to NOX enzymes, but investigating the possibility that PGE1 could
induce PKARIα dimerisation was still considered worthwhile. AVRMs, HEK 293 or BAEC cells
were treated with 10 μM PGE1 for 30 min to assess the formation of PKARIα dimerisation post
treatment via immunoblotting but kinase oxidation was not observed in any of the cell types
(Figure 3.5).




Figure 3.4 Monoamines do not induce PKARIα disulfide dimerisation in HEK 293 cells. Serum
starved HEK 293 cells were treated with either (A) noradrenaline or (B) serotonin (1nM- 1 mM)













Figure 3.5 PGE1 does not induce PKARIα disulfide dimerisation. (A) Serum starved HEK 293
cells (B) ARVMs (C) BAECs were treated with PGE1 (1 or 10 μM) for 30 min. The percentage of
PKARIα disulfide dimer was analysed after detection of PKARIα by immunoblotting and is
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3.3.3 Investigating the role of cAMP in PKARIα disulfide dimer formation
The conformational change induced in PKARIα upon cAMP binding may prevent the formation
of the PKARIα disulfide bonds in a similar way that cGMP binding to PKGIα precludes its
dimerisation194. Conversely, the conformational change upon cAMP binding may enhance
PKARIα disulfide dimer formation. In order to determine the effect of cAMP on PKARIα
disulfide bond formation HEK 293 cells were pre-treated with the β-adrenergic receptor
agonist isoprenaline, which leads to increased intracellular cAMP, and subsequently treated
with 50 μM or 500 μM H2O2. Isoprenaline treatment did not significantly modulate PKARIα
disulfide dimerisation at either of the H2O2 concentrations used (Figure 3.6).
Receptor-mediated cAMP elevation will increase cAMP only in specific subcellular
compartments. Compartmentalisation of cAMP production may limit its binding to subtypes of
PKA other than PKARIα, and therefore limit the potential to detect any effect it may have on
disulfide dimerisation. To overcome this potential issue that may occur due to
compartmentalisation of cAMP using receptor mediated cAMP elevation, cells were treated
with a stable, cell-permeable form of cAMP, 8-CPT-cAMP. Treatment of cells with 100 μM 8-
CPT-cAMP either prior to, or post-application of 500 μM H2O2 did not significantly alter the
formation of the PKA disulfide bond (Figure 3.7).
Figure 3.6 Isoprenaline does not modulate PKARIα disulfide dimerisation. HEK 293 cells were
treated with isoprenaline (10 nM) for 10 min and subsequently treated with H2O2 (50 or 500
μM) for 10 min. The percentage of PKARIα disulfide dimer was analysed after detection of
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A
Figure 3.7 8-CPT-cAMP does not inhibit or reverse PKARIα dimerisation in rat vascular
smooth muscle cells. (A) VSMCs were treated with 8-CPT-cAMP (100 μM) for 10 min and
subsequently treated with H2O2 (500 μM) for 10 min or, (B) treated with H2O2 (500 μM) for 10
min and then 8-CPT-cAMP (100 μM) for 10 min. The percentage of PKARIα disulfide dimer was
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The inability to detect any significant changes in PKARIα monomer/dimer ratio after cAMP
elevation may be due to the length of time cells were exposed to cAMP or H2O2. Given more
time cAMP may occupy more PKARIα binding sites, and as such the duration of 8-CPT-cAMP
pre-treatment was extended to investigate whether this would alter the PKARIα disulfide
formation in HEK 293 cells after H2O2 treatment. Figure 3.8 shows the revised experimental
plan. However even with this expanded protocol where HEK 293 cells were pre-treated with 8-
CPT-cAMP for between 0.5 and 30 min prior to treatment with H2O2 (50 or 500 μM), there
were no significant differences in PKARIα disulfide formation at any time point (Figure3.9).
Figure 3.8 Revised experimental protocol to investigate potential for 8-CPT-cAMP to
modulate PKARIα disulfide dimer.
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Figure 3.9 8-CPT-cAMP does not modulate PKARIα disulfide dimerisation in HEK 293 cells.
HEK 293 cells were treated with 8-CPT-cAMP (100 μM) for 0-30 min and subsequently treated
with (A) 500 μM H2O2 or (B) 50 μM H2O2 for 10 min. The percentage of PKARIα disulfide dimer
was analysed after detection of PKARIα by immunoblotting and is represented in the
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Further experiments were conducted to elucidate whether cAMP could modulate the PKARIα
disulfide dimer. In the following studies cells were pre-treated with H2O2 and subsequently
treated with 8-CPT-cAMP to determine if cAMP could regulate PKARIα disulfide as indicated in
the experimental protocol (Figure 3.10). Treatment of cells with 8-CPT-cAMP did not
significantly alter PKARIα disulfide dimer regardless of the length of time cells were exposed to
H2O2 at either high or low concentrations (Figure 3.11). In another experiment to investigate
whether cAMP could reverse PKARIα disulfide dimerisation HEK 293 cells were pre-treated
with H2O2 (400 μM) to induce the disulfide, the culture media was subsequently removed and
cells were then treated with 8-CPT-cAMP or vehicle in fresh media. PKARIα disulfide dimer was
monitored over 6 hours. There was no difference in the rate of PKARIα disulfide reduction
between vehicle and 8-CPT-cAMP treated cells (Figure 3.12). Taken together these
experiments suggest that pre-treatment with cAMP does not inhibit or reverse PKARIα
dimerisation, although this will be explored further in Chapter 5.
Figure 3.10 Experimental protocol to investigate 8-CPT-cAMP modulation of PKARIα disulfide
dimer.
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Figure 3.11 8-CPT-cAMP does not reverse PKARIα disulfide dimerisation in HEK 293 cells. HEK
293 cells were treated with (A) 500 μM H2O2 or (B) 50 μM H2O2 for 0-30 min and subsequently
treated 8-CPT-cAMP (100 μM) for 10 min. The percentage of PKARIα disulfide dimer was












Figure 3.12 8-CPT-cAMP does not increase the rate of PKARIα disulfide reduction. (A)
Experimental protocol for monitoring 8-CPT-cAMP reduction of PKARIα disulfide. (B) HEK 293
cells were treated with 400 μM H2O2 10 min and subsequently treated with 8-CPT-cAMP (100
μM) in fresh culture media for between 10-360 min. The percentage of PKARIα disulfide dimer
at each time point was analysed after detection of PKARIα by immunoblotting and is
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3.3.4 Investigating the role of PGE1 and isoprenaline on PKA substrate phosphorylation
Activation of β-adrenergic receptors or EP receptors leads to cAMP elevation in distinct
subcellular locations leading to specific functional effects. Furthermore PGE1-dependent EP
receptor activation leads to elevated cAMP in subcellular compartments specific to type I PKA.
Therefore substrates that are phosphorylated after PGE1 treatment but not isoprenaline could
potentially be type I PKA-specific substrates.
PKA phosphorylation events can be monitored using immunoblotting with an antibody that
pan-specifically recognises the PKA phosphorylation consensus motif Arg-Arg-X-pSer/pThr. To
investigate potential type I PKA specific substrates ARVMs were treated with PGE1 or
isoprenaline for 10 min. The PKA substrate antibody detected bands at various molecular
weights which represented distinct PKA substrates. In AVRMs numerous proteins were basally
phosphorylated as demonstrated by the presence of bands in the absence of any intervention.
After treatment with 10 nM isoprenaline the signal from some bands became more intense,
and additional bands were detected indicating increased β-adrenergic receptor-dependent
phosphorylation of these substrates. H2O2 treatment also induced PKA substrate
phosphorylation as has been previously described170. However treatment with PGE1 (1 or 10
μM) did not appear to cause any additional phosphorylation of proteins above basal levels, nor
did it cause the appearance of additional bands (Figure 3.13).
The ability of PGE1 to induce substrate phosphorylation was also assessed in other cell types in
order to determine if the lack of detectable phosphorylation was specific to ARVMs. ARVMs,
HEK 293 cells and bovine aorta endothelial cells (BAECs) were treated with either 1 or 10 μM
PGE1. The pan-specific PKA substrate antibody detected an increase in PGE1-induced protein
phosphorylation in HEK 293 cells only, and therefore HEK 293 cells were selected as the cell
type of choice to investigate potential differences between PGE1- and isoprenaline-induced
phosphorylation (Figure 3.14).
HEK 293 cells were then treated with either PGE1 or isoprenaline to determine if there was
differential substrate phosphorylation, as monitored by immunoblotting with the pan-specific
PKA substrate antibody. There was no difference in the banding pattern between isoprenaline-
or PGE1-treated cells, and therefore this approach using was considered not viable for
identifying type I PKA-specific substrates (Figure 3.15).
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Figure 3.13 Isoprenaline or H2O2 but not PGE1 induces PKA-dependent substrate
phosphorylation in adult rat ventricular myocytes. ARVMs were treated with isoprenaline (1
or 10 nM), PGE1 (1 or 10 μM) or H2O2 (200 μM) for 10 min. PKA substrate phosphorylation was
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Figure 3.14 PGE1 induces PKA-dependent substrate phosphorylation in HEK 293 cells but not
ARVMs or BAECs. (A) HEK 293 (B) ARVM (C) BAEC cells were treated with PGE1 (1 or 10 μM) for
10 min. PKA substrate phosphorylation was assessed with a pan specific PKA substrate
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Figure 3.15 Isoprenaline or PGE1 induce the phosphorylation of the same substrates in HEK
293 cells. HEK 293 cells were treated with either isoprenaline (10 nM) or PGE1 (10 μM) for 10
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3.3.5 The acute effects of cAMP and H2O2 co-treatment on PKA-dependent substrate
phosphorylation
Elevated levels of both cAMP and oxidants together may occur simultaneously in physiological
or pathophysiological conditions in cells. As outlined above, I hypothesise that disulfide
formation in PKARIα increases its affinity for certain AKAP proteins. These AKAPs have specific
substrates they co-localise with, which would then be phosphorylated as a result of this
oxidant-induced complex formation. If this hypothesis is correct, one might predict that
treating cells with H2O2 to induce disulfide PKARIα and then consecutively or simultaneously
treating them with an agent that elevates intracellular cAMP would cause substrate
phosphorylation to a greater extent than cAMP alone. It was therefore important to
investigate cAMP elevating agents applied simultaneously with exogenously applied H2O2 and
attempt to model PKA substrate phosphorylation in this setting.
Initially VSMCs were used to try and model the effect of cAMP and H2O2 co-treatment on PKA
substrate phosphorylation due to their relevance in the cardiovascular system. Cells were pre-
treated with H2O2 for 10 min and then isoprenaline or PGE1 for a further 10 min and compared
against H2O2 or isoprenaline or PGE1 alone, as outlined in the experimental protocol (Figure
3.16).
Figure 3.16 Experimental protocol to investigate co-treatment of isoprenaline or PGE1 and
H2O2 on PKA substrate phosphorylation
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Various substrates were more phosphorylated after co-treatment compared to PGE1 or
isoprenaline or H2O2 alone, whilst others appeared to decrease (Figure 3.17). Due to the more
robust phosphorylation profile observed in HEK 293 cells, especially with PGE1 treatment, the
experiment was repeated using this cell line. When the total signal corresponding to PKA
phosphorylation events were summated, there was approximately a 2-fold increase in total
phosphorylation between vehicle treated cells and cells treated with either isoprenaline or
PGE1 (Figure 3.18). There was a slight trend towards increased substrate phosphorylation when
cells were treated with H2O2 alone, although this was not statistically significantly different
from control. There was also a trend towards increased phosphorylation of cells that had been
co-treated with H2O2 and a cAMP elevating agent compared to cells that had been treated
solely with isoprenaline or PGE1 alone (Figure 3.18).
Figure 3.17 Co-treatment with H2O2 together with isoprenaline or PGE1 potentiates
phosphorylation of specific PKA substrates. VSMCs were treated with H2O2 (250 μM) for 20
min, either isoprenaline (10 nM) or PGE1 (10 μM) for 10 min, or pre-treated with H2O2 for 10
min before subsequent treatment with either isoprenaline (10 nM) or PGE1 (10 μM). PKA
substrate phosphorylation was assessed with a pan specific PKA substrate antibody by
immunoblotting. Green arrows indicate substrates that have elevated phosphorylation relative
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Figure 3.18 Co-treatment with H2O2 and isoprenaline or PGE1 leads to increased ‘total’
phosphorylation of substrates in HEK 293 cells. HEK 293 cells were treated with H2O2 (500
μM) for 20 min, either isoprenaline (10 nM) or PGE1 (10 μM) for 10 min, or pre-treated with
H2O2 for 10 min before subsequent treatment with either isoprenaline (10 nM) or PGE1 (10
μM). PKA substrate phosphorylation was assessed with a pan specific PKA substrate antibody
by Western blotting. All phosphorylation events are summated and represented graphically for
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3.3.6 Modelling the chronic effects of cAMP and H2O2 co-treatment on PKA dependent
phosphorylation and PKARIα expression
So far the experiments have focused on acute activation of the cAMP signalling pathway and
likewise the application of exogenous ROS over a short time period. Pathologies, such as heart
failure, manifest over sustained period of time and therefore it was also important to
determine if chronic cAMP treatment impacts on PKARIα disulfide levels, PKA substrate
phosphorylation and PKARIα expression. To model a chronic response to cAMP, HEK 293 cells
were treated with vehicle or 8-CPT-cAMP for 6 or 24 hours. At the end of the 8-CPT-cAMP
treatment some cells were then treated with H2O2 to then compare their PKARIα disulfide
dimer and PKA-dependent phosphorylation in response to oxidants. To directly compare the
chronic response with the acute response some cells were also treated with 8-CPT-cAMP, H2O2
or co-treated with both for 10 min. The experimental protocol is outlined in Figure 3.19.
Acute treatment of HEK 293 cells with 8-CPT-cAMP (10 min) lead to an increase in total PKA
substrate phosphorylation. Treatment with 8-CPT-cAMP for 6 or 24 hours also induced PKA
substrate phosphorylation, which was comparable to acute treatment (Figure 3.20). 10 min of
8-CPT-cAMP and H2O2 co-treatment tended towards an increase in total phosphorylation but
this was not was not statistically significant compared to 8-CPT-cAMP treatment alone. There
was also a trend towards increased phosphorylation after 8-CPT-cAMP and H2O2 co-treatment
at both 6 or 24 hours, but again this was not statistically significant (Figure 3.20). Interestingly,
treatment of HEK 293 cells for 24 hours with 8-CPT-cAMP caused an approximate 2-fold
increase in PKARIα expression compared to vehicle treated controls. This increased expression
was detected at the both monomeric and dimeric levels (Figure 3.21). The relative increased
levels of PKARIα disulfide dimer was maintained even after cells had been subsequently
treated with H2O2 (Figure 3.21).
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Figure 3.19 Experimental protocol for investigating the responses of PKARIα following
chronic or acute exposure to 8-CPT-cAMP.
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Figure 3.20 Co-treatment of HEK 293 cells with H2O2 and 8-CPT-cAMP leads to increased
‘total’ phosphorylation of substrates after 10 min, 6 hours and 24 hours. HEK 293 cells were
treated with vehicle or 8-CPT-cAMP (100 μM) for 10 min, 6 hours or 24 hours. Some cells were
then treated with H2O2 (500 μM) for 10 min. PKA substrate phosphorylation was assessed with
a pan specific PKA substrate antibody by immunoblotting. All phosphorylation events are
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Figure 3.21 Treatment of 8-CPT-cAMP leads to increased expression of PKARIα and increased
PKARIα disulfide dimer after 24 hours. HEK 293 cells were treated with vehicle or 8-CPT-cAMP
(100 μM) for 10 min, 6 hours or 24 hours. Some cells were then treated with H2O2 (500 μM) for
10 min. Expression of PKARIα monomer and dimer were evaluated with a PKARIα antibody by
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3.3.7 Investigating PKARIα expression in a cardiac hypertrophy mouse model
It was tempting to conclude that increased cAMP concentrations caused increased expression
of PKARIα. Suprarenal aortic constriction is an animal model that mimics chronic pressure
overload-induced cardiac hypertrophy. Ligation of the aorta leads to compensatory elevated
levels of circulating catecholamines and consequently elevated cardiac cAMP to promote
positive inotropy and chronotropy196. Therefore this was an ideal model to investigate whether
cAMP could increase PKARIα expression in vivo. Male C57BL/6J mice (6 weeks, 20-22g) were
subjected to either sham surgery or aortic banding and protein expression was measured by
immunoblotting on Day 3 or 14 post-surgery. Banded animals had a 3-fold increase in PKARIα
expression on both Day 3 and 14 which was significantly different compared to sham animals.
PKARIIα expression levels were significantly reduced by approximately 20% on Day 3 compared
to sham animals. By Day 14 the deficit in PKARIIα protein concentration was not significantly
different from sham animals. The expression levels of the catalytic subunit of PKA (PKACα) and
calsequestrin remained unchanged at both time points (Figure 3.22).
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Figure 3.22 Aortic banding leads to increased expression of PKARIα and decreased
expression of PKARIIα. C57BL/6J mice underwent sham or aortic banding surgical procedure
and allowed to recover whilst others did not undergo any surgery as an additional control (NS).
Mice were sacrificed on Day 3 or Day 14, hearts were excised and homogenised for analysis by
Western blotting under reducing conditions. Anti-PKARIα, anti-PKARIIα, anti-PKACα and anti-
calsequestrin were developed on separate gels and used to assess protein expression which is
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3.4 Discussion
The studies in this chapter were focused on assessing the effects of cAMP on PKARIα dimer
formation and understanding the effects of cAMP and H2O2 on PKA phosphorylation events.
PKARIα potentially lies at the axis of cAMP and ROS signalling; here I attempted to ascertain
the biochemical consequence of these signal inputs occurring concomitantly. Interestingly, as
hypothesised, there was a trend towards increased global PKA substrate phosphorylation
when cells were co-treated with 8-CPT-cAMP and H2O2.
3.4.1 cAMP modulation of PKARIα disulfide dimer
PKARIα disulfide dimer is induced in a concentration-dependent manner after oxidant
treatment in ARVMs, HEK 293 cells, VSMCs and BAECs. Historically this disulfide was already
known to exist but was previously considered to be constitutive structural bonds197,198.
Furthermore SDS-PAGE is routinely carried out under reducing conditions which prevents
visualisation of disulfide complexes199-201. The oxidant-dependent modification can be detected
because samples are lysed and prepared in the presence of the alkylating agent maleimide.
Alkylation of free thiols prevents artificial oxidation which occurs during lysis when proteins
are removed from the reduced cellular environment and exposed to molecular oxygen in the
air. This intervention is crucial to ensure the oxidative modification that is being detected is
due to experimental intervention.
MAO has been proposed as a potential mediator of PKARIα oxidation due to ROS generation
during oxidative deamination of monoamines25,202. NA or 5-HT are capable of inducing PKARIα
oxidation in cardiomyocytes171 however I was unable to replicate this in HEK 293 cells. MAO-
dependent oxidant generation in HEK 293 cells has been described when the enzyme has been
over-expressed203,204. The lack of endogenous MAO expression or lack of monoamine uptake in
HEK 293 cells may be why PKARIα oxidation was not observed.
Treatment of cells with isoprenaline or PGE1 did not modulate PKARIα disulfide dimer.
Agonism of receptors such as the insulin receptor and the angiotensin II receptor have been
linked to NOX activation and consequent oxidant production205,206. There is a limited literature
that suggests activation of EP receptors is associated with decreased intracellular ROS in
cellular models of Alzheimer’s and oxidative renal medulla injury207,208, however neither EP nor
β-adrenergic receptor agonism modulated PKARIα disulfide dimer in the models used.
As previously discussed cGMP binding to PKGIα precludes the kinase from forming a disulfide
and it was anticipated that cAMP may have an effect on PKARIα via a similar mechanism194.
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However modulation of PKARIα disulfide dimer was not observed in cells treated with 8-CPT-
cAMP. Increasing the amount of time the cells were incubated with 8-CPT-cAMP, or modifying
the concentration of H2O2, did not alter the ability for 8-CPT-cAMP to regulate PKARIα disulfide
dimer formation. There is a considerable distance between the cyclic nucleotide binding
domains of PKARIα and the cysteines necessary for disulfide bond formation, whereas the
cysteines in PKGIα lie closer to the nucleotide binding domain, perhaps explaining why cyclic
nucleotide binding has an effect on disulfide dimerisation of PKGIα, but not PKARIα194. Given
the properties of cAMP it is unsurprising that there was no significant decrease in PKARIα
disulfide dimer as it has no intrinsic reducing capacity. Whilst the experiments thus far do not
indicate a role for cAMP in modulating PKARIα disulfide, I will present other lines of evidence
in Chapter 5 that suggests that cAMP can indeed regulate the redox state of PKARIα. Any
effects of cAMP on PKARIα disulfide may have potentially been missed as immunoblotting may
not be a suitable method to detect subtle changes in disulfide dimer formation that may occur
only in specific subcellular compartments.
3.4.2 Analysis of PKA substrate phosphorylation
PGE1 leads to elevation of cAMP in type I PKA domains188. Therefore substrates
phosphorylated by PGE1 could potentially be RIα specific substrates. Contrary to the literature I
did not detect PKA-substrate phosphorylation with the PKA-substrate antibody in
cardiomyocytes when cells were challenged with PGE1. This was surprising given that various
groups have reported increases in cAMP using radioimmunoassays or fluorescent microscopy
methods in cardiomyocytes after treatment with PGE1181,185,209. The PKA substrate antibody
might be limiting as it may only detect a certain cohort of substrates. Furthermore there is a
paucity of evidence in the literature regarding specific PKA-dependent substrates downstream
of PGE1 in the heart or in cardiomyocytes. EP receptor downregulation after isolation is a
speculative reason for the lack of detectable substrate phosphorylation. In contrast robust
PKA-substrate phosphorylation was observed in HEK 293 cells treated with PGE1. Several
studies report that PGE1 and isoprenaline cause cAMP elevation in distinct
microdomains188,210,211. FRET phosphorylation reporter probes directed to these distinct
microdomains reveal agonist-dependent phosphorylation211, and therefore it was reasonable
to assume that the profile of PKA phosphorylation events as detected by the PKA-substrate
phosphorylation antibody may differ between the two agonists. Surprisingly, the pattern of
substrate phosphorylation was similar for both PGE1 and isoprenaline in HEK 293 cells. This
may be because the pan-specific antibody is not as sensitive to changes in protein
phosphorylation as FRET reporter probes. Ultimately RIα specific substrates could not be
detected using this method.
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Whereas Brennan et al. monitered the phosphorylation of specific substrates using the pan-
specific antibody, I used ‘whole lane intensity’ to monitor global substrate phosphorylation.
Due to monitoring ‘total’ phosphorylation, I was unable to detect a significant difference
between control and H2O2 in contrast to the Brennan study, as only a few phosphorylation
events increased upon exposure to H2O2. Furthermore, Brennan et al., H2O2 caused the
phosphorylation of PKA substrates as detected by the pan-specific PKA substrate antibody in
ARVMs170. However in VSMCs or HEK 293 cells H2O2 alone induced only a minimal increase in
substrate phosphorylation. de Pina et al. suggest that H2O2 results in catalytic subunit
inhibition which would consequently decrease phosphorylation of PKA substrates, however a
decrease in basal phosphorylation was not observed in any cell type107. It has been argued that
the positive effect of oxidants on PKA phosphorylation events is due to inhibition of Ser/Thr
phosphatases rather than PKA activation212. The above experiments do not preclude this
possibility, but the differences in H2O2-dependent phosphorylation events observed in cell
types makes this unlikely. Rather several studies have suggested that the degradation of cAMP
by PDEs, and not phosphatase activity, is the main regulator of PKA phosphorylation
events213,214. In fact, the key factor in oxidant-dependent PKA phosphorylation may be the
concentration of endogenous intracellular cAMP in the different cell types. Basal cAMP levels
in cardiomyocytes are approximately 1.25 µM whilst in HEK 293 cells the concentration is
below 100 nM215. This suggests that oxidant-dependent PKA substrate phosphorylation is
contingent on the presence of cAMP rather than the activity of phosphatases. Since PKARIα is
the only isoform that can sense and transduce both oxidant and cAMP signals, it is reasonable
to suggest that is responsible for integrating the inputs to enhance substrate phosphorylation
in cardiomyocytes. Furthermore when HEK 293 cells and VSMCs were challenged with a cAMP
elevating agent and H2O2 together, there was a trend towards increased PKA substrate
phosphorylation compared to when cells were challenged with each agent alone. This again
suggests that PKARIα can transduce both cAMP and oxidant inputs to regulate substrate
phosphorylation, and that oxidants leads to potentiation of PKA-dependent substrate
phosphorylation. cAMP has been reported to only induce partial dissociation of the PKARIα
isoform from the catalytic subunits whereas substrate and cAMP together leads to full
dissociation189,193. I hypothesise that the enhanced substrate phosphorylation in the presence
of H2O2 and cAMP is due to increased affinity PKARIα disulfide dimer to an associated AKAPs
and therefore targeted to within close proximity of its substrates. The affinity between PKARIα
disulfide dimer and AKAPs will be explored further in Chapter 4.
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3.4.3 Increased Expression of PKARIα after chronic treatment with 8-CPT-cAMP
Interestingly HEK 293 cells exposed to 8-CPT-cAMP for 24 hours had increased expression of
PKARIα, some of which was in the disulfide state, which increased after the application of
H2O2. Pathological hypertrophy induced by aortic constriction is associated with elevated
concentrations of cAMP due to increased circulating catecholamines216,217, and therefore
provided a more relevant setting to investigate chronic cAMP on PKARIα expression. PKARIα
expression was upregulated in the in vivo cardiac hypertrophy model, an observation that is
also confirmed by Han et al. whilst PKACα expression remained constant and PKARIIα
expression was downregulated218. Interestingly, pathological hypertrophy has been associated
with a switch to foetal gene expression and PKARIα KO mice die during embryonic
development, thus this ‘PKA switch’ may be representative of a change in cardiovascular R
subunit phenotype219. It is likely that RIα expression is upregulated to compensate for the over
activity of the C subunits that would occur when cAMP levels are elevated. However it is
curious that RIα expression is increased given that it is the only isoform able to detect
oxidative inputs. It is therefore tempting to suggest that the increased expression of PKARIα is
not only to inhibit catalytic activity, but also to perhaps direct the cAMP signal to oxidant-
dependent PKA targets thus integrating the two signalling modalities. Although this cAMP-
dependent upregulation of PKARIα would be an interesting subject to pursue, it was deemed
to be outside the remit of this thesis.
3.4.4 Examination of PKARIα disulfide in different cell types
The susceptibility of PKARIα to disulfide dimerisation varied depending on the type of cell that
was being challenged with the oxidative stimulus. For example, cardiomyocytes were more
sensitive to 500 μM H2O2 treatment than HEK 293 cells. This concentration of H2O2 induced
almost complete dimerisation of PKARIα in this cardiomyocytes but only approximately half in
HEK 293 cells. This may be because the endogenous antioxidant system in HEK 293 cells has a
greater capacity to offset the increases in ROS. GSH is a vital antioxidant thiol for protection
against oxidative stress. Indeed, rat cardiomyocytes reportedly have a GSH concentration of
~11 nmol/mg concentration220 compared to HEK 293 cells which have a GSH concentration of
~30- 45 nmol/mg221-223, 3-4 times greater than myocytes. This difference in GSH concentration
between cell types is perhaps reflected in the sensitivity of PKARIα in cardiomyocytes to form a
disulfide dimer in response to acute H2O2 treatment, in comparison to PKARIα in HEK 293 cells.
Given this, throughout this thesis the concentration of oxidant used to treat cells has varied
depending on the cell type, with lower concentrations required to induce PKARIα disulfide
dimer in ARVMs and VSMCs compared to HEK 293 cells.
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In the absence of any exogenous oxidants cardiomyocytes tended to have a basal PKARIα
disulfide dimer of at least 50% which was very variable between isolations. This made it very
difficult to obtain consistent results when attempting to characterise PKARIα disulfide
response in this cell type. It is unknown whether this high level of oxidation is due to some
intrinsic characteristic of cardiomyocytes; if the cells are particularly sensitive to stress that
occurs during the isolation; or if the plating procedure causes them to produce oxidants. As
such, HEK 293 cells were used for many of the experiments as I was able to obtain a more
consistent level of PKARIα disulfide between experiments.
There is criticism that surrounds the use of exogenously applied H2O2, as its physiological
production would be tightly regulated in discrete subcellular compartments224,225. Moreover
the physiological and pathophysiogical concentrations of H2O2 in vivo has not been well
defined226. Throughout this report H2O2 concentrations from 50-500 μM have been used which
is within the range that has been routinely used in the literature227. Physiological and
pathophysiological concentrations have been recorded between 1-1000 μM227. It is important
to consider that exogenous H2O2 concentration is not the same as in the intracellular
environment, due to impedance by the cell membrane, and is estimated to be approximately
10% of the concentration applied228. Furthermore due to the activity of endogenous
antioxidant proteins it can be difficult to trap proteins in their oxidised form because they are
constantly being redox-cycled to their reduced form. Therefore it is often necessary to use
higher than may be physiologically-relevant concentrations of oxidising agent in order to
compromise the reducing system and allow detection or visualisation of the oxidative
modification being investigated.
3.4.5 Notes on anti-PKARIα from BD Transduction Laboratories
A range of PKARIα antibodies had been screened previously to determine which could most
reliably detect the PKARIα disulfide dimer. The BD Transduction Laboratories PKARIα antibody
was the only antibody that detected an increase in PKARIα disulfide dimer with increasing
concentrations of H2O2171. In some tissues such as cardiomyocytes there is a clear reciprocal
decrease in PKARIα monomer and increase in PKARIα disulfide dimer. However in H2O2 treated
HEK 293 cells the reciprocal decrease of PKARIα monomer is not very obvious despite a clear
and corresponding increase in the disulfide dimer. This has led to the conclusion that the
antibody has a higher affinity for the disulfide dimer than for the monomeric form of PKARIα.
It was important to bear this in mind when considering data obtained using this antibody as
presented throughout this thesis.
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3.4.6 Biological significance
PKA is an important mediator of cAMP signalling and regulates numerous cellular functions.
The RIα isoform can sense the redox potential of the cell via the formation of a disulfide bond
between the two regulatory subunits. Evidence suggests that PKARIα can integrate oxidant and
cAMP signals to enhance substrate phosphorylation and potentially fine tune functional
effects, but the exact mechanism remains to be elucidated170. In the next chapter I will
investigate whether the oxidant-potentiated PKA substrate phosphorylation is due to
increased affinity between PKARIα disulfide dimer and AKAPs.
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4 Assessing AKAP7 as a redox-dependent target for
PKARIα
4.1 Introduction
In the previous chapter it was shown that H2O2 potentiated cAMP-induced phosphorylation of
PKA substrates. The primary focus of this chapter is to investigate whether this is due to an
increased affinity between PKARIα disulfide dimer and AKAPs, thus leading to increased
phosphorylation of associated substrates. In addition to the findings of the previous chapter,
this hypothesis is also significantly based on evidence that a Cys17Ala PKARIα mutant had
decreased affinity for DAKAP2 compared to WT PKARIα (Figure 1.10)103.
A “redox dead” mutant Cys17Ser PKARIα knock-in (C17S PKARα KI) mouse that cannot form a
disulfide bond between the two regulatory subunits has been generated to study the effects of
PKARIα disulfide dimer on physiological responses. If the hypothesis is correct we might expect
these mice to have functional deficiencies due to a failure in AKAP targeting usually facilitated
by PKARIα disulfide during oxidant signalling (Figure 4.1). Indeed electrically stimulated
isolated ventricular myocytes from PKARα KI mice exhibit delayed decay of their calcium
transients compared to WT myocytes (Figure 4.2). This means in PKARα KI mice it takes a
greater length of time for SERCA2a to actively pump Ca2+ back into the SR. SERCA2a
underactivity could potentially be explained by decreased phosphorylation of the PKA
substrate phospholamban (PLB), perhaps caused by deficient targeting of C17SPKARIα to an
AKAP in the PKA/PLB/SERCA2a signalling complex. The AKAP that is thought to assemble this
complex is AKAP7y/δ as considered in more detail below.
4.1.1 AKAP7
The AKAP7 gene is located on chromosome 6 6q23 encodes for four splice variants α, β, γ and
δ that range from 81 to 353 amino acids in length, each targeted to a specific subcellular
location with differing functional roles229. AKAP7α/β are known as the short isoforms due to
truncations at the 5’ end compared to the large isoforms AKAP7γ/δ, but all four have a
conserved 64 amino acid sequence at the C-terminus that contains the A-kinase binding (AKB)
domain and a leucine zipper (Figure 4.3)230.
The α and β isoforms both contain membrane-targeting motifs located at their N-terminus
through myristoylation and dual palmitoylation of one glycine and two cysteine residues
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respectively, confirmed by immunofluorescence studies with constructs containing mutations
of these critical amino acids (Figure 4.3)231. Whilst relatively little is known about AKAP7β,
AKAP7α has been shown to co-immunoprecipitate with CaV1.2 channels isolated from rat heart
membrane extracts and skeletal muscle232,233. The C-terminus of CaV1.2 channels interacts with
the N-terminal AKAP7 leucine zipper mutation which results in a loss of co-purification and
inhibition β-adrenergic regulation of ICa in rat ventricular myocytes. Similarly, the use of AKB
domain peptides disrupted the PKA regulation of CaV1.2 currents in ventricular myocytes as
PKA-dependent phosphorylation of CaV1.2 channels is necessary to increase open channel
probability232. However the importance of AKAP7α mediated regulation of CaV1.2 channels has
recently been disputed. It was demonstrated that AKAP7α was not expressed in
cardiomyocytes and knockout of AKAP7 had no effect on CaV1.2 channel phosphorylation after
β-adrenergic stimulation234.
Figure 4.1 Proposed model of PKARIα disulfide dimer in WT vs PKARIα KI mice. Disulfide
PKARIα has greater affinity for AKAPs and leads to substrate phosphorylation. PKARIα KI mice
would have a lesion in phosphorylation due to aberrant or deficient targeting of
Cys17SerPKARIα.
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Figure 4.2 Cardiomyocytes from PKARIα KI mice have delayed Ca2+ transients. Unpublished
data kindly provided by Wagner and Maier (Gottingen University).
Figure 4.3 Schematic of AKAP7 splice variants α, β, γ, δ. The short isoforms of AKAP7
containing a membrane targeting domain indicated in light blue. Central conserved domain of
the large isoforms is highlighted in red. The location of the putative ‘redox switch’ cysteines
are indicated by the black Cs. The dashed lines and adjacent black square is the AKB domain.
Figure adapted from Gold et al. 2008229
C C
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4.1.2 Role of AKAP7γ/δ
The long isoforms of AKAP7 have been shown to regulate PLB phosphorylation140,235, insulin
secretion230,231, and renal homeostasis236,237. AKAP7γ has also been shown to bind the lipid-
dependent PKC to amplify phosphorylation through this kinase238,239. There is conflicting
evidence regarding the cellular location of AKAP7γ. Brown et al. visualised GFP-AKAP7γ in the
nucleus consistent with its N-terminal nuclear localisation signal240, whilst Trotter et al.
visualised it diffusely throughout the cytoplasm, but this was likely an artefact due to loss of
localisation due to over-expression149.
The crystal structure of the conserved central domain of both AKAP7γ and δ reveals a bi-lobal
and globular α–β-type architecture consisting of four α-helices and eight β-sheets. Each lobe
contains four-stranded antiparallel β-sheets, which assemble at the core of the domain (Figure
4.4)229. Characterisation of the domain also revealed that AKAP7 interacts with the nucleotide
5’AMP in the physiological micromolar concentrations. 5’AMP is a product of PDE-dependent
hydrolysis of cAMP and therefore AKAP7δ may play a role as an AMP sensor, coupling AMP
binding to PKA affinity to further regulate cAMP signalling.
There is conflicting evidence as to whether AKAP7 binds to RI and/or RII. The use of cAMP
analogues conjugated to agarose beads is an affinity chromatography technique commonly
used to enrich PKARI/II, which can also co-capture interacting proteins such as AKAPs. Using
this method combined with mass spectrometry-based quantitative proteomics Aye et al.
described AKAP7 as an RII specific AKAP. The authors used three different
immobilized cAMP analogues to enrich for PKAR and its interacting proteins from HEK 293
cells. Stable isotope labelling was used to identify and differentially quantify the four R
subunits that were preferentially enriched. This allowed AKAPs that were RI-specific, RII-
specific or dual-specific to be determined121. In contrast, Brown et al. confirmed that AKAP7γ
bound RI using a yeast two-hybrid system. The exact region was identified via systematic
truncation of AKAP7γ, revealing binding involves the same region previously shown to bind RII.
Co-immunoprecipitation using an RI antibody in HEK 293 cells also confirmed the interaction
between RI and AKAP7γ240. Investigating whether this interaction is influenced by the redox
state of RIα is central to the present studies.
The consensus is that AKAP7δ is localised to the SR where it assembles a supramolecular
complex of consisting of PKA and PLB in close proximity to SERCA2a, and therefore regulates
Ca2+ re-uptake back into the SR140,241,242. Mutations that disrupt PLB association with AKAP7γ/δ
reduced PLB phosphorylation and AKAP7δ siRNA delayed calcium re-uptake in neonatal
cardiomyocytes treated with NA. The AKAP7δ binding sequence was mapped to amino acids
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13–20 in PLB which overlaps with the PKA phosphorylation site at Ser16140. Therefore when
phosphorylated PLB does not bind to AKAP7γ/δ which is hypothesised to provide another level
of dynamic regulation to facilitate the lowly abundant PKA (100–200 nM) to phosphorylate the
relatively highly abundant PLB (50 μM)235. AKAP7γ/δ also co-ordinates the dephosphorylation
of PLB through interactions with inhibitor-1 (I-1) and protein phosphatase 1 (PP1). PKA
phosphorylates I-1 (Ser35) to activate and consequently inhibit PP1, the primary phosphatase
responsible for dephosphorylating PLB241. This suggests that AKAP7 assembles a signalling
complex through binding of activating and deactivating proteins to tightly regulate PLB
phosphorylation and therefore SERCA2a activity and the rate of Ca2+ re-uptake into the SR. The
PKARIα disulfide dimer may further regulate this phosphorylation based on its redox-
dependent affinity for AKAP7.
Contrary to this substantive evidence supporting a role for AKAP7γ/δ in cardiomyocytes
function, an AKAP7 KO mouse was found to have a normal response to adrenergic stimulation.
Both Cav1.2 and PLB were similarly phosphorylated when WT or AKAP7KO mice were
compared in response to isoprenaline. Furthermore AKAP7 knock out had no effect on the rate
of PLB dephosphorylation234. However, the presence of adaptive, compensatory mechanisms
in this KO mouse cannot be excluded.
4.1.3 Putative AKAP7γ/δ oxidation
Close examination of the AKAP7δ crystal structure reveals a pair of cysteine residues (Cys268
and Cys 282) on adjacent β-parallel sheets that reside in close proximity to each other (Figure
4.4). The crystal structure also displays Cys282 in two different conformations in space.
Therefore it is tempting to speculate that AKAP7δ may exist in a reduced form or an oxidised
form involving an intramolecular disulfide bond. Interestingly, these thiol groups are likely to
be adjacent to the R binding site (which was not resolved in the crystal structure) and
therefore the putative thiol oxidation may alter affinity of the AKB for PKAR, or I speculate may
participate in a mixed disulfide AKAP7-PKARIα complex to regulate substrate phosphorylation.
The major aim of this chapter was to establish whether the PKARIα-AKAP interaction is
regulated by the redox state of PKARIα. cAMP tethered to agarose beads has been used
extensively in the literature to co-purify PKAR subunits with AKAPs and was the primary
method used here to investigate the putative redox state-dependent interaction of these
proteins. A secondary aim was to determine whether AKAP7 is itself redox regulated, and if so,
whether this alters the AKAP’s affinity for PKARIα. This led to the development of an assay to
determine whether a protein is sensitive to reversible oxidative modifications. The assay
requires labelling of reactive thiols with a 5 kDa PEG-maleimide tag which retards protein
Assessing AKAP7 as a redox-dependent target for PKARIα
102
migration during SDS-PAGE. The modification can subsequently be visualised by an upward
shift of the protein of interest on an immunoblot.
Figure 4.4 Crystal structure of AKAP7δ central domain. The position of the putative ‘redox
switch’ cysteines are shown as ball and stick models. Cys282 is presented in two different
conformations. The proximity between the potential disulfide bond in AKAP7δ and the AKB
domain in the primary sequence may regulate AKB affinity to PKAR (PDB: 2VFK).




Antibody Purchase Code Company Species Dilution
anti-AKAP7 ab30987 Abcam Rabbit 1:1000
anti-AKAP7 ARP36331_T100 Aviva Systems
Biology
Rabbit 1:1000
anti-AKAP7 ARP36331_T200 Aviva Systems
Biology
Rabbit 1:1000
Anti-His sc-803 Santa Cruz
Biotechnology
Rabbit 1:1000














Anti-SKIP GTX101952 GeneTex Rabbit 1:500
Anti-ChChd3 ab99491 Abcam Goat 1:500
Anti-Strep-HRP 3999 Cell Signaling
Technology
- 1:1000
Table 4.1 Antibodies used in Chapter 4
4.2.2 Generation of His-AKAP7δ construct
The cDNA encoding AKAP7δ was amplified by PCR and ligated into a His-TOPO vector to
generate His-AKAP7δ. The His-tag was present at the N-terminal end of the AKAP7δ protein.
After transformation, DNA was isolated from colonies and the presence of inserts was verified
by restriction digestion. Insert DNAs were sequenced to ensure that a particular insert was in-
frame with the His-tag.
Assessing AKAP7 as a redox-dependent target for PKARIα
104
4.2.3 Generation of GFP-AKAP7γ mutants
GFP-AKAP7γ in pEGFP-C2 was a kind gift from Dr. Carmen Williams (University of Pennsylvania,
US). The cysteines residues hypothesised to be susceptible the oxidation in GFP-AKAP7γ were
systematically mutated. Amino acid substitutions (C229S), (C243S) and (C229S/C243S) were
introduced using the Quik-Change Site-Directed Mutagenesis Kit (Agilent) according to the
manufacturer’s instructions.
4.2.4 PEG-maleimide switch assay
HEK 293 cells were scraped and harvested in buffer containing 100 mM Tris pH 7.4, 100 mM
maleimide and 1% SDS. Each sample was incubated at 50°C for 25 min to increase the
efficiency of maleimide-alkylation of free thiols. Excess maleimide was then removed using
ZebaTM Spin desalting columns (Thermo Scientific) with elution into fresh tubes. To reduce any
oxidant-induced modification, 50 mM DTT was then added to each sample and incubated at
room temperature for 20 min. The samples were desalted again to remove the excess DTT and
eluted directly into 5 mM PEG-maleimide and 1% SDS. Samples were rotated for 2 hours on a
blood wheel at 4 °C. The labelling reaction was quenched with an equal volume of SDS-PAGE
sample buffer containing 100 mM maleimide. Samples were run on a non-reducing SDS-PAGE
and banding pattern assessed by Western immunoblotting. An overview of the protocol is
given in Figure 4.5.
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Figure 4.5 Overview of the PEG-maleimide switch method. A target protein containing a thiol
residue that has undergone an oxidative modification (-SNO nitrosation, -SOH- sulfenation, -
SG- glutathiolation, -SR disulfide bond formation) is shifted on an immunoblot by the PEG-
maleimide whilst an unoxidised protein runs at its predicted mass. Cells are lysed in a buffer
contain the alkylating agent maleimide. Maleimide irreversibly alkylates free thiol residues
leaving any oxidative modification in the protein unaltered. Subsequently DTT is incubated
with the lysate to reduce any oxidative modification that was originally present in the protein.
These now reduced thiols are free to be alkylated by PEG maleimide. The oxidation state is
‘switched’ with PEG-maleimide, and therefore only proteins that were originally oxidised
should contain the PEG-maleimide, which produces a 5 kDa shift that can be detected on an
immunoblot.
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4.2.5 Affinity pull down with cAMP-agarose
HEK 293 cells were seeded in 12 well plates to approximately 80% confluent, lysed in ice-cold
lysis buffer (100 mM Tris pH 7.4, 100 mM maleimide and 1% Triton X-100) and maintained at 4
°C. Subsequent centrifugation at 15,000 g for 15 min in a tabletop Eppendorf centrifuge at 4 °C
yielded a soluble supernatant and insoluble fraction. SDS-sample buffer was added to an
aliquot of the supernatant and designated as the input. Agarose beads were washed with lysis
buffer containing 1% Triton X-100 to minimise non-specific binding. cAMP-agarose beads were
then added to the remainder of the soluble fraction and the lysate-bead suspension rotated
for 2 hours at 4 °C. Lysates were then centrifuged for 30 seconds at 1500 g, SDS-sample buffer
was then added to an aliquot of this flow-through and this was designated as the unbound
fraction. Subsequently, beads were washed 3 times by centrifugation (1500 g for 30 seconds)
in wash buffer. Next SDS-PAGE sample buffer was added to the beads for elution. This was the
designated as the capture.
Optimisations: The cAMP-agarose experiments were optimised in numerous ways. Initially the
dilutions of input, capture, and unbound fractions were kept constant to allow direct
comparison of captured proteins across the three fractions. In later experiments, captured
proteins were concentrated by eluting in a small volume of SDS-sample buffer (indicated in
figure legends) in order to increase the probability of observing co-capture proteins on
immunoblots. Numerous cAMP-agarose beads were tested including: 8-(2-aminoethylamino)-
adenosine- 3', 5'- cyclic monophosphate (8-AEA-cAMP), 2-(6-aminohexylamino)-adenosine- 3',
5'- cyclic monophosphate (2-AHA-cAMP), 8-(6- aminohexylamino)-adenosine- 3', 5'- cyclic
monophosphate (8-AHA-cAMP) (BIOLOG). Furthermore in later experiments HEK 293 cells
were seeded in T75 flasks, increasing the concentration of protein in each reaction to ~2
mg/ml. Finally, several buffers were screened to optimise the method and are outlined in
section 4.3.5.
4.2.6 Affinity pull down with Ni-NTA-agarose
HEK 293 cells seeded in 12 well plates to approximately 80% confluent, lysed in ice-cold lysis
buffer (100 mM Tris pH 7.4, 100 mM maleimide and 1% Triton X-100) and the lysate was
maintained at 4 °C. Subsequent centrifugation at 15,000 g for 15 min yielded a soluble
supernatant and insoluble fraction. SDS-sample buffer was added to an aliquot of the
supernatant and designated as the input. Ni-NTA-agarose beads were washed with lysis buffer
containing 10 mM imidazole to prevent non-specific binding and then incubated with lysates
on a blood wheel for 2 hours at 4°C. Beads were subsequently washed three times in lysis
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buffer containing 20 mM imidazole, eluted with 250 mM imidazole, before the addition of x2
SDS-PAGE sample buffer.
4.2.7 CaprotecTM capture compound assay
HEK 293 cells were treated as described, washed in ice-cold PBS, lysed (20 mM HEPES pH 7.5,
250 mM sucrose, 150 mM NaCl, 5 mM MgCl2, 0.2% n-dodecyl-β-D-maltoside and protease
inhibitor) and underwent freeze-thaw cycles in liquid nitrogen to use the C8-cAMP caproKitTM
as per the manufacturer’s instructions. Cell lysates were incubated with C8-cAMP capture
compound (Figure 4.6) and rotated end-over-end for 30 min at 4°C. Samples were
subsequently UV irradiated for 10 min in the caproBoxTM (to cross-link C8-cAMP bound PKAR
with binding partners) which maintains samples at 4°C. Cross-linked samples were then
incubated with streptavidin beads, to capture C8-cAMP bound proteins via the biotin tag, for
30 min at 4°C. Beads were then washed (x5) in the designated wash buffer before the addition
of x4 SDS-PAGE sample buffer. Samples were then boiled at 95°C for 5 min to disrupt the
streptavidin and biotin interaction.
Optimisation: To increase the efficiency of PKAR capture the concentration of C8-cAMP
capture compound was decreased from 10% to 5% (vol/vol).
Figure 4.6 CaprotecTM C8-cAMP capture compound used in cross-linking experiments. Figure
adapted from Lou et al. 2009243.
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4.3 Results
The Cysteine Oxidation Prediction Algorithm (COPA) is able to predict with 80.4% accuracy
whether a cysteine is susceptible to reversible oxidation using 11 parameters that include
distance to the nearest cysteine sulphur, the solvent-accessible surface area of the target
cysteine thiol and distance to the nearest basic amino acid244. COPA predicts that by virtue of
the proximity between Cys268 and Cys282 in the central conserved domain of AKAP7δ these
cysteines are susceptible to oxidation, despite their relatively high pKa (Table 4.2).
Table 4.2 Cysteine Oxidation Prediction Program analysis of AKAP7δ cysteines based on
crystal structure
4.3.1 Investigating AKAP7 migration on immunoblots
To determine whether AKAP7 was sensitive to oxidative modifications it was necessary to
obtain an antibody that could detect AKAP7 in various tissues. Inter- and intramolecular
disulfide bonds can potentially be detected by immunoblotting. For example, the migration
after SDS-PAGE of oxidised PTEN is subtly altered due to the presence of an intramolecular
disulfide bond245 whilst inter-protein disulfide can be detected by retardations of migration as
seen with PKARIα in Chapter 3. It was expected that commercial antibodies would be able to
detect both the AKAP7γ and AKAP7δ isoforms due to the similarity between their primary
sequences.
Isolated rat hearts and ARVMs were treated with various concentrations of H2O2 (0-500 μM)
and AKAP7 gel migration was analysed using commercially available AKAP7 antibodies. Figure
4.7 shows a representative blot from rat heart homogenate and ARVMs of one such antibody
(ARP36331_T200 from Aviva System Biology) used to detect AKAP7. The profile of all the
AKAP7 antibodies used was similar, producing many bands on an immunoblot, the pattern of
which changed depending on the tissue, H2O2 treatment, the presence of maleimide in the
sample buffer and whether the samples had been boiled or not. As such it was difficult to have
confidence that any of the bands definitively represented either AKAP7 isoform.
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Figure 4.7 Commercial AKAP7 antibodies produce multiple bands in rat heart homogenate
and ARVMs. (A) Rat heart homogenate was perfused with 100 μM H2O2 (B) ARVMs were
treated with 0-500 μM H2O2. Immunoblots probed with anit-AKAP7 (ARP36331_T200). Black
arrows indicate expected molecular weight of AKAP7.
37 -
37 -
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Unfortunately, a significant period of time was spent attempting to optimise these
immunoblotting conditions and interpret immunoblots using these commercial antibodies to
AKAP7. Due to the uncertainty of which, if any, band represented AKAP7 it was decided to
switch to an over-expression system to achieve confidence in detection. HEK 293 cells were
transfected with titrated concentrations of either His-AKAP7δ or GFP-AKAP7γ DNA to optimise
protein expression as monitored by immunoblotting (Figure 4.8A and B). It was decided that
500 ng/ml and 250 ng/ml were an optimal concentrations of His-AKAP7δ and GFP-AKAP7γ DNA
to use respectively. It was also salient that the commercial antibodies were unable to detect
either of the over-expressed AKAP7 isoforms (Figure 4.8C and D). Thus all subsequent
experiments investigating AKAP7 were conducted in transiently transfected HEK 293 cells and
protein detection was facilitated by antibodies to their respective affinity tags.
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Figure 4.8 AKAP7 commercial antibodies failed to detect His-AKAP7δ or GFP-AKAP7γ. HEK
293 cells were transfected with His-AKAP7δ (0-2000 ng) or GFP-AKAP7γ (0-2500 ng) DNA and
were harvested after 24 hours. Immunoblots were probed with anti-His, anti-GFP, anti-AKAP7
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The migration of His-AKAP7δ and GFP-AKAP7γ was assessed by SDS-PAGE under non-reducing
or reducing conditions after transfected HEK 293 cells were challenged with 0-500 μM H2O2.
There was no identifiable shift in migration of His-AKAP7δ either with H2O2 treatment or after
samples were analysed in the presence of the reductant 2-mercaptoethanol (Figure 4.9A).
Under control conditions GFP-AKAP7γ ran just below 75 kDa, with a small proportion of the
protein possibly aggregating at the top of the above the 200 kDa marker (Figure 4.9B). The
putative inter-protein disulfide between AKAP7γ and PKARIα would be expected to form at
approximately 125 or 175 kDa depending on whether the two R subunits were disulfide linked
too. Thus these ultra-high bands were considered likely to be aggregatory artefacts caused by
H2O2 treatment.
Figure 4.9 AKAP7 migration on SDS-PAGE remains unaltered with H2O2 treatment. HEK 293
cells transfected with either (A) His-AKAP7δ or (B) GFP-AKAP7γ were treated with H2O2 (0-500
μM) for 10 min. Samples were run in parallel in the presence of 2-mercaptoethanol (5%) for
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4.3.2 Optimisation and validation of PEG-maleimide switch method
The PEG-maleimide switch method was a technique developed during these studies to analyse
proteins, such as AKAP7, that may be susceptible to reversible oxidative modifications. The
5kDa PEG-maleimide adducts to thiol residues that are susceptible to oxidation, thus retarding
the migration of the protein during SDS-PAGE. Throughout development and validation of this
novel method PKARIα and PKGIα were used as readouts as they are known to undergo
reversible thiol oxidation.
In HEK 293 cells treated with H2O2 (100 μM) PKGIα exhibited PEGylation following processing
with PEG-maleimide switch assay (Figure 4.10). The higher 50 mM concentration of DTT used
in the reduction step of the assay slightly improved the extent of PEGylation compared to 20
mM, and thus became the standard concentration used in the subsequent experiments.
However the addition of SDS during the reduction step was found to be unnecessary. Having
successfully applied the protocol to cell models, the method was then assessed for its utility in
the analysis of cardiac tissue. Both PKARIα and PKGIα were found to be PEGylated, thus
indicating oxidation, in heart exposed to H2O2 for 10 min but not in controls (Figure 4.11). To
validate the specificity of the method, calsequestrin, a protein not known to be susceptible to
thiol redox modifications was assessed using the PEG-maleimide switch method. There was no
shift in calsequestrin in heart samples that were assayed, consistent that it is indeed
insensitive to reversible oxidative modifications and that the method is able to discriminate
between redox sensitive proteins and proteins that are not susceptible to reversible oxidative
modifications (Figure 4.11).
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Figure 4.10 Characterisation of the PEG-switch assay in HEK 293 cells. HEK 293 cells were
treated with H2O2 (100 μM) and lysates underwent PEG-maleimide switch processing. The
reduction step of the process was carried out using various concentrations of DTT (0-50 μM) in
the absence or presence of 1% SDS. Immunoblot was probed with anti-PKGIα.
Figure 4.11 PKARIα and PKGIα but not calsequestrin are sensitive to reversible oxidative
modification. Rat hearts were perfused with H2O2 (0- 250 μM) for 10 min, homogenised and
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The method was then applied to HEK 293 cells that had been transfected with GFP-AKAP7γ.
GFP-AKAP7γ did not shift in vehicle-treated cells but did demonstrate a H2O2 concentration-
dependent PEGylation indicating that AKAP7γ may be susceptible to reversible oxidation
(Figure 4.12A). As the GFP protein itself contains two cysteine residues it was necessary to
confirm that the observed shift in GFP-AKAP7γ was not due to the oxidation of those thiols.
Consequently GFP was transfected into HEK 293 cells but was not PEGylated after the samples
were processed using the PEG-maleimide switch method, indicating that the oxidation of
cysteines in GFP are not responsible for the labelling (Figure 4.12B). To establish which
cysteines are responsible for the putative disulfide bond that would explain the reductive-
labelling of GFP-AKAP7γ, the cysteine residues were systematically mutated to serine residues
to form three new GFP-AKAP7γ constructs. These included GFP-C229SAKAP7γ (C229S), GFP-
C243SAKAP7γ (C243S) and the double mutant GFP-C229S/C243SAKAP7γ (C229/C243).
Mutations of these cysteines should result in abrogation of the PEGylation. Surprisingly all
three constructs exhibited PEG-maleimide shifts that were comparable to wild type GFP-
AKAP7γ indicating that these cysteines were not responsible for the previously observed
PEGylation (Figure 4.12C). This unexpected observation using the cysteine mutants would
appear fully at odds with AKAP7γ being susceptible to disulfide formation. Since the cysteine
residues are conserved between AKAP7γ and AKAP7δ it is reasonable to suggest that the two
isoforms would demonstrate similar levels of susceptibility to redox modification. Indeed
AKAP7δ was not PEGylated after PEG-maleimide switch processing suggesting that it was not
susceptible to reversible redox modification (Figure 4.12D).
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Figure 4.12 PEG-maleimide switch analysis provides evidence that AKAP7 can be reversibly
oxidised. HEK 293 cells were transfected with (A) GFP-AKAP7γ, (B) GFP alone, (C) C229S, C243S
or C229/C243 or (D) His-AKAP7δ. Cells were treated with H2O2 (0-500 μM) 24 hours post-
transfection, lysed and underwent PEG-maleimide switch processing. Immunoblots were
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4.3.3 Investigating the AKAP7 and PKARIα interaction with immunofluorescence
Immunofluorescent imaging allowed visualisation of co-localisation between AKAP7 and
PKARIα and determination of whether this interaction was dependent on the redox state of
PKARIα. HEK 293 cells were transfected with His-AKAP7δ or GFP-AKAP7γ prior to treatment
with vehicle or H2O2 (500 μM) and detection was enabled by the His-antibody for AKAP7δ, GFP
for AKAP7γ and anti-PKARIα. Transfection efficiency was not determined, but above
experiments indicated that both AKAPs were expressed in HEK 293 cells without gross
detriment to cell viability. Furthermore cells transfected with GFP-AKAP7γ were visualised
using the microscope prior to commencement of the immunofluorescence protocol to ensure
protein expression. Both AKAP7 isoforms appeared to accumulate in the nucleus whilst
AKAP7δ also appeared in the nuclear membrane (Figure 4.13 and 4.14). In some cells AKAP7
was present diffusely throughout the cytoplasm. PKARIα was consistently found diffusely
throughout the cytoplasm and also in the nucleus, but did not appear to co-localise specifically
with either AKAP. Additionally there was no detectable change in subcellular location of any of
the proteins upon the addition of H2O2.
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Figure 4.13 AKAP7δ does not co-localise with PKARIα in HEK 293 cells.Representative immunofluorescent image. HEK 293 cells were
treated with vehicle or 500μM H2 O
2 and then stained with AKAPδ (red) and PKARIα(green) antibodies. The nucleus was stained with
b4′,6-diamidino-2-phenylindole (DAPI, blue).
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Figure 4.14 AKAP7γ does not co-localise with PKARIα in HEK 293 cells.Representative immunofluorescent image. HEK 293 cells were
treated with vehicle or 500μM H2 O
2 and then stained with the PKARIα(green) antibody whilst GFP-AKAP (red) was visualised using GFP
tag.  The nucleus was stained withb4′,6-diamidino-2-phenylindole (DAPI, blue).
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4.3.4 Investigating the His-AKAP7δ interaction with PKARIα and PKARIIα using Ni-NTA-
agarose
The working hypothesis being tested was that during oxidative conditions the PKARIα disulfide
dimer will bind to His-AKAP7δ with greater affinity than under control conditions when the
thiols of RIα are in the reduced state (Figure 1.10). One method to investigate this putative
redox-dependent interaction between PKARIα and AKAP7δ was to utilise the affinity His tag on
His-AKAP7δ has for nickel ions immobilised on agarose beads, attempting to co-purify PKARIα
from HEK 293 cell lysates with it. His-AKAP7δ was successfully purified from lysate in vehicle
treated and H2O2 (500 μM) treated HEK 293 cells. However, PKARIIα, but not PKARIα, was
unexpectedly co-captured with His-AKAP7δ using Ni-NTA-agarose and this association tended
to increase with exposure to H2O2 (Figure 4.15). The co-capture of PKARIIα was specifically due
to its interaction with His-AKAP7δ as PKARIIα was not pulled down in cells that were not
transfected with His-AKAP7δ.
Previous experiments using the PEG-maleimide switch method indicated that His-AKAP7δ was
not susceptible to reversible oxidative modifications. Therefore it was considered that an
oxidative modification on PKARIIα may be responsible for the H2O2-dependent increase in
affinity between the two proteins. To investigate whether PKARIIα was susceptible to
reversible oxidative modifications HEK 293 cells and rat hearts were treated and perfused
respectively with various concentrations H2O2 (0- 500 μM) and the PEG-maleimide switch assay
was performed. Immunoblotting demonstrated that PKARIIα became PEGylated in samples
that had been challenged with H2O2 suggesting that PKARIIα is susceptible to reversible
oxidative modifications (Figure 4.16). Therefore the redox state of PKARIIα may modulate its
affinity for His-AKAP7δ.
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Figure 4.15 AKAP7δ interacts with PKARIIα. Untransfected or His-AKAP7δ transfected HEK 293
cells were treated with H2O2 (500 μM) and lysates were incubated with Ni-NTA-agarose.
Immunoblots were probed with anti-His, anti-PKARIα or anti-PKARIIα. The extent of PKARIIα
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Figure 4.16 PKARIIα is sensitive to reversible oxidative modification. Rat hearts were
perfused or HEK 293 cells were treated with H2O2 (0- 500 μM) for 10 min, homogenised and
underwent PEG-maleimide switch processing. Immunoblots were probed with anti-PKARIIα.
50 -
50 -
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4.3.5 Investigating the interaction between PKAR subunits and AKAP7δ and AKAP7γ using
nucleotides immobilised on agarose beads
Experiments were conducted using various analogues of cAMP immobilised on agarose beads
via a flexible spacer in the 2’or 8’ position on the adenine ring. These serve as bait for PKARIα
which may co-purify with AKAP7δ, AKAP7γ or other AKAPs. Again by treating HEK 293 cells
with either vehicle or H2O2 it may be possible to determine if PKARIα has increased affinity for
AKAPs under oxidative conditions compared to controls.
HEK 293 cells were transfected with His-AKAP7δ or GFP-AKAP7γ, treated with H2O2 (0- 500
μM) one day post transfection and subsequently harvested. Lysate was incubated with cAMP-
agarose for 2 hours, beads were washed and captured proteins were eluted using SDS-sample
buffer. PKARIα was present in the capture consistent with the protocol working (Figure 4.17).
PKARIα was not present in the unbound fraction which suggests that the capture was efficient,
but interestingly and of particular note it was predominantly captured as a monomer despite
having initially been oxidised. This observation forms the basis of my investigations
documented in Chapter 5 where it is considered in more detail. Unfortunately neither AKAP7
isoform was co-captured with PKARIα (Figure 4.17). Before concluding that the proteins do not
interact, I attempted to optimise the experimental conditions to promote likelihood of AKAP7
being co-captured. This is outlined in the methods section; briefly it included using different
types and lengths of linker that conjugated cAMP to the agarose, experimenting with different
incubation or wash buffer compositions, varying the volume of beads and the volume of HEK
293 cell lysate, and testing different elution protocols. It was not deemed necessary to
extensively document all of these optimisations below, but some key steps are included below.
However, the essential message was this extensive optimisation unfortunately did not lead to
the co-capture of AKAP7 and PKARIα.
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Figure 4.17 AKAP7 is not co-captured with PKARIα. AKAP7δ or AKAP7γ were transfected into
HEK 293 cells and treated with H2O2 (0-500 μM) and lysates were incubated with 8-AEA-cAMP-
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cAMP-agarose has been used in many studies to co-capture PKA regulatory subunits with
AKAPs. The authors of these articles have used many different buffer compositions and have
successfully co-captured AKAPs with PKA. Different buffers were comprehensively screened to
determine the best method for AKAP co-capture, with DAKAP-1 being used as a positive
control. In these experiments 11 different buffers were used and are outlined in Table 4.3. HEK
293 cells were lysed in the designated buffer, none of which contained maleimide to replicate
studies from the literature and PKARIα was captured in all of the experiments and
predominantly in the disulfide dimer form (Figure 4.18). DAKAP1 was co-captured only with
buffers 3, 7 and 9. A comparison of PKARIα in the input vs. the unbound fraction gave an
indication of how efficient the captures were and thus, Buffer 3 was used in subsequent
analyses.
Number Buffer Detergent Additional Components Source
1 100 mM Tris pH 7.4 1% Triton-X100 150 mM NaCl -
2 100 mM Tris pH 7.4 1% Triton-X100 150 mM NaCl, 1mM
EDTA, 1mM EGTA
-
3 100 mM Tris pH 7.4 none 150 mM NaCl -
4 50 mM Tris pH 7.4 1% NP-40, 0.5%
C24H39NaO4,
0.1% SDS
500 mM NaCl 246
5 50 mM Tris pH 7.4 0.5% Triton-X100 150 mM NaCl, 1 mM
EDTA
247
6 20 mM MOPS pH 7.0 1% Triton-X100 150 mM NaCl, 10 mM
MgCl2,
248
7 20 mM MOPS pH 7.0 none 10 mM NaCl, 2 mM
EDTA, 2 mM EGTA
249
8 20 mM HEPES pH 7.4 1% Triton-X100 150 mM NaCl, 5 mM
EDTA
-
9 50 mM K2HPO4 pH 7.0 0.1% Tween-20 150 mM NaCl 121
10 10 mM K2HPO4pH 7.0 1% Triton-X100 150 mM NaCl, 5 mMEDTA
236
11 20 mM HEPES pH 7.5, 0.1% n-dodecyl-β-
D-maltoside
250 mM sucrose, 150
mM NaCl, 5 mM MgCl2
243
Table 4.3 Table of buffers screened in cAMP-agarose experiments
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Figure 4.18 Buffer screen for cAMP-agarose capture in HEK 293 cells. 11 different buffers
(outlined in Table 4.3) were used in cAMP-agarose experiments to co-capture DAKAP-1. HEK
293 cells were lysed (without maleimide) in the designated buffer and lysates incubated with
2-AHA-cAMP-agarose. I- input, C- capture, U- unbound. Captures were x20 concentrated
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Capture experiments with Buffer 3 (100 mM Tris-HCl, pH 7.4, 150 mM NaCl, no detergent)
were scaled-up to increase the protein in each assay to approximately 2 mg/ml. Maleimide
was added to allow comparison of vehicle- and H2O2-treated captures. Figure 4.19 shows
PKARIα was efficiently captured but neither the established PKARIα-specific AKAP, SKIP, nor its
associated PKA substrate, ChCHd3, were co-captured. DAKAP1 was co-captured as previously
observed although its known binding partner DRP1 was not. Despite this the phosphorylation
of DRP1 appeared to increase with H2O2 treatment and this warranted further investigation.
To confirm that the co-capture of DAKAP1 was due specifically to its interaction with PKARIα
and not due to non-specific binding to the agarose, HEK 293 cells were treated with H2O2 (0-
500 μM) and lysed in buffer 3. As a negative control cAMP (1 mM) was added to compete for
PKARIα binding during the incubation step. PKARIα and DAKAP1 were captured as previously
observed. However in samples that were incubated with cAMP, PKAR binding was significantly
abrogated but the extent of DAKAP1 capture remained the same, indicating that it was likely
to be bound non-specifically to agarose (Figure 4.20A). Furthermore examination of the
phospho-status of DRP1 revealed no significant difference when HEK293 cells were treated
with on with H2O2, 8-CPT-cAMP alone or H2O2 with 8-CPT-cAMP (Figure 4.20B). Given that the
interaction between PKARIα and DAKAP1 could not be established it was decided against
pursuing further studies using this method to capture PKARIα and AKAPs.
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Figure 4.19 2-AHA-cAMP-agarose capture with Buffer 3 in HEK 293 cells. HEK 293 cells were
treated with H2O2 (500 μM) and lysates were incubated with 2-AHA-cAMP-agarose. Captures
were x20 concentrated compared to input. Immunoblots were probed with anti-PKARIα, anti-
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Figure 4.20 2-AHA-cAMP-agarose capture with Buffer 3 and cAMP negative control in HEK
293 cells. (A) HEK 293 cells were treated with H2O2 (0-500 μM) and lysates were incubated
with 2-AHA-cAMP-agarose. cAMP (1 mM) was added to lysate during incubation was used as
negative control. Captures were x20 concentrated compared to inputs. Immunoblots were
probed with anti-PKARIα or anti-DAKAP1. (B) HEK 293 cells were treated with H2O2 (500 μM),
8-CPT-CAMP (100 μM) or both for 10 min. Immunoblots were probed with anti-pDRP1 and
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4.3.6 Investigating the CaprotecTM Capture Compound Assay as a method to capture
redox-dependent PKAR binding partners
The CaprotecTM Capture Compound Assay (CCCA) system was another means of potentially
identifying oxidant-dependant PKAR binding partners. The design of the capture compound
means that it labels proteins associated with PKAR that have been UV-cross-linked to a
molecule containing a biotin tag (Figure 4.6). Vehicle or H2O2 (500 μM) treated HEK 293 cells
were lysed and processed with CCCA. In preliminary experiments PKARIα was not efficiently
captured as determined by the relative amount of PKARIα that was present in the unbound
fraction (Figure 4.21A). However analysis with streptavidin-HRP antibody revealed a difference
in biotin labelled proteins between control- or H2O2-treated lysates in the unbound fraction
(Figure 4.21B).
In order to capture PKAR and biotin-labelled proteins more efficiently it was necessary to
adjust the protein/capture compound ratio and therefore in subsequent experiments the
volume of capture compound incubated with HEK 293 cell lysate was halved. The rationale
behind this was to decrease the concentration of unbound capture compound after lysate
incubation, and therefore decrease the competition between protein-bound capture
compound and free capture compound during incubation with streptavidin beads. Decreasing
the volume of capture compound increased the efficiency of the capture indicated by the
decrease in unbound PKARIα. Again streptavidin-HRP analysis of protein biotinylated during
the CCA procedure showed band pattern differences between control, H2O2 or isoprenaline (10
nM) treated HEK 293 cells (Figure 4.21B). The bands after H2O2 treatment may represent
redox-dependent PKAR binding partners.
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Figure 4.21 Optimisation of CaprotecTM capture with a biotinylated C8-cAMP capture
compound. (A) HEK 293 cells were treated with H2O2 (500 μM) and lysates (without
maleimide) were incubated with the C8-cAMP capture compound prior to UV irradiation.
Proteins were pulled-down with streptavidin beads. Recombinant-PKARIα and recombinant
PKARIα with cAMP analogue were used as a positive control or negative controls respectively.
(B) To optimise capture, samples were incubated with half the concentration of capture
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4.4 Discussion
The aim of this chapter was to determine whether PKARIα bound differentially to AKAPs
depending on its redox state. The primary approach was to use cAMP-agarose to co-capture
AKAPs after H2O2 treatment, but this was unsuccessful. AKAP7 has been reported to bind to
PKARIα240, however I was unable to corroborate this. Furthermore, AKAP7 was not found to be
sensitive to reversible oxidative modifications using the PEG-maleimide switch method that
was successfully developed and validated during these studies. AKAP7δ was found to interact
with PKARIIα, but not PKARIα, and this association may be redox-dependent.
4.4.1 AKAP7
The failure of all commercially-available antibodies tested to detect AKAP7 significantly
hampered the initial progress of the project. Jones et al. used AKAP7 KO animals to highlight
that such commercial antibodies for AKAP7 can detect non-specific bands around the expected
molecular weight of AKAP7 and lead to misidentification of the protein234. The authors
reported the loss of bands that represent AKAP7γ/δ at around 37 kDa in their AKAP7 KO
animals. In contrast other groups have reported AKAP7 at approximately 50 kDa140,236.
Furthermore many commercial antibodies for AKAP7 report a band at 50kDa. Therefore there
should be an element of caution when considering the established AKAP7 literature. Given
this, moving to a cell over-expression system to investigate AKAP7 was justified.
No co-localisation between PKARIα and either AKAP7γ/δ isoform was detected in
immunofluorescence studies. Both AKAP7γ/δ localised primarily to the nucleus and in a few
cells it was localised in the cytoplasm. Nuclear localisation was unsurprising given that both
isoforms contain an N-terminal nuclear localisation signal motif240,250. Speculatively the
presence of AKAP γ/δ in the cytoplasm could be due to saturation of nuclear binding sites.
Electrostatic attraction of positively charged amino acid residues on the exterior of AKAP7δ
concentrate in the tertiary structure to form a binding surface for negatively charged lipids in
the membrane250. This may explain why AKAP7δ was seemingly localised at the nuclear
membrane in this study. Despite this, the consensus in the literature is that AKAP7γ/δ binds to
the sarcoplasmic reticulum140,242,251. However, definitive verification of which would require
the expression of AKAP7 in its correct cellular localisation context. This is a disadvantage of
over-expression studies in HEK293 cells, but their ease of transfection makes them useful in
the study of protein-protein interactions.
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4.4.2 Analysis of cAMP-agarose capture experiments
In the present study I was unable to establish an interaction between any AKAP and PKARIα
with cAMP-agarose capture experiments, despite its extensive use in the literature for this
purpose246-249. This was surprising given that these experiments were carried out in accordance
with established protocols.
PKARIα and PKARIIα were consistently captured, the former with greater efficiency, however I
was unable to co-capture known RIα AKAPs including AKAP7γ/δ, DAKAP1, DAKAP2, SKIP or
smAKAP. It was decided to pursue this methodology despite the setbacks because the number
of studies in the literature suggests it should be a viable approach. A great deal of time was
spent attempting to optimise the method which included: increasing the concentration of
protein used in each capture experiment; screening different buffers based on published
studies and those routinely used in this laboratory in similar experiments; altering the capture
incubation time; changing the stringency of wash buffer, but unfortunately none of these
approaches succeeded. The length of the spacer arm is an important consideration as this can
influence access to binding sites due to steric hindrance. 8-AEA-cAMP-agarose beads, used
routinely in my studies, have a 2 carbon spacer arm which has previously used to capture
PKARIα together with AKAPs249,252,253. A hydrophilic 19 atom spacer that conjugates cAMP to
agarose has recently become available which may improve the ability to co-capture PKARIα
binding partners if this method was pursued in future studies.
DAKAP1 was captured on cAMP-agarose even in the presence of a high concentration of
competing cAMP meaning that it was bound non-specifically to the agarose. In contrast
Jarnaess et al. were able to pull down DAKAP1 successfully with PKARIα and these proteins
were not captured in the presence of cAMP246. Not all examples of cAMP-agarose studies in
the literature have used excess cAMP as a negative control; therefore it is possible that some
AKAP/PKA interactions reported using this technique may be due to non-specific binding.
Some studies have used mass spectrometry to identify AKAPs which can be a beneficial
approach because it does not depend on antibodies that are often not fit-for-purpose as
outlined in this chapter for AKAP7254. To the best of my knowledge no study thus far has
utilised excess cAMP in proteomic screens to limit false-positive identification of proteins due
to non-specific binding. If this crucial control is included, proteins that are identified in H2O2
treated lysates vs. controls can be cross-referenced against a list of proteins from samples that
were incubated with an excess of cAMP to ensure that they are bona-fide PKAR binding
partners.
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AKAP7γ has been shown to bind to both PKARIα240 and PKARIIα241, however I was unable to
verify this. In the present study using Ni-Ni-NTA-agarose I demonstrated that AKAP7δ bound to
PKARIIα but not PKARIα. Evidence of the isoform binding specificity of AKAP7δ is ambiguous.
AKAP7δ binding RIIα with high affinity has been demonstrated121,255 but there is appears to be
no information about its interaction with PKARIα. The interaction between AKAP7δ and
PKARIIα may be redox-regulated. This may have some biological significance in the kidney
where AKAP7δ has been shown to mediate PKA phosphorylation and consequent
redistribution of water channel aquaporin-2 to increase water reabsorption in the renal
collecting duct237. Hypothetically physiological oxidant signalling may regulate this
phosphorylation due to PKARIIα targeting to AKAP7δ. The PEG-maleimide switch method
showed PKARIIα to be susceptible to a reversible oxidative modification. de Piña et al. suggest
that ROS induces a disulfide between PKARIIα Cys-97 and the Cys199 in the catalytic subunit
thus rendering it inactive107. However I found no evidence of mixed disulfide between the two
proteins on immunoblots and the catalytic subunits were not co-captured with PKARIIα and
His-AKAP7δ after Ni-NTA-agarose pull down (not shown). The redox regulation of PKARIIα and
AKAP7δ requires further investigation but was beyond the scope of this study which focuses
on PKARIα.
4.4.3 Analysis of PEG-maleimide switch assay
The PEG-maleimide switch method has proved a powerful tool for identifying proteins that are
sensitive to reversible oxidative thiol modifications, successfully detecting redox state changes
in the established oxidant-sensitive proteins PKARIα and PKGIα. It employs a similar principle
to the biotin-switch method, a technique first described by Jaffrey and Snyder that enables
detection of proteins that have undergone thiol S-nitrosation256. However, the exchange of the
modified thiol with PEG-maleimide instead of biotin simplifies the protocol with the benefit
that it becomes unnecessary to purify the biotin-labelled samples which is associated with loss
of protein and experimental variability. Rather, PEGylated proteins can directly be detected
and identified by a shift on an SDS-PAGE gel. Furthermore, the proportion of protein that shifts
correlates with an increasing concentration of H2O2; providing a semi-quantitative method for
indexing a proteins candidate of interest for which there is an antibody available.
There are some potential caveats with the PEG-maleimide switch method. For example, some
proteins may lose their immunoreactivity when PEGylated, which seems to have occurred with
PEGylated-PKG. This can potentially be addressed by using an antibody that recognises a
different region of the protein of interest. In addition, some proteins have been identified as
being able to form solvent-inaccessible oxidative modifications that are resistant to reduction
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even in the presence of high concentrations of reducing agent257. This represents a potential
problem with the PEG-maleimide switch because it requires full reduction of the oxidative
modification for efficient PEGylating. Such proteins will not be PEGylated during processing
and consequently erroneously concluded to be insensitive to oxidative modifications (i.e.
generate a false negative). Another potential issue with the PEG-switch assay is that 5 kDa
PEG-maleimide may not adequately shift high molecular weight target proteins to allow
detection of oxidation using SDS-PAGE. This could be overcome by using higher molecular
weight PEG-maleimide variants. However, a larger PEG-tag may affect protein solubility or
immunoreactivity. Despite this, the PEG switch is an effective mechanism to rapidly determine
whether a protein of interest is sensitive to reversible thiol oxidation.
AKAP7γ, but not AKAP7δ, was PEGylated after H2O2 treatment but surprisingly a switch was
still observed with the C229S/C243S-AKAP7γ mutant. Mutation of the only other cysteine
(Cys12) in AKAP7γ would determine whether it was modified by oxidants, however since this
cysteine is also present in AKAP7δ, which was not PEGylated, it is unlikely that it is reversibly
oxidised. Instead it is probable that a cysteine in the linker region between GFP and AKAP7γ is
responsible for the PEGylation. This could be verified by sub-cloning AKAP7γ into another
vector however it was decided not to pursue this due to time constraints and other priorities.
Therefore given that there was no evidence of AKAP7 oxidative modification on immunoblots
and that the SR associated AKAP7δ didn’t switch it was concluded that AKAP7 was not
sensitive to reversible oxidation modification.
4.4.4 Analysis of CaprotecTM co-capture assay
cAMP-CCCA was another method explored to try and co-capture redox-dependent PKAR
binding partners. S-adenosyl-l-homocysteine and staurosporine have been used to selectively
isolate proteome subsets using CaprotecTM technology that utilises UV to crosslink proteins
and stabilise protein-protein interactions258,259. In this case cAMP bound to the capture
compound is able to pull out PKAR before UV irradiation to covalently bind PKAR binding
partners, thus purifying the subset of proteins before MS identification. This is an
advantageous technique given the difficulty to co-purify partners that have low affinity or low
abundance, as may be the case when using cAMP-agarose. The number of PKARIα binding
partners increased when cells were challenged with H2O2 and optimisation of the method
allowed capture of these proteins. These bands potentially represent AKAPs and associated
substrates and therefore it is in agreement with the hypothesis that elevated intracellular ROS
can target PKARIα to AKAPs. Furthermore artificial PKARIα oxidation that occurs during cell
lysis and processing (as these experiments were carried out in the absence of maleimide) does
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not lead to additional bands being observed, suggesting PKARIα redox targeting is a co-
ordinated intracellular process. Captured proteins can be identified via LC/MS after separation
by SDS-PAGE, band excision and tryptic digestion. Preliminary experiments with cAMP-CCCA
have yielded promising results but this would have to be scaled up to allow direct comparison
of PKAR binding partners from WT or C17S PKARIα KI cardiac tissue with or without H2O2
treatment. There is also the limitation that all regulatory subunits of PKA are likely to be
captured which may complicate interpretation of any results. Unfortunately CaprotecTM
stopped providing support for the technology as they have changed their commercial strategy,
as such further studies could not easily be pursued. Nevertheless cAMP-CCCA is potentially an
alternative method to cAMP-agarose capture to identify redox PKARIα binding partners.
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5 Investigating cAMP-induced reduction of disulfide
PKARIα
5.1 Introduction
In the previous chapter I made an unexpected, but intriguing, observation that incubation of
HEK 293 cell lysate with cAMP-agarose induced the reduction of disulfide PKARIα. This
potentially could be a novel mechanism by which cAMP regulates redox state of PKARIα and
therefore oxidant-dependent signalling. Although this is an interesting possibility, a major issue
with this being realistic, as expanded on below in detail, is that cAMP itself has no intrinsic
chemical reduction capability and so there is significant complexity associated with this
observation.
PKARIα is structurally mobile, undergoing large movements as PKARIα toggles between its
binding partners, namely cAMP and the catalytic subunits. cAMP first binds to the more
accessible phosphate binding cassette in the cAMP B site, as the residues required for stable
nucleotide binding in the cAMP A site are masked by the interaction between PKARIα and PKA-
C. Upon cAMP binding, the R subunit undergoes a large conformational change in response to
the disruption of the salt bridge between Glu261 and Arg366 to allow access of another cAMP
molecule to the cAMP A site and facilitate full release of the catalytic subunits (Figure 5.1). In
this way there is a communication pathway between the two cAMP-binding domains that
provides a mechanism for the cooperative activation of PKA260.
Hamuro et al. utilised amide hydrogen/deuterium exchange measured by mass spectrometry
to assess the structural dynamics, protein-protein interactions and protein-ligand interactions
of PKARIα261. With the exception of the centre of α-helix1 (residues 31-36 involved in PKARIα
dimerisation) and the adjacent turn which exchange relatively slowly, deuteration in the D/D
domain (residues 1-61) of PKARIα occurs rapidly indicating that it is a dynamic, disordered and
solvent exposed region. Interestingly binding of cAMP or the catalytic subunits to PKARIα
made no difference to the rate of deuteration in the D/D domain, implying a lack of allosteric
communication between the cAMP sites and D/D261. Despite this, it is reasonable to suggest
that binding of an AKAP to the D/D domain will affect its solvent accessibility, thus regulating
the availability of the cysteine residues in this domain to electrophilic attack. The large
conformational change that occurs when cAMP binds to PKARIα may lead to steric changes in
the AKAP-PKARIα complex that further regulates cysteine accessibility and susceptibility to
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attack by oxidants. This would represent a novel method of communication between the
cAMP binding sites and the redox cysteines in the D/D domain. I hypothesise that such steric
effects that may occur upon cAMP binding may explain the observed cAMP induced reduction
of PKARIα.
In this chapter I present evidence to suggest that under certain conditions cAMP can induce
the reduction of PKARIα, and that it participates in the resolution of a mixed disulfide complex
between PKARIα and tubulin, a novel redox-dependent AKAP.
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Figure 5.1 PKA undergoes a large conformational change upon cAMP binding. (A) Schematic
representing the two regulatory subunits of PKARIα. Shown are the N-terminal
dimerisation/docking domain (D/D) complexed with an AKAP helix (AKB), and the C-terminal
cyclic nucleotide binding site A and B (CNBA and CNBB). (B) Crystal structure of PKARIα (blue)
complexed with catalytic subunits (red) when inactive. cAMP (magenta) binding activates
PKARIα by inducing conformational change that unleashes catalytic subunits. AKB (green)
bound to D/D domain. Movement of cAMP binding domains may alter PKARIα-AKAP complex
conformation. (Figure adapted from Taylor et al. 2012112 and illustration by David S. Goodsell










Antibody Purchase Code Company Species Dilution
anti-Gapex-5 SAB4200099 Sigma Rabbit 1:1000
anti-caprin1 15112-1-AP Proteintech Rabbit 1:1000
Anti-α/β-tubulin 2148 Cell Signaling
Technology
Rabbit 1:1000
Table 5.1 Antibodies used in Chapter 5
5.2.2 Generation of PKARIα-cAMPand C17SPKARIα-cAMP constructs
The dominant negative mouse PKA plasmid M7 pdnPKA-GFP cDNA (Ungar & Moon, 1996)263
containing a Gly200Glu mutation in cAMP binding domain A was obtained from (Addgene
plasmid # 16716) (PKARIα-cAMP). PKARIα Cys17Ser mutation (C17SPKARIα-cAMP) was introduced
using the Quik-Change Site-Directed Mutagenesis Kit (Agilent) according to the manufacturer’s
instructions by Dr. Joseph Burgoyne.
5.2.3 Generation of V5-PKARIα and V5-C17SPKARIα constructs
Human PRKAR1A was isolated from transformed from DH5-α T1 phage resistant E. coli (DNA
Plasmid Repository, HsCD00040733). PKARIα Cys17Ser mutation was introduced using the
Quik-Change Site-Directed Mutagenesis Kit (Agilent) according to the manufacturer’s
instructions. PKARIα-WT and C17SPKARIα entry clones were then transferred to pcDNA ™3.2-
DEST Mammalian Expression Vector (C-terminal V5-tag) (Life Technologies) using Gateway® LR
Clonase® II Enzyme mix, to generate V5-PKARIα and V5-C17SPKARIα respectively.
5.2.4 HEK 293 cell lysate incubation with cAMP
HEK 293 cells were seeded onto a 12-well plate and incubated overnight. The next day cells
were treated with 500 μM H2O2 for 10 min, lysed (100mM Tris pH 7.4, 1% Triton, 150 mM
NaCl, 100 mM maleimide and protease inhibitor cocktail) and centrifuged at 15,000 g for 15
min at 4°C. The soluble fraction was incubated with 0-50 mM cAMP Na+ and rotated end-over-
end for 2 hours at 4°C. The reaction was terminated with x2 SDS-PAGE sample buffer
containing 100 mM maleimide.
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5.2.5 HEK 293 cell lysate incubation with DTT
HEK 293 cells were seeded onto a 12-well plate and incubated overnight. The next day cells
were treated with 500 μM H2O2 for 10 min, lysed (100mM Tris pH 7.4, 1% Triton, 150 mM
NaCl, 100 mM maleimide and protease inhibitor cocktail) and centrifuged at 15,000 g for 15
min at 4°C. Soluble fractions were incubated with 0- 100 mM DTT, and 1 mM cAMP was added
to the relevant lysates. Samples were briefly mixed and allowed to stand for 30 min at room
temperature. The reaction was terminated with 1 M maleimide before the addition of x4 SDS-
PAGE sample buffer.
5.2.6 Affinity Pull Down using cAMP-agarose with biotin maleimide
Samples were prepared as cAMP-agarose experiments, however, pre- and post-incubation
with cAMP-agarose an aliquot of lysate was de-salted to remove excess maleimide before
incubation with 0.5 μM biotin-maleimide for 1 hour at room temperature. The reaction was
terminated with x4 SDS-PAGE sample buffer containing 100 mM maleimide.
5.2.7 Sequential two dimensional non-reducing/reducing SDS-PAGE
Anti-PKARIα immunoprecipitations of PKARIα-cAMP transfected HEK 293 cells that had been
treated with vehicle or 500 μM H2O2 were resolved on 4-15% SDS-polyacrylamide gels (Bio-Rad
mini protean III system). After non-reducing electrophoresis, the entire lane containing the
resolved proteins was excised and rotated through 90° and laid horizontally on top of a large
format 1.5-mm thick 8% acrylamide gel. The gel slice was incubated in SDS sample buffer
containing 100 mM DTT (to reduce any proteins disulfide linked to PKARIα-cAMP) for 10 min. At
this stage proteins that were linked by a disulfide bond were separated by DTT treatment and
then resolved after SDS-PAGE further down the gel at their true weight in the second reducing
dimension. Control or H2O2 treated fractions were laid adjacent to each other on the large
format gel and run simultaneously to ensure that valid comparisons can be made between
treatments. Gels were stained with colloidal Coomassie Blue G stain to visualize the proteins
and then destained in 20% methanol. Protein spots that ran off of the diagonal and to the left
of the slope represented proteins were disulfide linked to PKARIα. Spots/bands were excised in
preparation for identification using liquid chromatography followed by tandem mass
spectrometry (LC-MS/MS), which was kindly performed by Dr. Xiaoke Yin.
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5.2.8 Immunoprecipitations
HEK 293 cells seeded in T75 flask were lysed in RIPA Buffer (50 mM Tris pH7.4, 500 mM NaCl,
1% NP-40, 0.5% C24H39NaO4, 0.1% Triton X-100, 100 mM maleimide and protease inhibitor
cocktail) and centrifuged at 2500 g for 5 min at 4°C. The supernatant was used for the
immunoprecipitation and the pellet was discarded. An aliquot of the supernatant was taken
and added to an equal volume of x2 SDS-sample buffer and this was designated as the input.
Lysates were incubated with anti-PKARIα and rotated end-over-end overnight at 4°C. In other
experiments lysates from V5-PKARIα transfected HEK 293 cells were incubated with anti-V5
conjugated to agarose beads. Immunoprecipitates were collected using Protein A/G Plus-
agarose beads (Santa Cruz Biotechnology, Inc.) that had been washed in RIPA buffer after 3
hours end-to-end rotation at 4°C. Samples were places in spin columns and centrifuged at
1500 g for 30 seconds at 4 °C. Flow through was collected and an equal volume of x2 SDS-
sample buffer was added to form the unbound. Samples were washed three times in in RIPA
buffer before beads were incubated with x4 SDS-sample buffer for 5 min and eluted as the
capture.
5.2.9 in situ proximity ligation assay (PLA)
Cells, treated as indicated, were fixed and blocked as per the standard immunofluorescence
protocol. The in situ PLA experiments were performed using the Duolink® In Situ Red Starter
Kit Mouse/Rabbit (Sigma) according the manufacturer’s instructions. Cells were incubated with
primary antibodies, anti-tubulin and anti-PKARIα, and thereafter incubated with PLA probes,
which are secondary antibodies (anti‐mouse and anti‐rabbit) conjugated to unique
oligonucleotides. Circularization and ligation of the oligonucleotides was followed by an
amplification step. The products were detected by a complementary fluorescently labelled
probe. Slides were mounted in Lisbeth’s medium onto microscope slides and were analysed
using confocal microscopy on an inverted microscope (Leica SP5 system) equipped with a blue
diode and argon and helium neon lasers.
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Figure 5.2 Schematic representing in situ proximity ligation assay. Figure adapted from
http://www.olink.com/
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5.3 Results
5.3.1 cAMP-agarose induced reduction of PKARIα
Experiments using cAMP-agarose led to the unexpected observation that PKARIα was captured
predominantly as a monomer, even after cells had been exposed to H2O2 to induce disulfide
(Figure 5.3). There was no PKARIα disulfide dimer in the unbound fractions, thus it is tempting
to suggest that cAMP binding had induced the reduction of PKARIα. Neither maleimide nor
cAMP-agarose altered the pH of the reaction mixture (data not shown) and the reduction was
observed regardless of the specific type of cAMP-agarose used. The ability of cAMP to regulate
the redox state of PKARIα could be biologically significant and therefore warranted further
investigation.
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Figure 5.3 PKARIα from HEK 293 cell lysate is reduced after incubation with cAMP-agarose.
HEK 293 cells were treated with H2O2 (0-500 μM), harvested in buffer containing 100 mM
maleimide and subsequently incubated with cAMP-agarose. PKARIα, which was then visualised
on non-reducing immunoblots, was captured and observed transitioned predominately to the
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The previous observations were performed with lysis buffer containing maleimide. When
cAMP-agarose experiments were performed without maleimide, PKARIα was artificially
oxidised in the air during cell lysis and captured predominantly in this dimeric disulfide form
(Figure 5.4). Therefore without maleimide PKARIα does not undergo cAMP-induced reduction.
To further investigate cAMP-induced reduction of PKARIα, HEK 293 cell lysate pre-treated with
H2O2 (500 μM) was incubated with various concentrations of authentic cAMP (1-50 mM)
instead of cAMP-agarose. Under these conditions cAMP alone was unable to induce the
reduction of PKARIα despite the experimental conditions being comparable to those carried
out with cAMP-agarose (Figure 5.5).
Figure 5.4 PKARIα from HEK 293 cell lysate without maleimide remains oxidised after
incubation with cAMP-agarose. HEK 293 cells were treated with H2O2 (0-500 μM), lysed and
then incubated with 8-AEA-cAMP-agarose. PKARIα detected on a non-reducing immunoblot
was captured and observed in the oxidised state.
50 -
100 -
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Figure 5.5 PKARIα from HEK 293 cell lysate is not reduced after incubation with authentic
cAMP. HEK 293 cells were treated with 500 μM H2O2 and lysates (containing maleimide) were
subsequently incubated with cAMP (0-50 mM). The proportions of PKARIα in the disulfide
dimeric state was then determined using non-reducing immunoblot analysis and is
represented graphically (n=6-7 ± SEM).
50 -
100 -
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5.3.2 Investigating effects of time and cAMP-agarose volume on PKARIα disulfide
reduction
There was also a lack of evidence supporting PKARIα induced reduction mediated through
cAMP in cellular models that modelled global PKARIα monomer and dimer ratios (Chapter 3).
Despite this, the initial observation robustly indicated that the nucleotide is capable of
inducing PKARIα reduction. I then rationalised that perhaps cAMP reduction may only occur
under specific conditions; certainly more complexity is anticipated as cAMP itself is not a
reducing agent. Consequently, I decided it was worthwhile to investigate this potentially
important observation further as it may have physiological significance.
To further characterise cAMP-induced PKARα reduction, PKARIα capture from H2O2 (500 μM)
treated HEK 293 cells lysate by cAMP-agarose was monitored over various time points (5-120
min). After 5 min PKARIα monomer and dimer are captured at a ratio matching that in the
input. However the concentration of captured PKARIα monomer increases over time to a
greater extent than the disulfide dimer (Figure 5.6A). This increased capture of monomer over
time relative to disulfide dimer may be accounted for by PKARIα disulfide dimer being reduced
to the monomeric form. In a separate experiment the effect of the volume of cAMP-agarose
beads on disulfide PKARIα reduction was also investigated. HEK 293 cell lysate was incubated
with various amounts of cAMP-agarose (0- 150 μL) and the extent of PKARIα capture was
assessed by immunoblotting. In the absence of cAMP-agarose, PKARIα was not captured and
the monomer and dimer was comparable between the input and unbound. cAMP-agarose
again induced the reduction of PKARIα from disulfide dimer to monomer, regardless of the
volume of cAMP-agarose used (Figure 5.6B). This indicates that the capture of disulfide PKARIα
by cAMP-agarose is not limited by saturation of “dimer-specific cAMP-agarose binding sites”
but rather suggests that cAMP-agarose is able to induce the reduction of PKARIα.
Investigating cAMP-induced reduction of disulfide PKARIα
149
Figure 5.6 cAMP-agarose induced reduction of PKARIα is not limited by time or agarose bead
volume. HEK 293 cells were treated with H2O2 (500 μM) and lysates were subsequently
incubated with 8-AEA-cAMP-agarose (100 μl) for (A) 5-120 min. (B) Lysates were incubated
with various volumes of 8-AEA-cAMP-agarose (0- 150 μL) for 120 min. PKARIα detected on a
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5.3.3 Investigating the reduction of PKARIα with NTA-Ni-agarose and 6-AH-AMP-agarose
HEK 293 cells were incubated with Ni-NTA-agarose or 6-AH-AMP-agarose to determine
whether the reduction of PKARIα to a monomer is specific to cAMP-agarose. The PKARIα
disulfide dimer from HEK 293 cells treated with H2O2 was not captured when incubated with
Ni-NTA- or 6-AH-AMP-agarose (Figure 5.7). Importantly the ratio of PKARIα monomer to dimer
in the input was comparable to the ratio in the unbound fractions, indicating that the induced
reduction of PKARIα is specific to cAMP-agarose.
A
B
Figure 5.7 Neither Ni-NTA or 6-AH-AMP-agarose induce PKARIα disulfide dimer reduction.
HEK 293 cells were treated with H2O2 (0-500 μM) and lysates were subsequently incubated
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5.3.4 Investigating effects of cAMP on DTT-dependent reduction of disulfide PKARIα
To further assess whether cAMP could regulate PKARIα disulfide dimer reduction, the lysate of
HEK 293 cells that had been challenged with H2O2 were incubated with cAMP (1mM) and
various concentrations of the reducing agent dithiothreitol (DTT) (0- 100 mM). The incubation
of lysate with DTT caused a dose-dependent decrease in PKARIα disulfide dimer. cAMP
potentiated DTT-induced reduction of PKARIα disulfide dimer, which was significantly different
at 75 mM compared to DTT alone (Figure 5.8A). To determine whether this cAMP potentiated
reduction required a component from the cell lysate, purified recombinant PKARIα was
incubated with DTT in the absence or presence of cAMP. Interestingly cAMP had no effect on
DTT-dependent reduction of recombinant-PKARIα disulfide, suggesting that another
component present in the cell lysate is necessary for cAMP to potentiate the reduction of
PKARIα (Figure 5.8B).




Figure 5.8 cAMP potentiates DTT-induced PKARIα reduction in HEK 293 cell lysate but not
purified recombinant PKARIα. (A) HEK 293 cells were treated with H2O2 (500 μM) and lysates
(containing 100 mM maleimide) were subsequently incubated with DTT (0-100 mM) in the
absence or presence of cAMP (1 mM) for 30 min at room temperature. The percentage of
PKARIα disulfide dimer was analysed after detection of PKARIα on a non-reducing immunoblot
and is represented graphically (n=4 ± SEM). (B) Recombinant PKARIα was incubated with
incubated with DTT (0-100 mM) in the absence or presence of cAMP (1mm) for 30 min at room
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5.3.5 Evidence for presence of free thiols during cAMP-agarose incubation
cAMP has no intrinsic capability to reduce PKARIα directly. However cAMP binding induces a
conformational change in PKARIα. This structural change in PKARIα may conceivably allow a
thiol containing protein or molecule to access and attack a sulphur atom in the disulfide bond
to enable the reduction of PKARIα to the monomeric state observed. However, the presence of
a free thiol during the capture phase is difficult to reconcile given that the HEK 293 cells are
lysed in the presence of an excess of the alkylation reagent maleimide. Studies in this
laboratory have demonstrated that efficient alkylation requires heating lysates containing
maleimide to 50°C in the presence of SDS. Such harsh conditions are not compatible with
cAMP-agarose experiments therefore it is possible that lysates may contain free thiols due to
inefficient alkylation. To test this hypothesis, lysates for cAMP-agarose incubation were
prepared as outlined above, but an aliquot was taken pre- and post-incubation, desalted to
remove excess maleimide and then incubated with biotin-maleimide (0.5 mM) for 1 hour at
room temperature to label any remaining free thiols. Immunoblotting using streptavidin-HRP
revealed multiple bands that represented biotin-maleimide labelled proteins before and after
cAMP-agarose incubation despite the lysis buffer contacting maleimide (Figure 5.9). Therefore
it is reasonable to conclude that there are free thiols available during cAMP-agarose
incubation that could potentially reduce disulfide PKARIα.
Figure 5.9 Free thiols are available during cAMP-agarose incubation. HEK 293 cells were
treated with H2O2 (500 μM) and lysates were subsequently incubated with biotin-maleimide
pre- and post-incubation with 8-AEA-cAMP-agarose. Biotin-maleimide labelled samples were







Investigating cAMP-induced reduction of disulfide PKARIα
154
If cAMP-induced reduction of PKARIα does necessitate a free thiol in the lysate, high
concentrations of H2O2 may lead to oxidation of this thiol and thus prevent disulfide PKARIα
from becoming reduced to its monomeric form. With this in mind, HEK 293 cells were treated
with high concentrations of H2O2 (0- 2 mM) and incubated with cAMP-agarose. In the input,
PKARIα dimer formation increased with increased concentrations of H2O2 that is particularly
striking at 1 or 2 mM H2O2. Despite this PKARIα was captured predominantly in the monomeric
form at all H2O2 concentrations, showing again that cAMP somehow facilitated reduction of
disulfide PKARIα (Figure 5.10). In cells treated with 1 mM or 2mM H2O2 there was increased
captured PKARIα disulfide dimer compared to 0 and 500 μM H2O2. This could mean that some
of the thiol(s) responsible for reduction of the PKARIα disulfide may become oxidised at this
time.
Figure 5.10 cAMP-agarose induced reduction of PKARIα is limited at high concentrations of
H2O2. HEK 293 cells were treated with H2O2 (0-2 mM) and lysates were subsequently
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5.3.6 Investigating cAMP-agarose induced reduction of PKARIα-cAMP
To further investigate the role of cAMP on PKARIα disulfide reduction, a dominant negative
PKARIα construct with a Gly200Glu mutation in the cAMP binding site that prevents cAMP
binding (PKARIα-cAMP) was generated. This construct was transfected into HEK 293 cells that
were subsequently treated with H2O2 (0- 500 μM) and incubated with cAMP-agarose. In
contrast to previous experiments the majority of PKARIα was detected in the unbound fraction
(Figure 5.11A). The small amount of PKARIα that is captured can be attributed to endogenous
PKARIα, whilst the inability for cAMP-agarose to capture PKARIα-cAMP is verification that the
mutations in the cAMP binding site were effective. Strikingly the ratio of PKARIα monomer and
dimer in the input is similar to the ratio observed in the unbound fraction. This further
demonstrates the requirement for cAMP to bind to PKARIα directly to induce reduction from
dimer to monomer. Interestingly, when PKARIα-cAMP cells were treated with H2O2 there was a
dose-dependent formation of high molecular complexes above the weight of the dimer. It was
hypothesised that these high molecular weight complexes could be PKARIα disulfide linked to
proteins. To confirm this, a mutant form of PKARIα-cAMP was engineered where Cys17, a critical
cysteine necessary for disulfide formation, was mutated to a serine residue (C17SPKARIα-cAMP).
HEK 293 cells were transfected with C17SPKARIα-cAMP which failed to dimerise upon H2O2 (0-
500 μM) treatment, and notably the high molecular weight complexes that were previously
observed were abrogated (Figure 5.11B). This suggests that PKARIα is capable of forming
mixed disulfide complexes with target proteins, and that the formation of these complexes is
contingent on the PKARIα disulfide dimer. Finally, in contrast to experiments undertaken with
non-transfected HEK 293 cell lysate, cAMP did not potentiate DTT-induced PKARIα disulfide
reduction in lysates from HEK 293 cell transfected with PKARIα-cAMP. This provides further
evidence that cAMP can regulate the redox state of PKARIα (Figure 5.11C).
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Figure 5.11 PKARIα-cAMP forms high molecular weight complexes when oxidised which is not
reduced by cAMP-agarose. (A) PKARIα-cAMP transfected HEK 293 cells were treated with H2O2
(0-500 μM) and lysates were subsequently incubated with 8-AEA-cAMP-agarose. Red boxes
indicate high molecular weight complexes (B) PKARIα-cAMP or C17SPKARIα-cAMP transfected HEK
293 cells were treated with H2O2 (0-500 μM). (C) PKARIα-cAMP transfected HEK 293 cells were
treated with H2O2 (500 μM) and lysates (with 100mM maleimide) and were subsequently
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5.3.7 Identification of proteins present in PKARIα-cAMP high molecular weight complexes
H2O2-treated HEK 293 cells transfected with PKARIα-cAMP formed high molecular weight
complexes. Biologically these high molecular weight complexes may represent AKAPs that
PKARIα is targeted to under oxidative conditions. These complexes are observed only with a
mutant form of PKARIα that cannot bind to cAMP. Therefore this may suggest that a
transitory, intermediate mixed disulfide normally forms in WT PKARIα, but this interaction is
stabilised in the mutant that cannot bind cAMP. cAMP may induce a conformational change
that brings a free thiol into close proximity required to bring a necessary free thiol into close
proximity to attack a sulphur atom in the mixed disulfide bond and result in cAMP-induced
reduction of PKARIα via thiol disulfide exchange. Figure 5.12 illustrates a model of how H2O2
and cAMP may act co-operatively to regulate the PKARIα redox state, and consequently the
PKARIα interaction with AKAPs.
As the high molecular weight complexes may represent potential PKARIα disulfide-dependent
AKAPs, it was rational to identify them using mass spectrometry. This was achieved by first
immunoprecipitating PKARIα-cAMP from transfected HEK 293 cell lysate, and then performing
two-dimensional sequential non-reducing-reducing diagonal gel electrophoresis169. Coomassie
Blue staining allowed visualisation of spots that run off the diagonal and to the left of the slope
which represented proteins that were disulfide-bound to PKARIα. These spots were excised
and identified using liquid chromatography – mass spectrometry (LC-MS/MS).
Figure 5.13 shows the Coomassie Blue stained gels of two independent experiments that were
carried out with vehicle- or H2O2-treated PKARIα-cAMP transfected HEK 293 cells. Using
immunoprecipitation rather than total cell lysate meant the diagonals and protein spots were
faint, but were still visible with the naked eye for excision. LC-MS/MS analysis of tryptic digests
identified 8 proteins as outlined in Table 5.2. To verify these targets as bona fide PKARIα
oxidant-induced binding partners, immunoprecipitation of PKARIα-cAMP from HEK 293 cell lysate
followed by immunoblotting for the protein of interest was performed. It was expected that
under control conditions these proteins would run at the expected weight, but in H2O2 treated
samples a proportion of the protein would run 100 kDa higher due to the disulfide link with
PKARIα disulfide.




2 induces disulfide bond in







AKAP (observed in PKARIα -cAMP)
















sulphur atom in the mixed
disulfide bond inducing thiol-
disulfide exchange. PKARIα
is
reduced to a monomer and the
AKAP now contains an intra-
molecular disulfide bond.
-




change and therefore the mixed
disulfides can be observed after
cAMP-agarose incubation.
Figure 5.12 A proposed model for cAMP-induced PKARIα reduction
Investigating cAMP-induced reduction of disulfide PKARIα
159
Figure 5.13 Coomassie Blue -stained diagonal gels of PKARIα-cAMP immunoprecipitates. Shown
here are examples of two stained gels from independent experiments. PKARIα-cAMP transfected
HEK 293 cells were treated with vehicle or H2O2 and then immunoprecipitated with anti-
PKARIα. Samples were run under non-reducing conditions in the first dimension and under
reducing conditions in the second (so called diagonal electrophoresis). Bands were
subsequently excised after Coomassie staining and proteins present identified using LC-
MS/MS.
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Table 5.2 Summary of proteins identified from excised spots that ran off the diagonal after gel electrophoresis.
Exclusion criteria: 2 unique peptides, 99% protein threshold, 90% peptide threshold
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GTPase-activating protein and VPS9 domain activating protein 1 (GAPex-5) was assessed due
to the relatively high number of spectral counts from the data set and because it has 26
cysteines in its primary sequence. Unfortunately the GAPex-5 antibody did not recognise a
protein at the predicted molecular weight and therefore no conclusions could be drawn
(Figure 5.14A). Caprin-1 has been identified as an AKAP350 binding partner thus making it an
interesting candidate for further investigation264. The caprin-1 antibody detected a band at the
correct weight in the input, and although a small amount was detected in the
immunoprecipitate, there was no difference between vehicle- or H2O2-treated HEK293 cells
(Figure 5.14B).
Tubulin has previously been suggested as a PKARIα AKAP265. Immunoblots for tubulin from the
two PKARIα-cAMP immunoprecipitates that were analysed by mass spectrometry, revealed
tubulin running at its expected weight and also at approximately 150 kDa in samples that were
treated with H2O2, consistent with a mixed disulfide complex with PKARIα (Figure 5.15AB). In
support of this, the PEG-maleimide switch method revealed that tubulin was PEGylated after
HEK 293 cells were treated with increasing concentrations of H2O2 (0- 500 μM) indicating that
it is sensitive to reversible oxidative modifications (Figure 5.15C).
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Figure 5.14 GAPex-5 and Caprin-1 are not redox state-dependent PKARIα binding partners.
HEK 293 or PKARIα-cAMP transfected HEK 293 cells were treated with vehicle or H2O2 were
immunoprecipitated with anti-PKARIα. (A) GAPex-5 was not detected at the expected
molecular weight on an immunoblot as indicated by the black arrow. (B) Caprin-1 was
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Figure 5.15 Tubulin forms a high molecular weight complex with PKARIα-cAMP and is sensitive
to reversible oxidative modifications. PKARIα-cAMP transfected HEK 293 cells were treated with
vehicle or H2O2 and the immunoprecipitated with anti-PKARIα. Immunoblots were probed with
(A) anti-PKARIα or (B) anti-tubulin. (C) H2O2 treated (0-500 μM) HEK 293 cells underwent PEG-
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5.3.8 Investigating the PKARIα and tubulin interaction
Further immunoprecipitation experiments were conducted in an attempt to verify the
interaction between PKARIα and tubulin. HEK 293 cells were transfected with either PKARIα-
cAMP or C17SPKARIα-cAMP and treated with H2O2 (500 μM). These experiments were performed
using exactly the same protocol above whereby tubulin was co-captured or was identified by
LC-MS/MS as part of a high molecular weight PKARIα complex. However quite inexplicably in
these experiments, which were carried out at later date, tubulin was co-captured but was now
observed at its expected molecular weight only (Figure 5.16). It is worth noting that only a
small proportion of tubulin migrated at the higher weight complexes in the original
experiments, and as explained above this is potentially only a transient, intermediate
interaction. Despite the inability to detect a higher molecular weight complex, these
immunoprecipitations still corroborated that PKARIα-cAMP and tubulin exist in a complex, as
tubulin was co-captured to a greater extent in cells where PKARIα-cAMP was over-expressed.
However, unlike the LC-MS/MS immunoprecipitations there did not appear to be a difference
between in the PKARIα-tubulin interaction when cells were treated with H2O2. In
immunoprecipitation experiments where HEK 293 cells were transfected with V5-PKARIα or
V5-C17SPKARIα (these constructs had wild type cAMP binding sites), PKARIα was pulled down
and tubulin was co-captured using a V5 antibody conjugated to agarose beads with no
difference observed between vehicle or H2O2 treatment (Figure 5.17). Again, in non-
transfected cells the amount of tubulin that was captured was significantly less than in
transfected cells.
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Figure 5.16 Tubulin is co-captured with PKARIα-cAMP or C17SPKARIα-cAMP. PKARIα-cAMP or
C17SPKARIα-cAMP transfected HEK 293 cells were treated with vehicle or H2O2 and their lysates
immunoprecipitated with anti-PKARIα. Immunoblots were probed with an antibody for either
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Figure 5.17 Tubulin is co-captured with V5-PKARIα or V5-C17SPKARIα. V5-PKARIα or V5-
C17SPKARIα transfected HEK 293 cells were treated with vehicle or H2O2 and
immunoprecipitated with a V5 antibody conjugated to agarose beads. Non-reducing
immunoblots were probed with the antibody for either PKARIα or tubulin. The extent of co-
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The interaction between PKARIα and tubulin was further examined in vascular smooth muscle
cells by co-immunostaining. Tubulin staining allowed visualisation of the microtubules. The
pattern of PKARIα immunofluorescence was diffuse throughout the cell and overlapped with
that of tubulin (Figure 15.18). However, there was no clear difference in co-localisation when
cells were treated with vehicle or H2O2 (500 μM). Due to the ubiquitous nature of both of the
proteins a more specific imaging technique was required to discern any differences between
normal and oxidised conditions. Proximal ligation assay technology allows the detection of
protein-protein (<40 nM apart) interactions of in situ. Figure 15.19 shows incubation with
tubulin and PKARIα antibodies together generated staining in VSMCs following vehicle- or
H2O2-treatment, whilst incubation of each antibody individually as negative controls generated
negligible signals. H2O2 did not appear to increase the fluorescent signal which is consistent
with the immunoprecipitation experiments. Taken together the immunoprecipitation and
immunofluorescence experiments confirm tubulin as an AKAP.
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Figure 5.18 PKARIα is localised to tubulin in VSMCs.Representative immunofluorescent image. VSMCs were treated with vehicle or H
2 O
2
(500μM)and then stained with tubulin (green) and PKARIα(red) antibodies. The nucleus was stained withb4′,6-diamidino-2-phenylindole
(DAPI, blue).
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Figure 5.19 PKARIα is localised to tubulin in VSMCs.Representative image of Proximity Ligation Assay. VSMCs were treated with
vehicle or H2 O
2 (500μM) and then stained with tubulin and PKARIαantibodies. The nucleus was stained withb4′,6-diamidino-2-
phenylindole (DAPI, blue). Each red dot represents the detection of protein-protein complexes.
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5.4 Discussion
cAMP activates PKARIα to induce substrate phosphorylation and here it is demonstrated that
cAMP may also govern the localisation of PKARIα through its capacity to modulate the redox
state of PKARIα. cAMP-agarose appears to induce the reduction of PKARIα from a disulfide
dimer to a monomer, perhaps via allosteric modulation of a PKARIα-AKAP disulfide
intermediate that leads to the reduction of the mixed disulfide complex and of PKARIα.
Evidence of a cAMP- and redox-dependent transitory PKARIα-tubulin mixed disulfide complex
was provided, as well as confirmation of tubulin as a bona-fide AKAP. Ultimately the redox-
dependent interaction between tubulin and PKARIα may govern the phosphorylation of
microtubule associated proteins which is explored in Chapter 6.
5.4.1 PKARIα reduction induced by cAMP-agarose
cAMP-agarose induced the reduction of PKARIα disulfide dimer in the presence of the
alkylating agent maleimide, but failed to do so in the absence of maleimide. Figure 15.20
shows a model of what may be occurring under the two different conditions. As the redox
state of PKARIα can be stabilised with maleimide-containing lysis buffer, and this is protective
against artificial air oxidation, it is reasonable to assume that maleimide is capable of alkylating
the disulfide PKARIα cysteines more rapidly than oxygen is able to induce disulfide formation.
Therefore when cAMP induces the reduction of the PKARIα disulfide the free thiols rapidly
react with maleimide, thus stabilising the monomer to allow detection of PKARIα in this form.
Without maleimide, the free thiols simply re-oxidise in air after cAMP induced PKARIα disulfide
reduction and therefore PKARIα is observed as a dimer on an immunoblot. To the best of my
knowledge, there is no report of cAMP-agarose influencing the redox state of PKARIα. Typically
alkylating agents such as maleimide are not included in the buffers used to prepare samples or
during SDS-PAGE as it has been here, thus PKARIα would always be observed at 50 kDa under
the standard reducing conditions that are widely used.
Investigating cAMP-induced reduction of disulfide PKARIα
171
Figure 5.20 Model of disulfide PKARIα reduction during exposure to cAMP-agarose in the
absence or presence of maleimide
The biotin-maleimide experiment demonstrates that there are free thiols in the lysate during
cAMP-agarose incubation. 0.5 mM biotin-maleimide was able to label thiols even after lysate
had been incubated with 100 mM maleimide, demonstrating the initial alkylation step is not
fully efficient. The thiol(s) responsible for reducing PKARIα must be, at least partially,
insensitive to air oxidation as well as resistant to maleimide alkylation (at the low temperature
used for preparing lysate for homogenates). However it must be reactive enough to reduce a
disulfide bond. This at first appears to be contradictory unless basally the thiol residue is
concealed and therefore protected from oxidation and alkylation, and then upon cAMP
binding, the structural conformation of the protein is altered thus revealing the free thiol
which is now capable of attacking the cysteine on PKARIα. A mechanism whereby a
conformational change can lead to the exposure of a reactive cysteine has previously been
proposed in APE180.
One such thiol-containing candidate protein that may be involved in disulfide PKARIα
reduction is thioredoxin (Trx). Members of this laboratory have used specially engineered mice
where the resolving Cys35 in Trx has been mutated to a serine residue. Consequently Trx
forms a mixed disulfide with target proteins and remains bound to them, enabling detection of
these targets through immunoprecipitation of Trx and immunoblotting for suspected binding
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partners. Using this method the known Trx target ASK1 was co-captured, as was the novel Trx
target PKGIα266. However, PKARIα was not co-captured suggesting that it is not a target of Trx
(data not shown). 1 mM or 2 mM concentrations of H2O2 led to increased capture of disulfide
PKARIα which may indicate oxidation of the hypothesised resolving thiol (potentially in
tubulin). To prove the existence of the resolving thiol systematic mutation of candidate
cysteine residues to serines would lead to the stabilisation and accumulation of the PKARIα-
AKAP intermediate post-H2O2 treatment.
In agreement with results presented above, it has previously described that high
concentrations of DTT are necessary to reduce PKARIα which perhaps suggest that the thiols
are reasonably inaccessible198. cAMP potentiated DTT-induced reduction of PKARIα but not
PKARIα-cAMP. This is consistent with the hypothesis that a cAMP-induced conformational
change can alter the accessibility of PKARIα cysteines involved in dimer formation to DTT and
other free thiols. DTT-inaccessible disulfides that become susceptible to reduction after
allosteric modulation have been previously described in ionotropic glutamate receptors198 and
are also hypothesised to be present in titin267.
5.4.2 LC-MS/MS identification of tubulin
The high molecular weight complexes observed after H2O2 with PKARIα-cAMP potentially
provides insight into PKARIα redox signalling as they may represent intermediates that arise
from PKARIα targeting to AKAPs. MS analysis of tryptic digests excised from sequential non-
reducing-reducing SDS-PAGE analysis of PKARIα-cAMP immunoprecipitates identified tubulin as a
component of a high molecular weight complex.
Kuruso et al. previously demonstrated that PKARI forms a high molecular weight complex with
tubulin in both Aplysia and in mouse brain extract that was sensitive to the reducing agents
DTT and β-ME265. Furthermore this high molecular weight complex was lost in Aplysia ganglia
treated with serotonin, a neurotransmitter that elevates intracellular cAMP, an observation
that compliments the cAMP-agarose data in this Chapter. The authors also suggest that the
high molecular weight complex formation enriches PKARI at the synaptic end. In the context of
redox signalling, the presence of PKARIα within disulfide complexes may be a mechanism by
which oxidants intensify cAMP signals by concentrating the PKARIα holoenzyme in a specific
location.
A quantitative replicative proteomic approach would have been a more comprehensive
strategy for identifying PKARIα binding partners. Proteomics with replicates would have
allowed the identification of interactions that were reproducible (i.e. statistically significant)
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and so avoid false positive hits. This approach allows confidence that the identified protein are
genuine interactors of PKARIα and would be considered as part of future work to identify other
PKARIα binding partners that may interact via a similar redox mechanism to tubulin.
5.4.3 Tubulin as a redox sensitive protein
The α/β tubulin heterodimer contains up to 20 highly conserved cysteine residues268. Under
basal conditions these are not disulfide-linked but have been shown to transiently form
disulfides to aid correct folding269. 19 of the 20 cysteines are capable of reacting with disulfide
reagents (such as ODNB, DTNB, 2-DTP) and the accessibility of these cysteines is greatly
diminished when microtubules are intact268. Specifically, modification of Cys315, Cys316 or
Cys376 in α-tubulin and Cys129, Cys131 Cys242 or Cys356 in β-tubulin have been putatively
identified as redox sensitive cysteines. These cysteines are responsible for intra-protein
disulfides or disulfide homodimers under favourable oxidative conditions which can then be
reduced by the glutaredoxin reductase system270,271. Although it appears that no previous
studies have demonstrated that PKARIα can disulfide hetero-dimerise with other proteins,
tubulin has been shown to from such complexes. in vitro incubation of β-tubulin with
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) leads to the formation of high molecular
weight complexes that are reducible with β-ME272. Interestingly GAPDH was also identified as a
PKARIα disulfide binding protein from our proteomic screen and a potential redox interaction
between the three proteins may be a rational subject of future investigation.
5.4.4 Analysis of the oxidant-dependent interaction between PKARIα and tubulin
PKA regulatory subunits classically bind to an amphipathic α-helix and α/β-tubulin both
contain 12 α-helices. An examination of the X- ray crystal structure of the α/β- tubulin complex
shows a few of these helices face externally and could potentially be PKARIα binding domains
(Figure 5.21). Interestingly two cysteine residues (including the evolutionary conserved
Cys128) separated by an aspartic acid lie adjacent to the outward facing helix 3 on the β
subunit, and thus it is tempting to speculate that these cysteines may be involved in the redox
interaction between PKARIα and tubulin, but this requires further investigation.
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Figure 5.21 Crystal structure of α- and β-tubulin. The complex contains two proximal outward
facing cysteines (Cys128 and Cys130, indicated with white arrows) residues adjacent to an α-
helix
The tubulin antibody routinely used in the lab is a polyclonal antibody from Cell Signaling
Technologies. Using this antibody I was initially able to detect tubulin running as a high
molecular weight complex but subsequently this complex was no longer detected despite
experimental conditions being the same. Due to the polyclonal nature of the antibody there
may be slight batch-to-batch variation. This may mean that whilst one batch is able to detect
the high molecular weight complex another batch may not. Still, in this study the interaction
was established between tubulin and PKARIα via immunoprecipitations even if the oxidant-
dependent higher molecular weight were not consistently observed. This can potentially be
overcome by screening a number of other commercial tubulin antibodies from various
companies that have been able to detect tubulin dimers272,273. Co-localisation of PKARIα and
tubulin has previously been established. Immunofluorescent experiments show type I PKA is
localised to interphase microtubules in epithelial cells274. PKARIα regulates meiotic arrest in
oocytes mediated via co-localisation with tubulin275 and PKA-Cα is associated with acetylated
microtubules276. PLA is a useful tool to quantify such protein-protein interactions in their
natural context at physiological expression levels. PLA detects interactions at <40 nm277, and
therefore likely detected a direct in situ cellular interaction between PKARIα and tubulin for
the first time.
If PKARIα can be recruited to AKAPs such as tubulin via an inter-protein disulfide, and that
cAMP may modulate this disulfide bond, then perhaps cAMP may regulate PKARIα activity by
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more than just simply activating it. Figure 15.22 illustrates a proposed model whereby H2O2
targets PKARIα to tubulin, and once recruited, cAMP induces the reduction of the inter-protein
disulfide whilst also activating the kinase to permit substrate phosphorylation. At this point the
cycle continues whereby another PKARIα enzyme can be disulfide targeted to tubulin, reduced
via cAMP and simultaneously activated to phosphorylate the tubulin associated substrate. ROS
and cAMP work together to dictate the subcellular location of PKARIα, keeping the enzyme in
close proximity to the substrate and in a region of high cAMP concentration to increase local
responsiveness. The end result of this ROS and cAMP-dependent cycle is enhanced substrate
phosphorylation compared to cAMP alone, as observed in Chapter 3. cAMP and ROS signalling
are integral for correct cellular function and PKARIα is able to integrate these two inputs. The
physiological or pathophysiological context would determine whether ROS-potentiated
increase in PKA substrate phosphorylation would be beneficial or detrimental and such effects
are explored further in Chapter 6.
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Figure 5.22 A proposed model for the co-operative action of cAMP and ROS on PKARIαand tubulin to facilitate substrate phosphorylation
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6 Investigating the integration of cAMP and oxidant
signals by PKARIα on GEF-H1 phosphorylation
6.1 Introduction
In the previous chapter tubulin was identified as a novel redox-dependent PKARIα AKAP. If
tubulin is indeed an AKAP there will be substrates within the PKARIα-tubulin complex, and as
such, tubulin would serve to localise the kinase with these specific targets. It is logical to
predict that such substrates would be microtubule associated proteins (MAPs), a number of
which have previously been described as targets of PKA phosphorylation as considered below
in more detail. Therefore it is rational to suggest that the phosphorylation status of substrates
within the PKARIα-tubulin complex will be dependent on both oxidant and cAMP signals. This
chapter will aim to identify microtubule associated proteins (MAPs) that are differentially
phosphorylated by PKARIα depending upon the concentrations of oxidants and cAMP.
6.1.1 Role of the microtubules
α- and β-tubulin are major components of the microtubules, filamentous structures that are an
integral part of the eukaryotic cytoskeleton with many diverse roles including, organelle and
protein trafficking, mitosis, and broadly maintenance of cell structure and shape278. α- and β-
tubulin heterodimers bind head to tail to form protofilaments, 13 of which assemble laterally
to form a hollow tubule to make up a microtubule (Figure 6.1A). Microtubules are highly
dynamic polymers that are intrinsically polarised and switch between periods of slow growth
and rapid shrinkage279. GTP must be bound to α- and β-heterodimers to allow association with
other heterodimers, as such, the hydrolysis rate of tubulin bound GTP to GDP is thought to
determine the rate of microtubule depolymerisation at the dynamic plus end. The minus end
of the microtubules is usually stabilised by microtubule organising centres which in most cell
types is the centrosome280.
Broadly speaking there are three main classes of proteins that interact with the microtubules.
One class are the motor proteins such as kinesin and dynein that drive organelle transport281,
another class being MAPs that bind to tubulin to destabilise or promote microtubule
formation278. The phosphoregulation of MAP activity has been well documented282-284.
Hyperphosphorylation of the MAP tau leads to detachment from tubulin and reduction in
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microtubule stability, a hallmark of Alzheimer’s disease285. Similarly phosphorylation of MAP2
inhibits its microtubule stabilising activity286. In contrast, stathmin forms a ternary complex
with an α/β-tubulin heterodimer to prevent microtubule polymerisation, whilst stress-induced
phosphorylation inhibits this action287,288. The third class of proteins is a heterogeneous group,
including PKARIα, which bind to the microtubules as scaffolds or for other reasons that have
not yet clearly been defined. The redox regulated PKARIα-tubulin interaction may play a role in
microtubule dynamics but also in actin cytoskeleton dynamics through the phosphorylation of
the MAP, and the established PKA substrate guanine nucleotide exchange factor H1 (GEF-H1).
6.1.2 RhoA and GEF-H1
Guanine nucleotide-binding proteins of the Ras homology family (Rho-GTPases) are
intracellular signalling molecules that cycle between an active GTP bound and an inactive GDP
bound conformation289. RhoA is a well-characterised GTPase that is best known for binding to
and activating effector kinases Rho-associated protein kinase 1 and 2 (ROCK1/2) to induce
local actin filament assembly289. For GTPase-dependent processes to proceed, guanine
exchange factors (GEFs) are necessary to catalyse the dissociation of GDP and permit the
binding of GTP to activate the protein. GEFs modify the nucleotide binding domain of GTPases
to decrease its affinity for GDP thus facilitating release and replacement with GTP. The active
GTP bound conformation of the G protein is favourable because the cytosolic concentration of
GTP is 10 times greater than GDP290.
GEF-H1 is a 100 kDa protein that contains the Dbl homology domain (DH) and an adjacent
pleckstrin homology domain (PH) that underpins its exchange activity and characterises the
RhoGEF family (Figure 6.1B). GEF-H1 activation of RhoA regulates actin cytoskeleton-
dependent processes, promoting paracellular transport291 and increasing endothelial barrier
permeability292-294. GEF-H1 also has a role in cytokinesis295, promotion of mitotic spindle
assembly296, enhancement of stress fibre formation297; therefore given this diverse number of
cellular roles its exchange activity must be tightly regulated. Uniquely GEF-H1 activity is
inhibited when bound to the microtubules. Mutations of key residues in the C-terminal zinc
finger are sufficient to disrupt the interaction and increase GEF-H1 exchange activity297.
Physiological or drug-induced depolarization of the microtubules releases GEF-H1, thus, it has
emerged as a prominent effector of microtubule-dependent RhoA activation294.
Investigating the integration of cAMP and oxidant signals by PKARIα on GEF-H1 phosphorylation
179
6.1.3 Phospho-regulation of GEF-H1
Phosphorylation of specific GEF-H1 residues can positively or negatively regulate its exchange
activity. ERK1/2 phosphorylates Thr678 to enhance GEF-H1 activity and promote RhoA-
dependent actin fibre assembly. In contrast, PKA phosphorylates GEF-H1 on Ser885 to promote
its association with 14-3-3η and inhibit its exchange activity298. Meiri et al. demonstrated GEF-
H1 phosphorylation was prevented by the PKA inhibitor H89. Furthermore, lysophosphatidic
acid (LPA)-induced actin stress fibre formation in fibroblasts was suppressed by forskolin (an
activator of AC) treatment directly due to the inability of GEF-H1 to activate RhoA (Figure
6.1C)298.
The oxidant-dependent interaction between PKARIα and tubulin may regulate phosphorylation
of MAPs such as GEF-H1. PKA-dependent phosphorylation of GEF-H1 represents a regulatory
mechanism to prevent over-activity of GEF-H1 and consequent RhoA-dependent actin fibre
formation that induces an increase in endothelial barrier permeability292,294,299,300. Exacerbated
vascular permeability and consequent interstitial fluid accumulation is associated with the
pathogenesis of sepsis301. As such, GEF-H1 phosphorylation may play a role in disease
progression. A mechanism for PKA to fine-tune the extent of GEF-H1 phosphorylation would
allow the cell to tightly co-ordinate downstream cellular responses. Here I present evidence
that suggests PKARIα can integrate oxidant and cAMP signals to synergistically phosphorylate
GEF-H1 to decrease RhoA activity and regulate endothelial barrier permeability.
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Figure 6.1 Overview of microtubules, GEF-H1 and RhoA. (A) Cartoon depicting the
arrangement of α- and β-tubulin as components of the microtubules. (B) A schematic
representing the domain structure of full length GEF-H1. Abbreviations: Zinc finger motif (ZF)
Dbl-homologous domain (DH), Pleckstrin domain (PH). (C) The role of GEF-H1 and PKA in the
classical RhoA signalling pathway. Figure adapted from Vydra and Havelka 2012302.




Antibody Purchase Code Company Species Dilution
anti-GEF-H1 4076 Cell Signaling
Technology
Rabbit 1:500
anti-pGEH-H1 ab74156 Abcam Rabbit 1:500
Table 6.1 Antibodies used in Chapter 6
6.2.2 Microtubule polymerisation assay
Cells were lysed in a microtubule stabilization buffer (100 mM PIPES (pH 6.9), 5 mMMgCl2, 1
mM EGTA, 30% glycerol, 0.125% Nonidet-P40, 0.1% Triton X-100, 0.1% Tween 20, 100 μM GTP,
1 mM ATP, and 2 μM paclitaxel and protease inhibitors) which was maintained at 37°C. Lysates
were centrifuged at 15,000 g for 30 min at 37°C. Soluble fractions were removed and added to
x4 SDS-sample buffer and represented unpolymerised microtubules. Pellets were resuspended
in microtubule stabilisation buffer, added to x4 SDS-PAGE sample buffer and boiled at 95°C for
5 min. This represented the polymerised microtubules.
6.2.3 PKARIα Cys17Ser knock-in mice
Mice constitutively expressing PKARIα Cys17Ser were generated for us on a pure C57BL/6
background by TaconicArtemis. A targeting vector was constructed for murine Prkar1a by
introducing the Cys17Ser mutation into exon 1 by site-directed mutagenesis and inserting an
FRT-flanked neomycin selection marker (to allow for selection of transfected embryonic stem
cells) close to the mutation to favour homologous recombination. Then screening by Southern
blot was carried out to identify if homologous recombination had occurred followed by
validation of the positive clones. Embryonic stem cell transfection was then carried out
followed by chimera generation. The chimeras were directly bred with an Flp deletor for the in
vivo deletion of the selection marker. As the embryonic stem cells always go germline,
chimeras can be directly bred to the deletor to obtain germline transmission and selection
marker deletion at the same time.
6.2.4 Analysis of GEF-H1 phosphorylation in aortic rings
The thoracic aorta was isolated, excised and cleaned to remove fat, connective tissue and
blood by Miss Alisa Kamynina. Aortas were cut into four equally sized ring and placed into 96
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well plates with pre –heated x media and incubated overnight at 37°C. Aortic rings were
treated with vehicle, 200 μM H2O2, 100 nM forskolin or co-treated with both on the
subsequent day for 10 min. Rings were snap frozen in liquid nitrogen, crushed on with pre-
cooled, small pestle and mortal and solubilised with x4 SDS-sample buffer prior to boiling at
95°C.
6.2.5 Induction of sepsis with cecal ligation and puncture
The cecal ligation and puncture (CLP) procedure was used as a model of sepsis and was
performed as described303. 9-15 week-old C57BL/6J mice were anesthetised using 5% (vol/vol)
isoflurane with oxygen (flow rate of 0.5 L/min) in an induction chamber and subsequently
maintained with 2% isoflurane with oxygen (flow rate of 0.5 L/min) via a nose cone. Mice were
placed on a heating pad to maintain body temperature and positioned in dorsal recumbency. A
10 mm laparotomy was performed, and the cecum was exteriorised. The distal half of the
cecum was subjected to ligation with suture and subsequently punctured twice with a 19-
gauge needle. The cecum was gently squeezed to exteriorise a 1-2 mm of cecum content and
then replaced in the abdomen. Sham operated mice underwent an identical procedure
without cecal ligation and puncture. The abdominal wall incision was subsequently sutured
shut. After surgery, mice were injected with analgesia (Vetergesic, Alsoe Ltd, 0.1 mg/kg)
intraperitoneally and resuscitated with 1 ml per 30 g body weight subcutaneous injection of
pre-warmed physiological salt solution (Normasol, STERETS). Animals were left to recover for
30 min in an incubator at 26°C. Sham mice received 0.5 ml saline per 30g body weight
subcutaneously instead of 1 ml. All surgical procedures were kindly performed by Miss Alisa
Kamynina. After 24 h lungs were harvested, snap-frozen in liquid nitrogen and stored at -80°C.
Lung homogenates (100 mM Tris pH 7.4, 100 mM maleimide, protease inhibitor, 10% w/v)
were re-suspended in non-reducing SDS-PAGE sample buffer.
6.2.6 Sepsis score
The sepsis score, reflecting the severity of the disease, was assessed at 24 h immediately prior
to culling and recorded for each mouse. The evaluated parameters were general appearance,
eye appearance, activity, level of consciousness, response to stimuli, respiration rate and
respiration quality. Mice were given a score from 0 to 5 for each parameter, with 5 indicating
the most severe state. After the parameters were assessed the modal value was taken to be
the sepsis score for each mouse. The sepsis scores were then averaged to give a sepsis score
for each experimental group. Blinded observations and assessment was conducted by Miss
Alisa Kamynina.
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6.3 Results
6.3.1 Investigating the effect of PKA activation on microtubule dynamics
As demonstrated in the previous chapter PKARIα interacts with tubulin. To investigate whether
the redox-dependent PKARIα-tubulin interaction has an effect on microtubule dynamics, a
microtubule polymerisation assay was conducted in HEK 293 cells. The presence of tubulin in
the detergent-soluble fraction represented the free tubulin at the time of cell lysis, whilst
purification of tubulin in the pellet represented tubulin that was polymerised as microtubules.
The percentage of tubulin in each fraction was subsequently determined by immunoblot
analysis.
PKA activation did not significantly alter the percentage of free tubulin in the supernatant after
10 min (control: 37±2% vs. 8-CPT-cAMP: 32±7% vs. H2O2: 30±2% vs. cAMP + H2O2: 38±7%) or
120 min treatment (control: 37% ± 2% vs. 8-CPT-cAMP: 26% ± 4% vs. H2O2: 35% ± 9% vs. cAMP
+ H2O2: 33% ± 3%) (Figure 6.2). HEK 293 cells were also treated with the microtubule stabilising
agent paclitaxel, or the microtubule depolymerising drug nocodazole as controls to ensure the
assay was functioning as expected. The percentage of tubulin in the soluble fraction after
paclitaxel treatment was significantly lower (5±1%) compared to control (37±2%), whilst the
percentage of tubulin in the soluble fraction was significantly higher post nocodazole
treatment (37±2% vs. 83±7%). These results substantiate that the assay was performing as
intended, but also confirmed that activation of PKA has no effect on microtubule dynamics.
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Figure 6.2 PKA activation does not alter microtubule dynamics in HEK 293 cells. HEK 293 cells
were treated with 8-CPT-cAMP (100 μM), H2O2 (500 μM) or co-treated with both for (A) 10 or,
(B) 120 min. Cells were also treated with paclitaxel (5 μM) or nocodazole (50 μM) for 30 min as
positive controls. Lysates were processed with the centrifugation protocol where S=
supernatant, representing free tubulin and P= Pellet, representing polymerised microtubules.
Immunoblots were probed with anti-tubulin and the % tubulin in each fraction was summated
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6.3.2 Investigating redox-dependent GEF-H1 phosphorylation
The next logical step was to investigate potential substrates within the PKARIα-tubulin
complex. As there is an oxidant-dependent interaction between the two proteins, the
presence of oxidants together with cAMP may lead to enhanced phosphorylation of any
associated substrates within the complex (Figure 6.3A). As previously discussed, the
microtubules bind to MAPs, many of which are susceptible to phosphorylation and have been
identified as targets of PKA. Some potential substrates could not be investigated as there were
no commercial antibodies available to interrogate their phosphorylation status. The remaining
proteins were separated into two categories according to whether their phosphorylation
status was known to alter microtubule dynamics or not (Figure 6.3B).
To investigate whether oxidants could potentiate PKA-dependent phosphorylation of these
substrates, HEK 293 cells were treated with 8-CPT-cAMP alone or co-treated with 8-CPT-cAMP
and H2O2 to simultaneously induce the PKARIα-tubulin oxidant-dependent interaction.
Stathmin, MAP4 and tau were each characterised as PKA substrates capable of regulating
microtubule dynamics, but their phosphorylation was either not detected or not altered by the
treatment interventions (Figure 6.3C). According to the literature GEF-H1 phosphorylation has
not been shown to alter microtubule dynamics. Figure 6.4 demonstrates that GEF-H1 was
present in HEK 293 cells, VSMCs, BAECs but not in ARVM. Treatment of HEK 293 cells with 8-
CPT-cAMP increased Ser885 GEF-H1 phosphorylation and this was potentiated approximately 2-
fold when HEK 293 cells were co-treated with 8-CPT-cAMP and H2O2 (Figure 6.4). This oxidant-
induced potentiation of GEF-H1 phosphorylation was also observed in VSMCs and BAECs.
Interestingly, longer immunoblot exposures demonstrated that GEF-H1 phosphorylation
tended to decrease with H2O2 treatment alone, implying that induction of PKARIα disulfide
dimer alone was not sufficient to activate PKARIα in this context. Furthermore, the H2O2
potentiation of GEF-H1 Ser885 phosphorylation was also clearly contingent on the presence of
cAMP.
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Figure 6.3 Stathmin, Tau and MAP4 are not phosphorylated as part of a PKARIα-tubulin
redox-dependent complex. (A) Model of the redox-dependent PKARIα-tubulin interaction
indicating phosphorylation of a potential substrate in the presence of oxidants and cAMP
(black circles). (B) Table of MAPs and their phosphorylation sites that are established PKA
substrates. Antibodies were not available for substrates in grey. Known effectors of
microtubule dynamics are shown in black and do not effect dynamics are shown in green. (C)
HEK 293 cells were treated with 8-CPT-cAMP (100 μM) or co-treated with 8-CPT-cAMP (100
μM) and H2O2 (500 μM). Immunoblots were probed with phospho- antibodies for stathmin
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Figure 6.4 8-CPT-cAMP-dependent GEF-H1 phosphorylation is potentiated by H2O2. HEK 293
cells, VSMCs and BAECs were treated with 8-CPT-cAMP (100 μM), H2O2 (500 μM) or co-treated
with both for 10 min. Immunoblots were probed with total or phospho-GEF-H1 antibodies.
Phosphorylation events in HEK 293 cells were summated and represented graphically (n= 6-11
± SEM,* p<0.05 vs control, # p<0.05 vs. cAMP)
100 -
100 - 100 -
100 - 100 -
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To further investigate the effect of oxidants and cAMP on GEF-H1 Ser885 phosphorylation HEK
293 cells were treated with 8-CPT-cAMP (0–300 μM) in the absence or presence of H2O2. At
concentrations of 3 μM 8-CPT-cAMP, GEF-H1 was phosphorylated but the effect of H2O2 was
negligible. However GEF-H1 Ser885 phosphorylation was significantly increased in the presence
of H2O2 at 30 μM or 300 μM 8-CPT-cAMP compared to 8-CPT-cAMP alone (Figure 6.5). This
again confirmed that the effect of oxidant-potentiated Ser855 phosphorylation is contingent
upon 8-CPT-cAMP concentration.
Figure 6.5 H2O2 potentiates GEF-H1 phosphorylation at higher 8-CPT-cAMP concentrations.
HEK 293 cells were treated with 8-CPT-cAMP (0.3-300 μM) in the absence or presence of H2O2
(500 μM) for 10 min. Immunoblots were probed with the phospho-GEF-H1 antibody.
Phosphorylation events were summated and represented graphically (n=3 ± SEM,* p<0.05 vs
vehicle)
100 -
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HEK 293 cells were treated with the PDE inhibitor IBMX (100 μM) to determine whether the
oxidant-potentiated Ser885 phosphorylation was due to PDE inhibition. IBMX caused a small
increase in Ser885 GEF-H1 phosphorylation whilst, as shown previously, H2O2 alone did not
increase Ser885 phosphorylation (Figure 6.6). Furthermore Ser885 phosphorylation of HEK 293
cells treated with 8-CPT-cAMP and IBMX was significantly lower than in cells treated with 8-
CPT-cAMP, IBMX and H2O2 together, again implying the H2O2 is potentiating phosphorylation
via a mechanism other than PDE inhibition. Taken together, this precludes H2O2 mediated
inhibition of PDEs as an explanation for oxidant-dependent potentiation of Ser885
phosphorylation.
Figure 6.6 IBMX and H2O2 contribute to GEF-H1 phosphorylation via different mechanisms.
HEK 293 cells were treated with a combination of 8-CPT-cAMP (100 μM), IBMX (100 μM)
and/or H2O2 (500 μM) for 10 min. Immunoblots were probed with the phospho-GEF-H1
antibody. Phosphorylation events were summated and represented graphically (n=3 ± SEM,*
p<0.05 vs control, # p<0.05 vs. cAMP + IBMX)
100 -
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6.3.3 Investigating pharmacological inhibition of PKA on GEF-H1 phosphorylation
To determine if indeed Ser885 phosphorylation was a PKA-dependent process HEK 293 cells
were pre-treated with pharmacological inhibitors of PKA. RP-8-cAMPS is an analogue of cAMP
that reversibly competes for the cAMP binding site on the regulatory subunits of PKA but does
not activate the kinase. RP-8-cAMPS (100 μM) pre-treatment for 30 min prior to 8-CPT-cAMP
or 8-CPT-cAMP and H2O2 co-treatment reduced Ser885 phosphorylation by 52% and 60%
respectively. The drug H89 inhibits the ATP binding site of the catalytic subunit of PKA. Pre-
treatment with H89 (1 µM) for 30 min completely abolished GEF-H1 Ser885 phosphorylation in
HEK 293 cells that had been challenged with 8-CPT-cAMP or 8-CPT-cAMP and H2O2 (Figure 6.7).
Taken together this indicates that ROS-potentiated Ser885 phosphorylation is dependent on
cAMP concentration and is likely to be PKA-dependent.




Figure 6.7 GEF-H1 phosphorylation is inhibited by RP-8-cAMPS and H89. HEK 293 cells were
treated with 8-CPT-cAMP (100 μM), with or without H2O2 (500 μM), in the absence or presence
of (A) RP-8-cAMPS or (B) H89 for 10 min. Immunoblots were probed with the phospho-GEF-H1
antibody. Phosphorylation events were summated and represented graphically (n=4-5 ± SEM,*
p<0.05 vs control, ** p<0.01 vs control, # p<0.05 vs. vehicle)
100 -
100 -
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6.3.4 Investigating PKARIα over-expression on GEF-H1 phosphorylation
The evidence thus far suggests that PKARIα disulfide dimer formation may contribute to
potentiated GEF-H1 phosphorylation. The effect of PKARIα over-expression on Ser885 GEF-H1
was next investigated. HEK 293 cells transiently transfected with V5-PKARIα exhibited
decreased Ser885 phosphorylation when treated with 8-CPT-cAMP or 8-CPT-cAMP and H2O2
together 24 hours post-transfection compared to untransfected cells, although this did not
reach statistical significance (Figure 6.8). HEK 293 cells transfected with the V5-C17SPKARIα, a
mutant form of PKARIα that cannot form the disulfide dimer, exhibited a further decrease in
Ser885 phosphorylation after 8-CPT-cAMP and 8-CPT-cAMP and H2O2 co-treatment, the latter
being significantly different compared to untransfected cells.
In separate experiments HEK 293 cells were transiently transfected for 72 hours with the
dominant negative constructs PKARIα-cAMP or C17SPKARIα-cAMP. This time was chosen to allow
maximum expression of these constructs, at which point cells were treated with 8-CPT-cAMP
or 8-CPT-cAMP and H2O2 together. Ser885 GEF-H1 phosphorylation in cells that had been
transfected with PKARIα-cAMP or C17SPKARIα-cAMP exhibited markedly reduced Ser885
phosphorylation to near baseline levels post treatment (% decrease in Ser885 phosphorylation:
PKARIα-cAMP 8-CPT-cAMP: 68%, cAMP + H2O2: 83%; C17SPKARIα-cAMP 8-CPT-cAMP: 78%, cAMP +
H2O2: 85%) (Figure 6.9). Finally, the expression of PKARIα-cAMP or C17SPKARIα-cAMP did not alter
PKARIIα or PKACα expression. These data suggests that cAMP binding to PKARIα is a
prerequisite for oxidant-potentiated PKA-dependent Ser885GEF-H1 phosphorylation.
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Figure 6.8 GEF-H1 phosphorylation is inhibited by PKARIα over-expression. HEK 293 cells
were transiently transfected with V5-PKARIα or V5-C17SPKARIα, and after 24 hours were
treated with 8-CPT-cAMP (100 μM), with and without H2O2 (500 μM) for 10 min. Immunoblots
were probed with anti-PKARIα or the phospho-GEF-H1 antibody. Phosphorylation events were
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Figure 6.9 GEF-H1 phosphorylation is inhibited by PKARIα-cAMP over-expression. HEK 293 cells
were transiently transfected with PKARIα-cAMP or C17SPKARIα-cAMP, and after 72 hours were
treated with 8-CPT-cAMP (100 μM), with and without H2O2 (500 μM) for 10 min. Immunoblots
were probed with anti-PKARIα, anti-PKARIIα, anti-PKACα or the phospho-GEF-H1 antibody.
Phosphorylation events were summated and represented graphically (n=4-5 ± SEM,* p<0.05 vs
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6.3.5 Investigating PKACα knock-down on GEF-H1 phosphorylation
To further investigate whether the PKA holoenzyme is necessary for cAMP/oxidant- induced
GEF-H1 Ser 885phosphorylation, HEK 293 cells were transfected with PKACα siRNA to delete the
phospho-active component of the holoenzyme. Firstly, the extent of PKACα knockdown was
assessed at various siRNA concentrations (10, 20 or 40 pmol) and different time points (24, 48
or 72 hours) to find the optimum conditions to conduct the experiment. Effective knockdown
was achieved at all concentrations and at every time point (Figure 6.10A). Interestingly, this
did not significantly alter basal global PKA substrate phosphorylation as determined by the
phospho-PKA substrate antibody. To determine the effect of PKACα knockdown on Ser885 GEF-
H1 phosphorylation HEK 293 cells were transfected with 20 pmol siRNA and subsequently
treated with either 8-CPT-cAMP or 8-CPT-CAMP and H2O2 after 48 hours. There was a trend
towards decreased Ser885 phosphorylation in HEK 293 cells transfected with siRNA-PKACα
knockdown relative to control cells, but this was not significantly different (Figure 6.10B).
Therefore, the α isoform of PKAC may be involved with PKA-dependent Ser885 GEF-H1
phosphorylation.
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Figure 6.10 GEF-H1 phosphorylation is decreased with PKACα knockdown. (A) HEK 293 cells
were transiently transfected with siRNA-PKACα (10-40 pmol) and harvested at 24, 48 or 72
hours (B) HEK 293 cells were transiently transfected with siRNA-PKACα (20 pmol) and after 48
hours were treated with 8-CPT-cAMP (100 μM), with and without H2O2 (500 μM) for 10 min.
Immunoblots were probed with anti-PKACα, anti-tubulin, anti-phospho-PKA substrate and the
phospho-GEF-H1 antibody. GEF-H1 Phosphorylation events were summated and represented
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6.3.6 Investigating the effect of microtubule stability on redox-dependent GEF-H1
phosphorylation
In the previous chapter it was suggested that PKARIα is capable of forming a disulfide bond
with tubulin. Since GEF-H1 has been shown to be associated with the microtubules, the
oxidant-dependent interaction between PKARIα and tubulin may explain the observed
increase in Ser885 phosphorylation when cells are co-challenged with both 8-CPT-cAMP and
H2O2. Therefore in this proposed model of oxidant-dependent GEF-H1 phosphorylation it is
rational to characterise the role of the microtubule network. To this end HEK 293 cells were
pre-treated with either nocodazole (50 μM) or paclitaxel (5μM) for 30 min and subsequently
treated with H2O2, 8-CPT-cAMP or 8-CPT-cAMP and H2O2 together. The immunoblots reveal
that simply challenging the cells with either paclitaxel or nocodazole increases Ser885 GEF-H1
phosphorylation, implying that disruption to the microtubules increases basal phosphorylation
of Ser885. Importantly, cells pre-treated with paclitaxel maintained their ability to potentiate
Ser885 GEF-H1 phosphorylation in an oxidant-dependent manner although this was markedly
reduced compared to control cells. However, H2O2 potentiated Ser885 GEF-H1 phosphorylation
was abrogated in cells pre-treated with nocodazole (Figure 6.11). This data suggests that an
intact microtubule network is necessary for oxidant-potentiated PKA-dependent Ser885 GEF-H1
phosphorylation.
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Figure 6.11 Microtubule dynamics alter H2O2-dependent potentiation of GEF-H1
phosphorylation. HEK 293 cells were pre-treated with paclitaxel (5 μM) or nocodazole (50 μM)
for 30 min and subsequently treated with 8-CPT-cAMP (100 μM), H2O2 (500 μM) or co-treated
with both for 10 min. Immunoblots were probed with the phospho-GEF-H1 antibody.
Phosphorylation events were summated and represented graphically (n=3-4 ± SEM,* p<0.05 vs
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6.3.7 Investigating the effect of oxidant potentiated GEF-H1 phosphorylation on stress
fibre assembly
When dephosphorylated GEF-H1 activates RhoA, which is a critical mediator of actin fibre
assembly. Phosphorylation of Ser885 on GEF-H1 has been shown to inhibit the capacity for GEF-
H1 to activate RhoA and thus limit actin cytoskeleton fibre assembly. To further investigate
whether ROS-potentiated PKA-dependent GEF-H1 phosphorylation exerted a functional effect,
HEK 293 cells were co-treated with 8-CPT-cAMP and H2O2 for 10 min, fixed and stained with
phalloidin to measure the extent of actin fibre assembly relative to control. Stress fibres were
detected basally under control conditions, however cells co-challenged with 8-CPT-cAMP and
H2O2 were unable to assemble stress fibres (Figure 6.12). The correlation between Ser885 GEF-
H1 phosphorylation and stress fibre formation implies that the concerted action of cAMP and
H2O2 together on PKARIα produces a functional response in this system.
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Figure 6.12 Co-treatment with 8-CPT-cAMP and H2O2 induced actin fibre loss in HEK 293 cells.
Representative immunofluorescent images. HEK 293 cells were treated with vehicle or 8-CPT-
cAMP (100 μM) and H2O2 (500 μM) together and then stained with phalloidin (green) to
identify actin fibres. The nucleus was stained with b4′,6-diamidino-2-phenylindole (DAPI, blue).
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6.3.8 Investigating the effect of GEF-H1 phosphorylation in C17S PKARIα knock-in mice
Similar to the PKARIα constructs that have been used throughout this investigation, this
laboratory has engineered a novel mouse that has had the PKARIα Cys17, a cysteine residue
critical for the formation PKARIα disulfide, mutated to a serine. It has been termed the C17S
PKARIα ‘redox-dead’ knock-in (KI). The RIα subunit in these mice are unable to form a disulfide
bond between the two subunits and therefore is theoretically unable to transduce any oxidant
signal that regulates PKARIα activity91. The data in this chapter thus far suggests a model in
which H2O2 potentiates cAMP-induced Ser885 GEF-H1 phosphorylation and that this is mediated
via the formation of the PKARIα disulfide dimer because it increases its interaction with
tubulin. To investigate this hypothesis further, thoracic aorta were isolated from both WT or
C17S PKARIα KI mice, cut into equal size strips, incubated overnight in media and subsequently
treated with H2O2 (200 μM), forskolin (100 nM) or forskolin and H2O2 administered
simultaneously. Forskolin directly activates adenylate cyclase to elevate intracellular cAMP,
and was used instead of 8-CPT-cAMP in this model due to concerns about the permeability of
8-CPT-cAMP in tissue raised during preliminary experiments (data not shown). The pattern for
Ser885 GEF-H1 phosphorylation in WT aortas was similar to the observed pattern in the cell
models as H2O2 potentiated forskolin-induced phosphorylation. However, in the C17S PKARIα
KI mice that cannot form the disulfide dimer, H2O2 failed to potentiate forskolin-induced Ser885
GEF-H1 phosphorylation, suggesting that the PKARIα disulfide dimer is necessary for this event
(Figure 6.13).
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Figure 6.13 H2O2 does not potentiate GEF-H1 phosphorylation in aortic rings from PKARIα KI
mice. Isolated aortic rings from WT and C17S PKARIα KI mice were treated with forskolin (100
nM), H2O2 (200 μM) or co-treated with both for 10 min. Immunoblots were probed with anti-
tubulin and the phospho-GEF-H1 antibody. Phosphorylation events were normalised to tubulin
as a measure of total protein, summated and represented graphically (n=3 ± SEM,* p<0.05 vs
vehicle).
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Having established GEF-H1 in PKARIα KI mice is not enhanced in the presence of cAMP and
H2O2 compared to WT animals, it was rational to investigate whether this deficit contributed to
(patho)physiology. Phosphorylation of GEF-H1 Ser885 inhibits its exchange activity to limit
RhoA-dependent stress fibre formation and decrease endothelial permeability. Sepsis occurs
when infection results in systemic inflammation accompanied by end-organ damage304. This is,
in part, mediated by an increase in vascular permeability which compromises microvascular
perfusion due to increased interstitial pressure301. Since GEF-H1 has been shown to regulate
vascular permeability, and levels of oxidants are elevated during disease progression305-307, a
model of sepsis was deemed appropriate to investigate oxidant signal transduction via PKARIα
disulfide dimer formation. I hypothesised that the C17S PKARIα KI animals will be more
susceptible to sepsis due to hypophosphorylation of GEF-H1 relative to WT mice, leading to
exacerbated endothelial permeability. Cecal ligation and puncture (CLP) is a widely used
animal model exhibiting many clinical features of sepsis and has previously been validated in
our laboratory303.
Mice were allowed to recover from sham or CLP surgery for 24 h before they were sacrificed,
and the lungs were harvested and homogenised for biochemical analysis. Immediately prior to
culling, mice were observed and assessed based on numerous criteria, including their physical
appearance and response to stimuli, and allocated a sepsis score out of 5 as a measure of
injury. A higher sepsis score indicated more severe disease progression. Table 6.2
demonstrates that PKARIα KI mice had a higher sepsis score compared to WT mice implying
more severe pathology 24 hours after CLP surgery. Furthermore there was a trend towards
increased PKARIα oxidation in CLP mice compared to sham mice, whilst as expected, KI animals
had no disulfide PKARIα. However there was no difference in GEF-H1 phosphorylation
between WT and C17S PKARIα KI mice regardless of whether they had undergone sham or CLP
surgery (Figure 6.14).
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Table 6.2 Sepsis score of WT and C17S PKARIα KI mice 24 hours after sham or CLP surgery
Figure 6.14 PKARIα oxidation, but not GEF-H1 phosphorylation, is elevated 24 hours after
CLP surgery. C57BL/6J WT and C17S PKARIα KI mice underwent sham or CLP surgical
procedure and allowed to recover for 24 hours. At this time lungs were excised and
homogenised for analysis by immunoblotting using anti-PKARIα, anti-GEF-H1, anti-pGEF-H1.
Phosphorylation events were normalised to total GEF-H1 protein summated and represented
graphically (n=3, n.s. = non-specific band).
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6.4 Discussion
In this chapter I examined the effect of PKARIα activation on microtubule dynamics. I also
explored the phospho-status of various MAPs including the known PKA substrate GEF-H1. For
the first time, I demonstrated that PKARIα and can integrate both H2O2 and cAMP signals to
enhance GEF-H1 phosphorylation.
6.4.1 PKARIα mediates the oxidant potentiated GEF-H1 phosphorylation
PKA has been demonstrated to phosphorylate the MAPs stathmin308, tau309, syntabulin310,
RASSF1A311, BIG1312 which all regulate microtubule dynamics. Despite this cAMP or H2O2 failed
to disrupt microtubule integrity in HEK 293 cells. Kratzer et al. demonstrated that pre-
treatment with the antioxidant N-acetyl cysteine prevented lipopolysaccharide (LPS)-induced
ROS-dependent disassembly of microtubules293. Furthermore 48 hour treatment of human
osteosarcoma 143B cells with H2O2 resulted in depolymerised microtubules313. The divergence
in results may be accounted for by differences in cell types or experimental protocols. To the
best of my knowledge there are no reports of GEF-H1 phosphorylation altering microtubule
dynamics and the findings discussed above are consistent with that.
H2O2 potentiated cAMP-dependent Ser885 GEF-H1 phosphorylation in a number of cell types.
Interestingly, H2O2 alone decreased Ser885 GEF-H1 phosphorylation which is confounding
because oxidants are broadly thought to inhibit phosphatases and consequently increase
protein phosphorylation314. However because of this decrease in phosphorylation it allows
phosphatase inhibition to be ruled out as the cause of H2O2 potentiated Ser885
phosphorylation. The decrease in phosphorylation observed when cells were treated with H2O2
alone also precludes the role of an unknown H2O2-activated kinase in oxidant potentiated
Ser885 phosphorylation. Furthermore pre-treatment of cells with the phosphodiesterase
inhibitor IBMX induced a slight increase in GEF-H1 phosphorylation, the opposite effect
observed with H2O2, therefore it is possible to rule out phosphodiesterase inhibition as a cause
of H2O2-potentiated GEF-H1 phosphorylation. Thus it is reasonable to suggest that the
integration of the cAMP and oxidant signals must occur at the level of the PKA holoenzyme;
furthermore it is likely that the disulfide PKARIα-tubulin interaction mediates this synergistic
phosphorylation of GEF-H1.
Over-expression of WT-PKARIα significantly increased disulfide dimer upon H2O2 treatment but
also decreased GEF-H1 phosphorylation. This is because the regulatory subunits inhibit PKA
catalytic activity regardless of their redox state. The over-expression of WT-PKARIα would
cause a rightward shift of the a concentration-response curve, meaning a greater
concentration of cAMP would be required to overcome the inhibitory effect of the regulatory
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subunits315, whilst H2O2-dependent potentiation of GEF-H1 phosphorylation would remain
intact as observed. In Chapter 3 the ability of cells to modulate cellular PKARIα concentrations
was described, and therefore PKARIα expression may represent an additional mechanism
whereby phosphorylation events are regulated in response to cAMP and oxidants. GEF-H1
phosphorylation was abrogated in cells over-expressing PKARIα-cAMP therefore I can conclude
that cAMP-dependent phosphorylation of GEF-H1 is primarily due to PKARIα activation.
Furthermore it highlights that this H2O2-induced potentiation is directly via PKARIα, as this is
also abrogated in PKARIα-cAMP transfected cells. It reveals for the first time that co-ordinated
oxidant and cAMP sensing at the PKARIα interface are both necessary for enhanced GEF-H1
phosphorylation.
siRNA experiments were designed to abolish GEF-H1 phosphorylation via knockdown of
PKACα. There was a trend towards decreased GEF-H1 phosphorylation with siRNA PKACα but
this was not significant. Furthermore global PKA phosphorylation remained unchanged despite
PKACα knockdown. Therefore other PKAC isoforms are likely to have a more prominent role in
the phospho-status of GEF-H1, at least in HEK 293 cells, an observation which merits further
investigation.
According to a local hypothesis which follows from my initial observation, an increased
interaction between tubulin and PKARIα is likely to be the mechanism underlying oxidant-
induced potentiation of GEF-H1 phosphorylation. The loss of oxidant potentiated GEF-H1
phosphorylation after treatment with the microtubule depolymerising drug nocodazole
highlights the necessity of an intact microtubule network for the phenomenon to occur, and
reinforces the idea that the redox control of the PKARIα and tubulin interaction is critical to
how oxidants potentiate GEF-H1 phosphorylation. Nocodazole disrupts the GEF-H1/tubulin
complex potentially negating any effect of enhanced tubulin/PKARIα interaction, but this
requires further investigation to better understand the mechanism.
6.4.2 Effect of GEF-H1 phosphorylation on actin fibres
Phosphorylation of Ser885 on GEF-H1 leads to inhibition of its guanine exchange activity and
therefore decreased activity of RhoA299. Confocal imaging demonstrated a loss of actin fibres
after co-treatment with cAMP and H2O2 indicative of a downstream physiological effect
consistent with RhoA inhibition. The PKA catalytic subunit can directly phosphorylate Ser188
RhoA in vitro316 and post-forskolin treatment in vivo317 thus inhibiting the small GTPase. Ser188
on RhoA is a well-established PKG site, however the importance or extent of PKA-dependent
Ser188 phosphorylation in vivo is unclear317. Furthermore cAMP influences actin cytoskeleton
arrangement independent of GEF-H1 and RhoA. The small GTPases Rac1 and Cdc42 are
activated by cAMP to oppose the actions of RhoA96. Therefore these factors cannot be
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discounted with respect to the loss of actin stress fibres in the confocal studies. The relative
contribution of each mechanism RhoA opposing mechanism is unknown; however forskolin
fails to suppress stress fibre formation in cells expressing a non-phosphorylateable GEF-H1
mutant, suggesting that GEF-H1 is an important cAMP target in regulating actin structures298.
Ser885 on GEF-H1 can also be phosphorylated by p21 activated kinase 1 (PAK1)318 and the
mitotic kinase aurora A/B295. Whilst there is no evidence that aurora A/B can be activated by
cAMP or H2O2, PAK1 is activated downstream of Rac1 and Cdc4 and has also been shown to be
directly phosphorylated by PKA319,320. Although unlikely, it is not possible to rule out the
involvement of PAK1 on GEF-H1 phosphorylation in this model without pharmacological
inhibition or knock-down. However over-expression experiments with PKARIα-cAMP directly
implicate the enzyme in oxidant-sensing and the H2O2-dependent potentiation of GEF-H1
phosphorylation. Furthermore, the importance of oxidant sensing by PKARIα was confirmed in
experiments using aortas from PKARIα knock-in mice, which did not undergo H2O2-potentiated
GEF-H1 phosphorylation compared to WT aortas. Thus disulfide bond formation in PKARIα is
necessary for enhanced GEF-H1 phosphorylation, and can integrate cAMP and oxidant signals
to fine-tune GEF-H1 phosphorylation.
6.4.3 Oxidant-dependent GEF-H1 phosphorylation in sepsis
GEF-H1 has many RhoA-dependent and -independent roles within the cell and has been
implicated with numerous diseases. GEF-H1 contributes to excitotoxicity and neuronal
plasticity321; acts as an adaptor protein during oncogenic RAS signalling322; and plays a role in
viral nucleic acid sensing as part of the innate immune response323. Ultimately the effect of
ROS-potentiated PKA Ser855 phosphorylation on these processes is unknown and would
warrant further investigation. GEF-H1 has been well-characterised as a mediator of LPS-
dependent endothelial barrier permeability via RhoA activation292-294,324,325. Interestingly LPS
activation of TLR4 receptors induces NOX-dependent oxidant stress326,327. LPS also stimulates
the release of the cytokines IL-1β and TNFα which also generates oxidants that can induce
PKARIα dimerisation173. Therefore GEF-H1 phosphorylation may represent a novel feedback
mechanism whereby PKA synergises the cAMP and oxidant signals to negatively regulate GEF-
H1 activity and prevent excessive endothelial cell permeability. I hypothesised that this may be
relevant during sepsis where LPS from gram negative bacteria contributes to the loss of
endothelial barrier integrity, disrupting the physical barrier between the circulation and the
interstitial space. Progressive subcutaneous and body-cavity oedema typically develops in
patients with sepsis due to this increase in vascular permeability301. The accumulation of
interstitial fluid increases the distance necessary for efficient diffusion of oxygen and
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simultaneously compromises microvascular perfusion due to increased interstitial pressure;
consequently elevated permeability is associated with the pathogenesis of sepsis328.
A preliminary study was conducted in WT and C17S PKARI KI mice using the CLP model of
sepsis. I hypothesised that the oxidant-dependent activation of PKARIα would lead to
enhanced GEF-H1 phosphorylation in the WT mice thus preserving some endothelial barrier
function compared to PKARIα KI. The lungs are an organ of particular interest because they
highly vascularised, express GEF-H1 and are susceptible to oedema during sepsis329,330. There
was a strong trend towards increased PKARIα disulfide dimer in the lungs of WT animals 24
hours post CLP implying an increase in cellular oxidants, and indicating that oxidant-dependent
PKARIα activation may be relevant in this disease. Furthermore the sepsis score, a measure of
sceptic injury that was visually determined by a blinded and independent investigator,
revealed that the progression of the disease was worse in WT mice compared to C17S PKARIα
KI mice. Despite this there was no difference in GEF-H1 phosphorylation between WT and
C17S PKARIα KI mice regardless of whether they had undergone sham or CLP surgery. Crucially,
it is not known how the concentration of cAMP may have been altered by the CLP intervention
in my studies, and this would be important to eventually define how this changes temporally,
as this is envisaged to significantly influence GEF-H1 phosphorylation. Wu et al. demonstrated
that cAMP levels are elevated in early sepsis (9 hours) but drop below baseline levels during
late sepsis (18 hours) in a rat CLP model331. If cAMP levels follow a similar pattern in our model
of CLP then this may explain why no difference in GEF-H1 phosphorylation was observed
between WT and KI animals. Speculatively, the higher sepsis score observed in the C17S
PKARIα KI mice may be related to exacerbated vascular permeability at earlier time-points.
Follow-up studies assessing a time course of sepsis to define if PKARIα serves as a coincidence
detector of oxidant and cAMP signals, thereby contributing to the pathogenesis of sepsis, are
clearly a logical way to proceed. Such studies would assess whether GEF-H1 phosphorylation
and consequently vascular permeability is enhanced in C17S PKARIα KI mice compared to WT.
Understanding the contribution of PKARIα at the interface of cAMP and oxidant signalling
could provide novel physiological and pathophysiological insights that could potentially be




This thesis described studies investigating oxidant-dependent interprotein disulfide bond
formation within PKARIα, interrogating whether these oxidation events modulates interactions
with AKAPs and the phosphorylation of associated substrates. A particular focus of these
studies was deciphering the impact of concomitant cAMP and oxidant signals on PKARIα
activation and downstream signalling.
7.1 Analysis of experiments with cAMP-agarose
Treatment of cardiomyocytes with H2O2 induces disulfide-formation in PKARIα and
simultaneously increases phosphorylation of PKA substrates170. However, the exact mechanism
of oxidant-dependent PKARIα activation is unknown. Upon examination of the PKARIα
structure it is evident that the disulfide bonds in PKARIα directly flank the α-helix binding
domain in AKAPs. Therefore it was a logical possibility that the presence or absence of the
disulfide bonds in PKARIα would modulate the affinity between the kinase and AKAPs due to
their proximity to the AKAP α-helix. Binding affinity measurements have been made that are
consistent with this hypothesis where mutation of the PKARIα cysteine residues necessary for
disulfide formation resulted in decreased affinity for DAKAP2103.
cAMP-agarose has been used extensively to co-capture AKAPs with PKAR subunits246-249,252.
cAMP-agarose pull-downs had been identified as an useful method to investigate whether
PKARIα bound to AKAPs with greater affinity under oxidising conditions as a disulfide dimer. I
was successfully able to capture PKARIα, but unfortunately I was unable to co-capture any
AKAPs using this method. This was despite numerous efforts to optimise the co-capture
protocol as previously outlined in Chapter 4. Considering that the optimisations were carried
out in accordance with various other published studies, it is difficult to reconcile why I was
unable to co-capture AKAPs. In my experiments I used cAMP tethered to agarose beads by a 2
or 8 carbon linker lengths. Although such cAMP-agarose beads have been used in published
studies249,252,253, it is possible that steric hindrance upon PKARIα binding results in loss of a
previously bound AKAP. As such a longer length linker between the agarose bead and cAMP
may aid the likelihood of AKAP co-capture in future experiments.
I was able to capture DAKAP1 but this was found to be non-specific, as excess free cAMP did
not reverse the association. Such negative controls appear not to have been used in published
studies with solid phase-cAMP, meaning that there could be false positive identifications in the
General Discussion
210
literature. Furthermore AKAP antibodies have been known to produce non-specific bands
which has purportedly led to false identification of AKAPs in PKARIα complexes234. Indeed, the
unreliability of AKAP antibodies was a considerable issue during these investigations,
exemplified by the AKAP7 antibodies detecting bands at unexpected molecular weights, or in
some cases no detectable bands at all. Therefore use of immunoblotting to assess presence of
candidate AKAPS may not be the most suitable methods for testing if oxidative conditions
modulates their interaction with PKARIα. These issues with immunoblotting may be overcome
by using LC-MS/MS, which potentially allows identification and quantification of changes in
AKAPs-PKAR association during oxidative conditions; assuming that AKAPs are indeed present
in the pull-downs. Ultimately use of cAMP-agarose to determine whether PKARIα disulfide
dimer has greater affinity for AKAPs was perhaps unsuitable because it was unexpectedly
found to induce the reduction PKARIα to its monomeric form, with a potential mechanism for
how this occurs being presented. Yeast two-hybrid screening has also been used to identify
AKAPs that bind PKAR146, with surface plasmon resonance having been valuable in defining the
affinity of such interactions240.
Another method that was explored to co-capture PKARIα with AKAPs during these
investigations was the CaprotecTM Capture Compound Assay (CCCA). The preliminary results
obtained with the CCCA were promising, as numerous proteins were co-captured with PKARIα
after H2O2 treatment. The CCCA allows covalently crosslinking a protein of interest, here RI, to
potential binding partners. Covalent crosslinking potentially overcomes loss of reversibly
bound interaction partners during co-capture experiments using cAMP-agarose. This is
pertinent as identifying PKARIα-specific AKAPs is known to be challenging because of their
transient interactions due the fast off-rate of binding146. Crosslinking would serve to stabilise
the interaction between PKARIα and its binding partners, thus increasing the likelihood of
detection by immunoblotting or MS. Unfortunately the manufacturers stopped providing
support for this product and there were issues with the quality control of subsequent CCCA
batches.
7.2 AKAP7
AKAP7 formed a major part of my investigations because of its potential redox-dependent
interaction with PKARIα. Electrically stimulated isolated ventricular myocytes from PKARα KI
mice exhibit delayed decay of their Ca2+ transients compared to WT myocytes (unpublished
data from Wagner and Maier, Gottingen University). Unphosphorylated PLB inhibits SERCA2a
to decrease the active transport of Ca2+ back into the SR. The delayed Ca2+ transient in PKARIα
KI myocytes could potentially by explained by SERCA2a underactivity due to decreased PKA-
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dependent phosphorylation of PLB. I hypothesised that this would be caused by deficient
targeting of C17SPKARIα to AKAP7, the AKAP thought to be responsible for assembling the
PKA/PLB/SERCA2a signalling complex at the SR140.
Furthermore, examination of the AKAP7 crystal structure revealed the presence of a putative
disulfide bond adjacent to AKB domain. I hypothesised that the formation of a disulfide bond
in AKAP7 under oxidative conditions may modulate the AKAPs affinity for PKARIα due to its
close proximity to the AKB domain. Unfortunately I was unable to co-capture AKAP7 with
PKARIα using cAMP-agarose. I was able to co-purify with PKARIIα, but not PKARIα, with His-
AKAP7δ using Ni-NTA-agarose, and this interaction appeared to increase after H2O2 treatment.
AKAP7δ and PKARIIα regulate water reabsorption renal collecting duct principal cells237, and
the potential for this process to be modulated by oxidants could provide an interesting subject
of future investigation.
7.3 PEG-maleimide switch assay
The PEG-maleimide switch assay was developed to identify proteins susceptible to reversible
oxidative modifications. This method involved chemically reducing reversibly oxidised thiols,
and then labelling them with the thiol alkylating agent PEG-maleimide. This reagent is
essentially maleimide with a PEG tag of a specified mass that adducts to a modified protein.
During these investigations PEG-maleimide that added 5 kDa to the molecular mass of the
protein was utilised. Changes in mass were monitored by western immunoblotting using a
specific antibody to the protein of interest, with an increase in mass in oxidant-treated
samples compared to control indicating reversible oxidation. The PEG-maleimide switch assay
successfully confirmed PKARIα and PKGIα were redox sensitive proteins thus validating the
method. Furthermore the assay enabled me to conclude that tubulin and PKARIIα were
susceptible to reversible thiol oxidation, but that AKAP7 is not susceptible to such
modification. This novel method involves fewer steps than conventional thiol-labelling
approaches such as the biotin-switch assay256 or the AMS assay332, thus there is less chance of
losing protein during preparation, it is quicker and easier to perform and also is likely more
quantitative.
7.4 Modulation of PKARIα disulfide dimer by cAMP
One of the primary findings of these investigations was the discovery that cAMP-agarose can
induce the chemical reduction of disulfide PKARIα, despite the experiments occurring under
oxidising conditions (in the air). Since cAMP has no intrinsic reducing properties, I
hypothesised that the reduction of PKARIα was due to the conformational change in PKARIα
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that occurs upon cAMP binding, perhaps allowing a free thiol on another proximal protein to
access and reduce the disulfide in the kinase. PKARIα requires a surprisingly high concentration
of DTT to reduce its disulfides198. In Chapter 5 I demonstrated that the concentration of DTT
that is necessary to reduce PKARIα is decreased in the presence of cAMP, an effect that is lost
with the PKARIα-cAMP mutant. Therefore the idea that a cAMP-induced conformational change
of PKARIα can increase the solvent accessibility of the disulfide is feasible. In Chapter 6 I
presented a model whereby the free thiol responsible for the cAMP-induced reduction of
disulfide PKARIα is present on a closely associated AKAP, such as tubulin. The physiological
effect of the cAMP-induced reduction of disulfide PKARIα remains to be fully elucidated, but as
previously suggested it may lead to enhanced local substrate phosphorylation. The cycle of
oxidant-dependent PKARIα recruitment to AKAPs and cAMP-dependent reduction would keep
multiple holoenzymes in close proximity to an associated substrate and in a region of high
cAMP concentration to increase local responsiveness.
Curiously treatment of cells with 8-CPT-cAMP did not induce the reduction of PKARIα. This may
suggest that whilst there is evidence supporting a role for cAMP in the modulation of PKARIα
disulfide dimer, such results may be experimental artefacts that are not relevant in cells or in
vivo. However, due to the compartmentalised nature of cAMP/PKA signalling it is tempting to
suggest that cAMP-induced reduction of PKARIα occurs in vivo, but perhaps in very specific
subcellular locations. As such, when monitoring global PKARIα levels via immunoblotting after
cells are treated with 8-CPT-cAMP, subtle changes in disulfide dimer may not be detectable.
Identifying cAMP-induced reduction of PKARIα in cell models requires further investigation,
and may potentially be achieved by monitoring PKARIα disulfide in fractionated cell or tissues
samples.
7.5 H2O2 potentiates PKA substrate phosphorylation
H2O2-induced phosphorylation of PKA substrates has previously been demonstrated in
cardiomyocytes170 and I was able to corroborate this during my investigations. Interestingly
this effect was not as robust in VSMCs or HEK 293 cells. Cardiomyocytes have at least 10 times
higher basal cAMP levels compared to HEK 293 cells215, which has led me to hypothesise that
H2O2-induced phosphorylation of PKA substrates is contingent upon the concentration of
cAMP. This hypothesis may be examined in future experiments, for example, pre-treatment of
cardiomyocytes with the adenylate cyclase inhibitor 2′,3′-Dideoxyadenosine (ddA), to decrease
intracellular cAMP levels, prior to treatment with H2O2. This could reveal the importance of
cAMP in H2O2-induced phosphorylation of PKA substrates. Indeed, there was a trend towards
increased PKA substrate phosphorylation when HEK 293 cells were co-treated with both cAMP
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and H2O2 compared to cAMP or H2O2 alone. This suggests further that the presence of cAMP is
necessary for H2O2-induced PKA substrate phosphorylation. This led to the postulation that
PKARIα operates as a co-incidence detector, capable of integrating concomitant oxidant and
cAMP signals to enhance substrate phosphorylation, a concept that was explored further with
tubulin and GEF-H1.
7.6 Tubulin as a PKARIα redox-dependent AKAP
cAMP-agarose induced the reduction of PKARIα disulfide dimer. Furthermore the mutant
PKARIα-cAMP formed high molecular weight complexes in the presence of H2O2, which
reinforced the idea that cAMP has a role in reversing PKARIα disulfide, perhaps through a
mechanism that involves a thiol present on a proximal AKAP i.e. tubulin. To unify the two
observations I hypothesised that these high molecular weight bands represented transitory
intermediates of PKARIα complexed with AKAPs by an inter-protein disulfide bond; that these
complexes formed upon H2O2-induced targeting of PKARIα to AKAPs; and because they were
only evident with the PKARIα-cAMP mutant, that cAMP binding was required to catalyse the full
resolution of the complex resulting in PKARIα being reduced to its monomeric form.
LC-MS/MS analysis of samples resolved using diagonal gel electrophoresis identified tubulin as
one of the high molecular weight complexes formed when cells expressing the mutant PKARIα-
cAMP were exposed to H2O2. This was validated in anti-PKARIα immunoprecipitates where
tubulin was observed to run above its normal weight after H2O2 treatment, potentially in a
disulfide linked complex with PKARIα. Many redox modifications, such as short-lived
intermediates involved in thiol-disulfide exchange reactions, can often be difficult to detect
due to their labile nature and low stoichiometry at any given time. This may explain why it is
not possible to observe disulfide linked complexes with WT PKARIα because they are quickly
resolved. Mutation of the cAMP binding site slows the reduction of the intermediate disulfide
complex (hypothetically due to the lack of conformational change in PKARIα), thus permitting
detection of PKARIα disulfide-bound to tubulin. The stoichiometry of the PKARIα-tubulin high
molecular weight complex was fairly low, as may be anticipated in reactions that can redox
cycle. This is a potential reason why no differences were observed between control and H2O2
treated cells in the immunofluorescence experiments.
As previously suggested an oxidant-dependent interaction between PKARIα and an AKAP
would serve to localise the kinase to specific substrates during oxidative signalling. Evidence
suggests that a significant proportion of the PKA holoenzyme remains intact at physiological
and even supraphysiological concentrations of cAMP189. The PKARIα holoenzyme undergoes
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partial dissociation in the presence of cAMP but full dissociation in the presence of cAMP and
substrate, a feature that is unique to the RIα isoform189,193. It is reasonable to suggest that full
dissociation of the PKARIα holoenzyme complex would translate into enhanced substrate
phosphorylation compared to partial dissociation. Therefore the increased interaction
between PKARIα and tubulin in the presence of oxidants would rationally lead to enhanced
phosphorylation of substrates associated with this complex, as was the case with GEF-H1. The
integration of oxidant and cAMP signals may allow the cell to dynamically regulate
phosphorylation events to fine-tune functional responses to several stimuli simultaneously. It
has been suggested that there is differentiation between type I and type II PKA signalling
downstream of specific GPCR activation, although I saw no evidence of this181. Perhaps the
ability of PKARIα to integrate concomitant oxidant signals extends this paradigm to ensure
further selectivity and specificity of cAMP signal transduction.
The exact mechanism of the redox-dependent PKARIα-tubulin interaction remains to be
elucidated and may be the subject of future investigations. Systematic mutation of candidate
cysteine residues on tubulin and subsequently monitoring for loss of high molecular weight
complexes in vitro or in cells may help define which cysteines were important for the PKARIα
redox interaction. Complex formation between PKARIα and tubulin has previously been
described265, consistent with my findings documented here. To the best of my knowledge it is
the only example of a novel disulfide-linked PKARIα interaction with an AKAP, and it remains to
be determined if tubulin contributes an α-helix to the interaction. The cytoplasmic tail of the
AKAP α4-integrin binds to a C-terminal region of PKARIα, but this not via an amphipathic
helix150. Likewise, pericentrin sequesters PKA to the centrosome through a 100 amino-acid
domain that interacts with a leucine rich region of RIIα333. Furthermore, RI binding to dual-
specificity AKAPs can be enhanced through an additional sequence outside of the amphipathic
helix, termed the RI specifier region (RISR)334. As such an interaction between PKA and an AKAP
that does not involve a classical AKAP helix, in this case an inter-protein disulfide between
PKARIα and tubulin, is not without precedence. I observed numerous high molecular weight
complexes with anti-PKARIα after H2O2 treatment, and therefore there may be other AKAPs
that also interact with PKARIα via an inter-protein disulfide bond. Identifying these putative
redox-dependent PKARIα AKAPs is worth considering as part of future investigations.
7.7 Oxidant-potentiated GEF-H1 phosphorylation
It was reasonable to suggest that an increased interaction between tubulin and PKARIα under
oxidative conditions would lead to enhanced phosphorylation of substrates associated with
the complex. Indeed the phosphorylation of GEF-H1, a MAP, and known PKA substrate, was
General Discussion
215
enhanced when cells were co-treated with both cAMP and H2O2 compared to cells treated
with cAMP or H2O2 alone. Furthermore GEF-H1 phosphorylation was abrogated when cells
were transfected with PKARIα-cAMP, highlighting the importance of cAMP sensing at the level of
PKARIα for GEF-H1 phosphorylation. The ability of PKARIα to sense oxidant concentration via
the formation of the disulfide dimer was found to be necessary for oxidant-potentiated GEF-
H1 phosphorylation, as evidenced by the loss of this effect in the aortas of C17S PKARIα KI
mice. Taken together PKARIα detects both cAMP and oxidant signals to enhance GEF-H1
phosphorylation. PKA-dependent phosphorylation of GEF-H1 Ser885 inhibits its GTP exchange
activity and therefore decreases RhoA-dependent actin cytoskeleton assembly, thus
maintaining endothelial cell barrier integrity and limiting vascular permeability96,294. Here, I was
able to demonstrate that co-treatment of cells with cAMP and H2O2 lead to a decrease of actin
fibres in HEK 293 cells.
Although the results from the aortas from C17S PKARIα KI mice is promising, in the context of
vascular permeability it is still necessary to determine whether cAMP combines with H2O2 to
enhance GEF-H1 phosphorylation in endothelial cells isolated from WT mice. Subsequently it
will also be necessary to interrogate whether the H2O2-potentiated GEF-H1 phosphorylation is
lost in endothelial cells from C17S PKARIα KI mice. If as expected there is a difference in the
GEF-H1 phospho-status between the WT and KI mice an endothelial monolayer permeability
assay could be used to determine if there is a difference in endothelial barrier integrity
between WT and C17S-PKARIα KI mice. Measurement of the flux of fluorescent labelled
dextran (FITC-dextran) across an endothelial cell monolayer335 can be used to quantify the
degree of endothelial permeability after treatment with cAMP, H2O2 or co-treatment with both
cAMP and H2O2. I anticipate that the endothelial cells from PKARIα KI mice will be more
permeable to FITC-dextran as they cannot sense cellular oxidants to enhance GEF-H1
phosphorylation, leading to more RhoA-dependent actin fibres and thus greater endothelial
permeability.
7.8 PKARIα oxidant-dependent GEF-H1 phosphorylation in sepsis
Inflammatory mediators such as TNFα and IL-1β that are upregulated during sepsis contribute
to oxidant production during this time, and may contribute to the associated increase in
vascular permeability. I hypothesised that PKARIα can synergise cAMP and oxidant signals to
limit vascular permeability via the phosphorylation of GEF-H1 (Figure 7.1).
As of at the time of writing, I was able to conduct a small preliminary in vivo experiment to
evaluate the development of sepsis in WT and C17S PKARIα KI mice. PKARIα oxidation was
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elevated in WT mice, but contrary to my hypothesis GEF-H1 phosphorylation appeared to
decrease. Reasonably this could be because intracellular cAMP levels are low 24 hour post
sepsis induction. My studies in cells suggest oxidant-dependent phosphorylation of GEF-H1 is
contingent upon the presence of cAMP. Although these initial findings do not categorically
disprove my hypothesis, further studies assessing a time course of sepsis, and in which cAMP
concentration, PKARIα oxidation, GEF-H1 phosphorylation are monitored, is required. Future
work may also focus on measuring vascular permeability in vivo, comparing WT and C17S
PKARIα KI mice basally or after sepsis. This can be achieved using Evans Blue, a dye that
conjugates to serum albumin and can subsequently be detected and quantified in organs as a
measure of endothelial permeability. I anticipate that the PKARIα KI mice will have a greater
amount of blue dye in their organs, indicating increased vascular leak, especially at earlier time
points of the CLP model. GEF-H1 activity regulates numerous cellular processes, including
epithelial and endothelial permeability294,336, inflammation330, oncogenic signalling322 and
neuroplasticity321. How PKARIα oxidant-dependent GEF-H1 Ser885 phosphorylation may impact
on these various functions seems important to define in future studies.
The importance of oxidant-dependent PKARIα activation was recently demonstrated in models
of angiogenesis/vascular growth91. C17S PKARIα KI mice suffered an impairment of vessel
growth highlighting the oxidant-sensing ability of PKARIα for adequate physiological responses.
I was able to demonstrate that PKARIα forms an oxidant-dependent disulfide-linked complex
with tubulin, thereby regulating the phosphorylation of the associated substrate within the
complex. Indeed PKARIα serves as a co-incidence detector that is able to integrate cAMP and
oxidant signals to synergistically activate PKARIα, leading to the phosphorylation of GEF-H1.
7.9 Other Experimental Limitations
As previously discussed the concentration of H2O2 used in experimental studies is the subject
of controversy. 500 μM H2O2 was routinely used throughout this thesis to induce PKARIα
oxidation however some may consider this concentration to only be relevant to pathological
conditions rather than homeostatic oxidative signalling. Whilst the evidence for ROS-
potentiated GEF-H1 phosphorylation presented in this thesis is robust, it should be cautiously
interpreted, as with all results obtained with exogenously applied oxidants.
Throughout this thesis 8-CPT-cAMP was used to activate PKA. The reasons for this are two-
fold: cAMP is not cell-permeable; and the use of beta-adrenergic receptor agonists or forskolin
may only produce cAMP in specific subcellular compartments. The membrane permeable 8-
CPT-cAMP (and other cell-permeable cAMP analogues) is routinely used at a concentration of
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100 μM and above337-340, as was the case in these studies too. However, the permeability of
these analogues has not been well characterised. An important question becomes: what is the
final intracellular concentration of the cAMP analogue? If these molecules are specifically
designed to be membrane permeable, it is reasonable to suggest that the intracellular
concentrations approach the applied concentration. This would put the intracellular
concentration of cAMP at 100-1000 times greater than the basal cAMP concentration in the
cell types I used throughout this thesis. This is potentially further exacerbated because cAMP
analogues tend to be more resistant to degradation by PDE’s. As such, the results obtained
here and throughout the established literature with cAMP analogues should be approached
with caution when relating them to physiology/pathology. Furthermore, I routinely used
different cell types to investigate the biochemistry related to PKARIα signalling. These cells
were grown on plastic 6-well or 12-well plates; however there is now a greater appreciation
that results obtained from cells grown on plastic without the context of extra-hormonal
signals/physical interactions that are present in normal physiology can have a profound effect
on downstream cellular signalling.
7.10 Future Research
Primarily I will continue to investigate the role of GEF-H1 in sepsis pathogenesis in mice, with
particular focus on determining at what time-point post sepsis induction GEF-H1
phosphorylation is maximal. From there I intend to continue to investigate PKARIα as a co-
incidence detector of oxidant and cAMP signals, and its role on GEF-H1 phosphorylation in the
context of sepsis. This will be achieved using PKARIα KI mice which I anticipate will have a
deficiency in their GEF-H1 phosphorylation due to their inability to transduce the oxidant
signal. I predict that GEF-H1 phosphorylation during sepsis would be beneficial and therefore I
would expect the PKARIα KI mice to have a more severe sepsis phenotype as a consequence.
Furthermore I will continue to evaluate the redox-dependent interaction between PKARIα and
tubulin whilst continuing investigations concerning the mechanism of cAMP-induced reduction
of PKARIα, and whether this phenomenon can be observed in vivo. Finally, I would like to
explore alternative methods of co-capturing PKARIα with AKAPs, to establish whether to
oxidation state of the kinase alters the affinity to proteins other than tubulin.
General Discussion
218
Figure 7.1 Working model of oxidant-dependent activation of PKARIα during sepsis. One
mechanism that lipopolysaccharide (LPS), tumour necrosis factor α (TNFα) and interleukin-1β
(IL-1β) contribute to the pathogenesis of sepsis is via increasing vascular permeability.
Furthermore LPS, TNFα and IL-1β have all been shown to induce ROS production during
disease progression. Adrenaline (A), noradrenaline (NA) and serotonin (5-HT) activate GPCRs to
stimulate cAMP production. PKARIα in WT mice synergises both ROS and cAMP signals to
enhance GEF-H1 phosphorylation in comparison to C17SPKARIα in KI mice that can only be
activated by cAMP. Phosphorylation of GEF-H1 decreases its nucleotide exchange activity and
consequently limits RhoA-dependent vascular permeability. As C17SPKARIα cannot sense the
oxidant signal, GEF-H1 will be hypophosphorylated in KI mice compared to WT mice. Therefore
in C17S PKARIα KI mice, the exchange activity of GEF-H1 will be elevated thus enhancing RhoA
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